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FOLATE BASED INHIBITORS OF THYMIDYLATE SYNTHETASE IN
EXPERIMENTAL AND CLINICAL CANCER 
DAWN LOUISE ALISON
SUMMARY
CB3717 (N-(4-(N-((2-amino-4-hydr oxy- 6 -quinazolinyl) 
methyl) prop-2-ynylamino) benzoylJ-L-glutamic acid) is a novel 
quinazoline folate analogue developed at the Institute of 
Cancer Research and selected on the basis of its potent 
inhibition of thymidylate synthetase. The introduction of a 
compound capable of producing a pure "thymineless" death was 
sought in the belief that this m i g h t  confer it w i t h  
advantageous properties and hence the departure from the 
t radi t i o n a l  e n z y m i c  locus of c l assical a n t i f o l a t e s , 
dihydrofolate reductase. Fluorinated pyrimidine compounds, 
though capable of metabolism to the thymidylate synthetase 
inhibitor, 5-fluorodeoxyuridine monophosphate, probably owe 
their cytotoxicity to a combination of factors including 
incorporation into RNA and this cannot be used to test the 
effects of an uncomplicated thymineless state.
Pre-clinical studies confirmed that the cytotoxic 
effect of CB3717 in tissue culture was associated with the 
inhibition of t h y m i d y l a t e  synthetase ana s i g n i f i c a n t  
antitumour activity was demonstrated in mice. At lethal 
doses in mice, renal and hepatic toxicity occurred but no 
evidence of gastrointestinal or bone marrow toxicity was 
found. An extensive phase I clinical trial incorporating 99 
patients is described, with a dose escalation from 1 0 0  to 
600mg/m and treatments being administered by a one hour or 
12 hour infusion at 3 weekly intervals. The dose limiting
17
toxicity was found to be renal at doses in the region of 
500-6OOmg/m^ when substantial reductions in glomerular 
filtration rates were noted. A dose of 400mg/m was
recommended for phase II evaluation using this schedule. 
Transient abnormalities in serum alanine transaminase levels 
typified the hepatic toxicity which occurred in -80% of 
patients at all dose levels and the association of this with 
variable m a l a i s e  led to attempts at a m e l i o r a t i o n  by 
p r o l o n g a t i o n  of the i n f u s i o n  to 1 2  h o u r s  or the
administration of prednisolone for one week after treatment. 
Neither manoeuvre was successful in preventing the enzyme 
elevation, but steroid therapy improved malaise in some 
patients. Several patients who received multiple courses of 
CB3717 (>4) appeared to develop tolerance with a return of 
transaminase levels towards normal values. Other toxicities 
observed were rashes (-1 0 %) and sporadic myelotoxicity 
affecting leucocytes and platelets with a 1 0 - 1 2  day nadir. 
N e i t h e r  of t h e s e  e f f e c t s  w e r e  d o s e  r e l a t e d .  
Gastrointestinal toxicity was not observed. Responses were 
seen in the following tumours: ovary (1 CR, i PR), breast (3 
PR), large cell bronchus (1 PR) and mesothelioma (1 PR).
A c o m p l e m e n t a r y  p h a r m a c o k i n e t i c  e v a l u a t i o n  was 
performed during the phase I study which established that 
25-30% of CB3717 was excreted in the urine in the first 24 
hours after treatment, implying that the majority was
eliminated in the bile. The finding of an estimated 5% of
total drug administered within the renal tissue of a patient 
who died 8  days after a treatment at 330mg/m gave support 
to the hypothesis that in man, as well as in mouse, renal 
toxicity was seconary to precipitation of CB3717. Peak 
plasma levels of drug were within the concentration range 
that was cytotoxic to T, 1 2 1 0 -- cells in vitro and ijn vivo. In 
1 1  patients who were studied after their first treatment
18
there was a weak correlation between peak plasma drug levels 
and the increment in plasma alanine transaminase levels 
(r=0.839, p=0.01). Additionally, CB3717 was found to be 
highly protein bound (97.6+^0.1%) and no metabolites were 
detected in plasma or urine.
Investigation of the hepatic toxicity observed in the 
phase I study was pursued using an animal model after it was 
e s t a b l i s h e d  that p l a s m a  alanine t r a n s a m i n a s e . l e v e l s  
increased in mice also, after an intraperitoneal injection 
of a therapeutic dose, reaching a peak by 6 hours and 
returning to normal by 24 hours. A slight and rather 
variable depletion of liver glutathione was observed but 
this was probably not causally related since a trial of N- 
acetylcysteine as an antidote was unsuccessful. Thymidine, 
folinic acid or 5-methyltetrahydrofolate similarly did not 
prevent CB3717 hepatitis. Treatment with the quinazoline 
analogues, CB3705 (N^-unsubstituted) and CB3714 (N^^-ethyl) 
did not cause liver enzyme elevation suggesting that the 
N-^-propargyl group of CB3717 may be culpable.
The effects of CB3717 on histamine and phenylalanine 
metabolism in man were investigated as potential mechanisms 
for its toxicity. Some antifolates inhibit the enzymes of 
histamine catabolism (histamine methyltransferase and 
diamine -oxidase) and therefore cause skin rashes and central 
nervous system effects. CB3717 did not inhibit either 
enzyme and plasma histamine levels were unperturbed from the 
normal range in 5 patients after treatment. Rises in plasma 
phenylalanine levels up to 3 times normal were detected in 
some patients. This may be 'related to d e p l e t i o n  of 
tetrahydrobiopterin pools (which is a cofactor in the 
hydroxylation of the aromatic amino acids), mediated by 
inhibition of dihydrobiopterin reductase. The clinical
19
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significance of this is uncertain but there is a possibility 
of an effect on neurotransmitter levels.
In parallel with the clinical investigations, cell 
lines cloned from an L1210 tumour line with acquired 
resistance to CB3717 were characterised and found to have 
increased thymidylate synthetase activity. The pattern of 
cross-resistance to other antimetabolites, which may have 
therapeutic implications, was also studied. No significant 
cross-resistance to methotrexate, 5-fluorouracil or 5- 
fluorodeoxyuridine was found. It was concluded that further 
clinical and biochemical studies with this promising new 
antitumour agent are merited.
■ X
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CHAPTER I
INTRODUCTION
1.1 Cancer - Some General Considerations
Cancer, as a disseminated disease, is a major 
cause of morbidity and mortality. Twenty two percent of the 
total deaths registered in England and Wales in 1982 were 
attributable to neoplasms ("Mortality Statistics Cause" 
1982, Office of. Population Censuses and Surveys, Series DH2 
No. 9, H.M.S.O.), the greater proportion of which comprised 
s o l i d  t u m o u r s  a r i s i n g  f r o m  the lung, b r e a s t ,  
gastrointestinal tract and ovary. Continued research into 
the causes and predisposing factors is undoubtedly required 
with the optimistic aim of prevention supervening treatment.
The situation is reminiscent of an earlier fight 
against infectious diseases where r e a l i s a t i o n  of the 
contributory role of unsanitary, crowded living conditions 
and contaminated water supplies led to improvements which 
were of major importance in the control of microbial 
illnesses. In this respect, antibiotic chemotherapy was, 
and still is, of secondary importance, and relevant to the 
control of bacterial disease in i n d ividuals not in 
populations. Unfortunately, an awareness of preventative 
measures is not always sufficient and lack of financial 
resources! a m o n g s t  other factors, has r e s t r i c t e d  the 
introduction of even simple public health measures in some 
developing countries where infectious diseases are still 
r ife.
22
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The parallel with cancer is e x e m p l i f i e d  by the 
depres s i n g  facts concerning lung cancer w h ere age- 
standardized death rates in men increased from 27/100,000 in 
1941-4 5 to 92/100,000 in 19 76-78 (Cancer Sta t i s t i c s  
Incidence, survival and mortality in England and Wales,
H.M.S.O., No 43 - Office of Population Censuses and Surveys
1981). Smoking is of course the most important aetiological 
factor in the development of lung cancer and it is strongly 
implicated in the cause of tumours of the head and neck 
(Shedd D.P. 1982). Widespread publicity of the harmful 
effects of smoking has so far failed to make any real 
impression on the population of smokers in Great Britain, 
where sadly the number of females who smoke continues to 
rise as do the numbers who die from lung cancer (Doll R.
1982). Thus the frailty of human nature coupled with 
ignorance of the factors which initiate many human tumours 
supplies an urgent need for more effective remedies.
Cytotoxic chemotherapy presently provides the mainstay 
of systemic cancer treatment, the numbers of antineoplastic 
agents having grown exponentially since 1946 when the first 
clinical reports of the use of nitrogen mustard alkylating 
agents appeared (Goodman L.S. ejt a_l 1946, Jacobson L.O. et 
al 1946, Rhoads C.P. 1946). A n t i f o l a t e s  joined the 
pharmacopoeia shortly afterwards with aminopterin (4-amino- 
4-deoxypteroylglutamic acid) being the first folate analogue 
to show clinical activity by producing temporary remissions 
in children with acute leukaemia (Farber S. et. cQ, 1948). 
M e t h o t r e x a t e  ( a m e t h o p t e r i n ,  4 - a m i n o - 4 - d e o x y - 1 0 -  
methylpteroylglutamic acid) was synthesised a year later by 
the same group (Seeger D.R. ejt a_l, 1949) and was thereafter 
established (and remains) in the treatment regimens for a 
variety of tumour types including choriocarcinoma (Hertz R., 
L e w i s  J.R. & Lipsett M.B., 1961) acute l y m p h o b l a s t i c
23
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leukaemia of childhood (Acute Leukaemia Group B 1965, 
Djerassi I. ■ et a_l 1967, Holland J.F. & Glide well 0. 197 2, 
Wang J.J., Freeman A.I., & Sinks L.F. 1976), carcinoma of 
the breast (Eastern Cooperative Group In Solid Tumour 
Chemotherapy 1967 and reviewed by Carter S.K., 1976),
epidermoid cancer of the head and neck (Capizzi R.L. et a 1 
1970, Levitt M. et al 1973) and osteogenic sarcoma (Jaffe N. 
et al 1974).
In 1974, in an article entitled "The Rational Design of 
Folic Acid Antagonists" Mead wrote; "After this auspicious 
beginning to the antifolate era it was to be expected that 
more and better antifolates would soon be available. This 
was not to be and, twenty five years after the synthesis of 
aminopterin, the folic acid antagonist of choice in the 
treatment of human malignant disease remains the closely 
related compound methotrexate, amethopterin." (Mead J.A.R. 
1974). The purpose of this chapter is to r e v i e w  the 
properties of the classical antifolate methotrexate and then 
describe one rational approach to the design of a novel 
antifolate with emphasis on the different locus of action. 
The preclinical antitumour and toxicology data of this new 
compound,CB3717 (N- (4- (N- [ (2-amino-4-hydroxy-6-quinazolinyl) 
methyl]prop-2-ynylamino)benzoyl)-L-glutamic acid) which is a 
quinazoline folate analogue, will be summarised as a preface 
to the early clinical trial described in chapter II.
1.2 Methotrexate - Locus of Action
An antimetabolite has been defined as a compound
structurally related to a metabolite, which prevents its 
further utilisation by competing with it for an enzyme
(Connors T.A. 1976) Antifolates form part of this group,
their relevance to cancer treatment being discovered by
24
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Farber, who noted that the inje c t i o n  of folic acid 
conjugates (pteroyltriglutamic acid and pteroyldiglutamic 
acid) gave rise to an "acceleration phenomenon" i n t h e  
leukaemic process seen in the marrow and viscera of children 
with acute leukaemia and coupled this with some observations 
on folic acid deficiency to form the hypothesis that folic 
acid antagonists might be of use in- acute leukaemia (Farber 
S. 1947, Farber S. et. a_l 1949). This empirical approach led 
to the i n t r o d u c t i o n  of a m i n o p t e r i n  and m e t h o t r e x a t e  
(amethopterin), the structures of which are shown in Figure 
L I  along with the parent compound folic acid. ...Nichol and 
Welch showed that methotrexate blocked the activation of 
folic acid to "citrovorum factor"in 1950 (Nichol C.A. & 
Welch A.D. 1950), but it was several years later that the 
complexities of folate metabolism were elucidated and the 
potent inhibition of d i h y d r o f o l a t e  r e d u c t a s e  (DHFR, 
E.C.1.5.1.3) (the e n z y m e  c a t a lysing the r e d u c t i o n  of 
dihydrofolate to te trahydrofolate) by methotrexate was 
described (Futterman S. & Silverman M. 1957).
It is u s e f u l  at this p o i n t  to c o n s i d e r  the 
interconversions which take place in the folate metabolic 
pathways which allow the transfer of 1 -carbon fragments 
during the biosynthesis of purines, thymidine and amino 
acids. Details are shown in Figure 1.2.
T h e  k i n e t i c s  of the i n h i b i t i o n  of m a m m a l i a n  
dihydrofolate reductase by methotrexate although originally 
described as "stoichiometric" by Werkheiser (1961) are now 
recognised to be competitive with respect to dihydrofcJ&te 
although extremely tight binding. A pH dependence was 
elaborated by Bertino who found that inhibition was weaker 
at pH 7.6 than at pH 5.9 (Bertino J.R. 1967, Hillcoat B.L. & 
Johns D.G. 1967). The net effect of methotrexate is thus to
25
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FIGURE 1.1; The Structures of Folic Acid, Aminopterin 
and Methotrexate (Amethopterin)
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LIST OF ABBREVIATIONS FOR FIGURE 1.2
F .= Folic acid
FH 0 = 7 ,8 -dihydrofolic acid
FH^ - 5,6 ,1,8 -tetrahydrofolic acid
CH^FH^ = 5-methyltetrahydrofolic acid
CH 2 FH^ = 5, 1 O-methylenetetrahydrofolic acid
CHOFH^ = 1O-formyltetrahydrofolic acid
CHF.H^ =5 ,1O-methenyltetrahydrofolic acid
MTX = Methotrexate
Hx = Hypoxanthine
TdR = Thymidine
dUMP = 2 ‘-deoxyuridylic acid
TMP = Thymidylic acid
HCys = Homocysteine
Met = Methionine
DHFR = Dihydrofolate reductase
TS = Thymidylate synthetase
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deplete the cell of reduced folates and thereby secondarily 
impair the synthesis of thymidylate and purines, (see Figure
1.2). However, other biochemical-loci have been implicated, 
the most relevant being direct inhibition of thymidylate 
synthetase in some cell lines (Borsa J. & Whitmore G.F. 
1969a), and it has been suggested that both loci may be of 
importance in cell killing (Borsa J. & Whitmore G.F. 1969b, 
McBurney M.W. & Whitmore G.F. 1975).
An examination of the data on the reversibility of
methotrexate toxicity provides no simple answer to defining
*
the cytotoxic locus during methotrexate treatment. Goldin's 
p i o n e e r i n g  studies, with delayed a d m i n i s t r a t i o n  of 
citrovorum factor (folinic acid) after aminopterin treatment 
of tumour bearing mice (Goldin A. ejt a_l 1955), led to the 
introduction of clinical regimens utilising this principle 
with methotrexate (Capizzi R.L. ejt a_l 1970, Djerassi I. e_t 
al 1972, Levitt M. e_t cQ 1973 and reviewed by Bertino J.R.
1981). Similarly thymidine has been used as a rescue agent 
in methotrexate-treated tumour bearing mice (Tattersall 
M.H.N., Brown B., & Frei E. 1975) although other workers
found that non-tumour bearing mice required a purine source 
(hypoxanthine) in addition to thymidine to ensure protection 
from acute toxicity (Straw J.A. et al 1977). Interestingly, 
in leukaemic patients successful rescue with high doses of 
thymidine has been achieved (Howell S.B. e_t al^  1978). None 
of these data are inconsistent with DHFR being the primary 
locus of methotrexate action. For example, the differential 
ability of cells to salvage preformed purines and the 
differential supply of purines as a result of cell death may 
contribute to the varied response when thymidine is used as 
the sole rescue agent (reviewed by Jolivet e_t al 19 82). 
Indeed, there is some evidence to suggest that impairment of 
p u r i n e  synthesis is p r i m a r i l y  r e s p o n s i b l e  for the
■ ■ ■ 29
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gastrointestinal toxicity while that of thymidylate relates 
more to its myelosuppressive effects (Straw J.A. et al 
1977.).
The subject is complex but in a recent review Jackson 
and Grindey concluded that the interaction of methotrexate 
with DHFR alone can probably account for its observed 
effects (Jackson R.C. and Grindey G. 1984) "although the 
exact sequence of events that leads to irreversible damage 
is still far from clear." If the unbalanced growth caused 
by cessation of DNA synthesis in the presence of continued 
RNA and protein synthesis is lethal to cells this might be 
sufficient explanation (Cohen S.S. 1971). Whatever the 
mechanism, it is apparent that methotrexate exerts its 
d a m a g i n g  effects on cells during the S-ph a s e  when, 
necessarily, DNA replication is in process. The rapidly 
dividing cells of the gastrointestinal tract and bone marrow 
are thus particularly susceptible to this agent and this is 
evident in its clinical toxicity profile where mucositis and 
myelosuppress ion are dominant (reviewed by Chabner B.A,
1982) .
1.3 The Design of a Novel Antifolate
Considerable effort has been expended on attempts to 
produce an antifolate with superior activity, increased 
tumour selectivity and an improved therapeutic index 
c o m p a r e d  to methotrexate. A d e t a i l e d  r e v i e w  of the 
compounds developed ;is outside the scope of this thesis but 
it is g e n e r a l l y  tr u e  t h a t  a g e n t s  w i t h  a l t e r e d  
physicochemical and pharmacokinetic properties have been 
sought rather than agents with differing cyctotoxic loci. 
One example is metoprine (DDMP) which is one of several 
lipophilic 2,4-diamino pyrimidines shown to inhibit DHFR
30
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(Greco W.R. & Hakala M.T. 198Q, Browman G.P. et al 1980). 
Several cell lines resistant to methotrexate are sensitive 
to m e t o p r i n e  but this is p r o b a b l y  a c c o u n t e d  for by 
differences in membrane transport of the two compounds 
(Sirotnak F.M. et al 1982). Clinical trials showed that the 
lipophilic properties of metoprine did enable it to cross 
the blood-brain barrier more effectively, but also led to a 
very prolonged half life and an extended toxicity risk 
(Miller D.S. ejt aJ 1976). Antitumour activity was rather 
limited. Additionally it was noted that triazinate (a 
triazine folate analogue) and metoprine gave rise to central 
nervous system toxicity and dermatological toxicity (Skeel 
R.T. et a1 197 6 , Currie V.E., Kemp in S.T. & Young C.W. 1980) 
which are thought to be mediated by inhibition of histamine 
metabolising enzymes (Duch D.S., Bowers S.W. & Nichol C.A. 
1978). A more recently developed lipophilic DHFR inhibitor, 
trimethoxybenzyl aminoquinazoline (TMQ, or trimetrexate) has 
a different transport mechanism from methotrexate (reviewed 
by Jackson R.C. ej: aJL 1984) but in preclinical studies was 
found to be a potent inhibitor of histamine metabolism (Duch 
D.S., Edelstein M.P. & Nichol C.A. 1980). This topic is 
discussed more fully in Chapter IV but clearly the current 
clinical trials of trimetrexate will be of great interest. 
Some other antifolate compounds include 10 propargyl 
aminopterin (and alkyl homologues of methotrexate) and 1 0  
deaza-aminopterin, but once again in vitro ^ and in vivo 
studies suggest that.there is no substantial advantage of 
these over methotrexate (Piper J.R. et aj. 1982, Sirotnak
F.M. et al 1982).
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1.4 The Rationale For A Folate Based Inhibitor of
Thymidylate Synthetase
In 1981 T.R. Jones and co-workers presented the in 
vitro and in vivo results of studies with a quinazoline 
folate analogue, CB3717, which had been specifically sought 
and. selected from a s e r i e s o f  similar compounds for its 
potent inhibition of thymidylate synthetase (E.C.2.1.1.45) 
(Jones T.R. et: al. 1981). The reasons for such a novel 
approach, which departed from the dogma of DHFR inhibition, 
were made evident in this paper with some of the ground., 
having been prepared by an earlier publication of Calvert ejt 
al in which antifolates with dual biochemical loci of action 
were described (Calvert A.H. erf aJL 1980). The case for 
direct inhibition of thymidylate synthetase by a folate 
analogue will be re-presented here.
Firstly, there is circumstantial evidence to suggest 
t h a t  a d i f f e r e n t i a l  r e s p o n s e  of t u m o u r  and h o s t  
g a s t r o i n t e s t i n a l  tissue to the a n t i purine effect of 
methotrexate may exist such that avoiding it, may result in 
diminished gastrointestinal toxicity (Harrap K.R., Taylor
G.A. & Browman G.P. 1977) whilst preserving an antitumour 
effect (Tattersal M.H.N. £t jal 1974). Secondly, Borsa and 
Whitmore proposed that impairment of purine synthesis' by 
methotrexate, in some systems, may be deleterious to its 
cytotoxicity (Borsa J. & Whitmore G.F. 1969c). Thirdly, 
cells with acquired resistance to methotrexate, due either 
to e l e v a t i o n  of DHFR levels or altered D H F R  kin e t i c s  
(reviewed by Bertino J.R. et al, 1981), should not be cross- 
resistant to an inhibitor of TS.
R e f l e c t i o n  on the c h a r a c t e r i s t i c s  of established 
f l u o r i n a t e d  p y r i m i d i n e s  w h ich we r e  d e s i g n e d  to be 
metabolically activated to TS inhibitors, highlights the
■ '  32
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desirability of a folate analogue for this purpose. Figure
1.3 shows the structure of the two best studied (and to date 
most widely used) fluorinated pyrimidines, 5-fluorouracil 
and 5 - f l u o r o - 2 ' - d e o x y u r i d i n e , alongside the naturally 
occurring pyrimidines and nucleosides which they mimic. On 
Figure 1.4 their metabolic pathways are detailed. There is 
extensive literature on these compounds which were first 
s y n t h e s i s e d  in 1957 (Duschinsky R., P l e v a n  E. and 
Heidelberger C. 1957) and for some years it was believed 
that their antitumour effect was a result of thymine 
deficiency, caused by inhibition of TS by a metabolic 
product, 5-fluorodeoxyuridine monophosphate (Cohen S.S. et 
_al/ 1958,. Danneberg P.B., Montag B.J. & Heidelberger C. 
1958) (see figure 1.4). It is now appreciated that other 
loci are probably of importance including incorporation of 
5 ‘-FUTP (another metabolic product) into RNA (Martin D.S. 
1978 and reviewed by Chabner B.A. 1981). Incorporation into 
DNA has also been reported (Danenberg P.V. et: al 1981, Major 
P*P. e_t cQ 1982). Additionally, FdUMP inhibition of TS is 
compromised in whole cells by the development of raised 
levels of dUMP, the competing substrate (Lockshin A. & 
Danenberg P.V. 1981). In the case of inhibition mediated by 
a folate analogue, the competing substrate for TS is a 
vitamin and therefore only able to accumulate to a limited 
extent. Further, the many anabolic and catabolic routes 
available to the fluorinated pyrimidines provides several 
ways of resistance development by appropriate enzyme 
deletion or overproduction (reviewed by Ardalan B., Cooney 
D. and MacDonald J.S. 1980). Folate analogues are active 
per se and generally little catabolisea (Jacobs S.A. et al
1976). In summary then, it can be strongly argued that the 
introduction of a folate analogue inhibitor of thymidylate 
synthetase might provide an important addition to the 
cytotoxic armoury as well as a unique opportunity to-.test
s34
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FLUOROPYRIMIDINE METABOLISM
CL—  f lu o ro  — j S — a la n in e  CO2  +  N H 3
2 RN AIE TY
F l l» ^ - F |1 R  ; r - * F l lM P : — »•F u n p  7 ^ F l tTP
7 7 7X.  i
10FCDR — > FUDR X±FdUM P«—- FdUDP
dUMP — - »<JTMP
1 = Uracil and thymine degrading enzymes
2 = Phosphoribosyl transferase ;
3 = Uridine phosphorylase
4 = Uridine and cytidine kinase
5 = Uridylate kinase
6 = RNA polymerase
7 = Phosphatases
8  = Deoxyuridine phosphorylase
9 = Thymidine Phosphorylase
10 = Deoxycytidine deaminase
11 = Thymidine Kinase
12 = Thymidylate synthetase
13 = Ribonucleotide reductase
FU = 5-Fluorouracil
FUDR = 5-Fluoro-21-deoxyuridine
FIGURE 1.4: Pathways of Fluorinated Pyrimidine
Metabolism
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the efficacy of pure tnymineiess death.
1.5 Development of CB3717
In 1968 Hutchinson reported the antifolate properties 
of a new series of 2,4-diamino quinazoline folate analogues, 
inhibition of DHFR being a primary locus (Hutchinson D.J. 
1968) (The quinazoline ring structure and numbering system 
is s h o w n  in Figure 1.5). Later, c o m p o u n d s  wi t h  this 
configuration were demonstrated to be capable of thymidylate 
synthetase inhibition (McCuen R.W.'& Sirotnak F.M. 1975, 
Calvert A.H. e_t glI 1980) although tight binding to DHFR had 
also been noted (Folsch e_t a_l 1971, Calvert A.H. e_t a_l 
19 8  0 a). W o r k e r s  at the Institute of Cancer R e s e a r c h  
(England) then pursued a study of 2 - a m i n o - 4 - h y d r o x y  
quinazolin.es and discovered that the incorporation of a
c
methyl group into the position produced weaker TS
inhibition (Jones T.R. 1980, Calvert A.H. et. al. 1980a) 
whilst in the position, improved TS inhibition occurred
(Calvert A.H. et^  al 1980b). The latter o b s e r v a t i o n  
confirmed some earlier studies of Bird (Bird O.D., Vaitkus 
J.W. & Clarke J. 1970). By substituting aliphatic chains of 
increasing length it was then discovered that.an ethyl group 
gave optimal inhibition of TS (Calvert A.H. e_t a_l 1980b). 
Jones and co-workers subsequently introduced the unsaturated 
ally! and propargyl groups at the  ^ position and found 
that this improved the inhibition of TS by 3 and 30 fold 
respectively (Jones T.R. et al 1981). Figure 1.6 shows the 
structures of these compounds with details of their TS 
inhibitory properties. Sixty four analogues of CB3717 (the 
fljlO^propargyl compound) were evaluated in total, but none 
displayed superior properties and hence CB3717 was chosen 
for further investigation and clinical study. A review of 
the iii vitro and in vivo findings will follow.
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FIGURE 1.5: Structures of a Pteridine Ring Compound
(Folic Acid) and a Quinazoline Ring Compound
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House
Number R
Thymidylate 
Synthetase 
Iso (nM)
. CB 3715 -c h 2~c h 2-c h 3 170
CB 3716 -c h 2-ch=c h 2 69
CB 3717 -c h 2-c =ch 5
FIGURE 1.6: Inhibition of Thymidylate Synthetase
by Quinazolines
From Jones T.R. et al, 1981
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1.6 Biochemical Properties of CB3717
The enzyme locus of prime importance in this discussion 
is thymidylate synthetase (E.C.2.1.1.45) which catalyses the 
conversion of deoxyuridine monophosphate (dUMP) to thymidine 
monophosphate (dTMP) as discovered in 1957 (Friedkin M. and 
Kornberg A. 1957). The methyl group is derived from the 
cosubstrate 5,10-methylene tetrahydrofols.te which is itself 
oxidised to dihydrofolate during the reaction (Fig. 1.7) 
This reaction p r o vides the only source of t h y m i d i n e  
nucleotides synthesised de novo in a cell. In the initial 
studies with CB3717 Michaelis-Menten kinetics were assumed 
and it was found that inhibition of TS from L1210 cells 
a p p e a r e d  to be c o m p e t i t i v e  w i t h  r e s p e c t  to 5,10 
methylenetetrahydrofolate with a Ki in the region of InM 
(Jones T.R; et. al^  1981). Subsequently, Zone B analysis for 
tight - b i n d i n g  inhibit ion has been applied to CB3717 
inhibition of TS from highly purified enzyme derived from 
L1210 cells (Jackman e t a l  1984) and WIL2 ly mphoblas to id 
cells (Jackson R.C., Jackman A. L. & Calvert A.H. 1983) 
leading to the conclusion that CB3717 does inhibit TS 
competitively with respect to 5 ,1 0 -CH 2 FH^ with a Ki of 4.2nM 
and 4.9nM respectively.
Dihydrofolate reductase is also inhibited by CB3717, 
the Ki for purified rat liver enzyme being 14nM (Jones T.R. 
et al 1981). Despite this several pieces of data derived 
from tissue culture experiments suggest that TS and not DHFR 
is the cytotoxic locus. Firstly for L1210 leukaemia cells 
grown in tissue culture the ID^q of CB3717 was 5uM and 
reversal of growth inhibition was achieved with lOuM 
thymidine whilst folinic acid, up to lOOuM, was only capable 
of partial reversal (Jones T.R. e_t al 1981). M o r e  
importantly, delayed rescue from CB3717 toxicity (up'to 8
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hours) was possible with thymidine in WIL2 cells (Jackson 
R.C. e_t a_l 1983), while delayed rescue from MTX toxicity was 
not possible. Parenthetically, a cell line 600 fold 
resistant to MTX by vitrue of raised DHFR levels (L1210/R71) 
was also found to be sensitive to CB3717 with an ID^q of 
14uM (Jones T.R. et aJL 1981). Secondly, measurement of 
dihydrofolate pools (FH2) in WIL2 lymphoblastoid cells 
treated with equitoxic doses of CB3717 and MTX, gave very 
different results with no accumulation of FH 2  after CB3717 
and marked elevation of FH 2  after MTX (Jackson R.C. et al 
1983). Thirdly, in the same paper Jackson and co-workers 
provided data on purine nucleotide pools, using the same 
system, and established that at equivalent doses MTX 
depleted ATP and GTP pools whilst CB3717 did not. Further 
evidence for CB3717 inhibition of TS was also provided by 
estimation of pyrimidine deoxynucleotide pools in cells 
exposed for 16 hours to an IC 5 Q concentration of drug. An 
8 8 % decrease of cellular dTTP occurred in the presence of a 
2,300% increase in dUMP clearly indicating an effect on TS, 
either directly or indirectly (Jackson R.C. e_t al 1983). 
Finally, the elegant mathematical model, developed by 
Jackson to predict the outcome of compounds which inhibit 
both DHFR and TS, supported the h y p o t h e s i s  that TS 
inhibition was rate-limiting for CB3717 (Jackson R.C. e_t a_l
1983). As an addendum, some work covered later in this 
thesis, ’(Chapter VI) relating to experimental resistance to 
CB3717, has provided additional support for this belief with 
the characterisation of an L1210 cell line approximately 100 
fold resistant to CB3717 and with up to 40 fold increased TS 
activity.
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1.7 Animal Studies With CB3717
I.7.a. Antitumour Testing
The L1210 tumour test in mice p r o v i d e d  the m o s t  
striking example of _in vivo antitumour activity. BDFI mice 
were injected with 5x10^ L1210 cells intraperitoneally 
(i.p.) on day 0 and were treated either by a single dose of 
CB3717 i.p. or 5 consecutive daily doses beginning on day 3. 
The results (taken from T.R. Jones _et a_l 1981) are shown in 
Table 1.1. A five day schedule was required for the 
therapeutic effect which showed dose dependence. No 
s i g n i f i c a n t  whole animal toxicity was o b s e r v e d  and 
superiority over methotrexate in the same system was- 
d e m o n s t r a t e d  (see Figure 1.8). S i m i l a r  results were 
ob t ained when LI 210 cells (1x10^) were injected 
intravenously and followed by 5 daily treatments with 
optimal doses of methotrexate or CB3717 i.p. (see Figure 
1-9) .
Against the ADJ/PC 6 tumour model which is normally used 
as a screen for alkylating agents, CB3717 showed significant 
activity, causing 84% inhibition of tumour growth at the 
m a x i m a l .tolerated dose compared with 42% inhibition by 
methotrexate (data of A.L. Jackman & P.M Goddard). Other 
screening tests were disappointing with no significant 
activity being seen against a TLX5 lymphoma inoculated 
subcutaneously, or against a human tumour choriocarcinoma 
xenograft (data of A.L. Jackman & P.M. Goddard).
42
In summary, the unique biochemical locus of CB3717 and 
its jLn vitro activity against cell lines resistant to 
methotrexate coupled with evidence of some activity in 
animal screening models was thought to warrant an evaluation 
of its capabilities in man. This necessitated preliminary 
animal toxicology studies, which are described below.
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I.7.b. Toxicology Studies
These studies were performed by A.L. Jackman and A.H. 
Calvert using nine week old male and female Alderley Park 
mice. Two schedules were employed, the first comprising a 
single 5 day course of treatment with CB3717 at doses of 
62.5, 125, 250 and 500mg/kg in direct comparison with
methotrexate at doses of 1,2,4 and 8 mg/kg. The second 
schedule involved 4 repeated 5 day courses of treatment with 
10 day intervals between each course. The doses on this 
occasion were 25, 50, 100 and 200mg/kg and 0.75, 1.5, 3 and 
6 mg/kg for CB3717 and methotrexate respectively. The 
results are summarised below.
Single 5 day schedule
It was found that animals receiving toxic doses of 
CB3717 (~300mg/kg) died after the first or second dose of 
drug and at very high doses (~500mg/kg), the animals became 
cold and hypokinetic, dying from convulsions within 1 0 - 1 2  
hours. In contrast, animals dying from methotrexate 
toxicity did so 6-9 days after starting treatment with 
characteristic weight loss and diarrhoea. CB3717 treated 
animals did not lose weight or develop diarrhoea. The 
LD50s, calculated from this study, are shown below (measured 
in mg/kg daily for 5 days)
males
females
Methotrexate
5.2.
4.6
CB3717
380
330
LD50 (mg/kg) in Mice For MTX and CB3717
No haematological abnormalities were noted in CB3717 treated
animals whilst leucopenia was found in female mice treated 
with 4mg/kg methotrexate. No significant changes were seen 
in femoral bone marrow preparations.
Macroscopically, irregular pitting of the kidney 
surfaces of a n i m a l s  r eceiving an LD2 0 dose of CB3717 
(250mg/kg) was noted. The three animals which survived 
doses of 500mg/kg and all 10 which survived 125mg/kg showed 
no obvious ill effects when observed for a further 262 days.
Repeated 5 day course
Deaths occurred only in animals treated at 200mg/kg 
CB3717 (one male animal on day 4, 2 females on days 3 and 5 
all within the first 5 day course). In the methotrexate 
group, deaths occurred following the first, second and third 
courses, the c a l c ulated LD50 for this p r o t o c o l  being 
3.7mg/kg for males and 4.6mg/kg for females. Again weight 
loss and diarrhoea were features of methotrexate treatments 
only.
Macroscopically, abnormalities of the kidneys, as 
before, and testicular atrophy, were observed in animals 
sacrificed from the 200mg/kg CB3717 group. In the dose 
group of lOOmg/kg CB3717 animals sacrificed after 262 days 
showed no macroscopic lesions. Again, no significant 
haematological or bone marrow changes were found.
Histological Examination - Performed by British Industrial 
Biological Research Association (BIBRA)
CB3717 caused kidney damage in male and female mice in 
both the single course and repeated course study. This was 
typified by proximal tubular necrosis with subsequent
" "" 48
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regeneration of the epithelium with radial tracts of 
interst i t i a l  fibrosis and a m i xed i n f l a m m a t o r y  cell 
infiltrate. The severity of the kidney damage was clearly 
dose related and varied from mild to moderate in animals 
treated with 62.5mg/kg in the acute study and with 50mg/kg 
in the repeated dosing study. Severe kidney damage was 
restricted to animals treated with 250mg/kg or 200mg/kg in 
the acute and repeated dosing studies respectively. The 
sequelae to kidney damage involved the development of radial 
scarring of the cortex.
Testicular atrophy was also observed, being most severe 
in animals in - the repeated dosing study, and was dose 
related, approaching 1 0 0 % atrophy in several animals of the 
high dose group.
1.7c Study to determine the cause of death in animals 
treated with a lethal dose of CB3717
To complete the toxicological evaluation of CB3717 in 
mice an additional study was undertaken to determine the 
cause of death in animals treated with a lethal dose of 
CB3717. Forty mice were injected intraperitoneally with 
300mg/kg CB3717 and ten were sacrificed 24 hours later, two 
having died within this time period. The remaining twenty 
eight animals were injected with a second dose of 300mg/kg 
CB3717, and ten of these were sacrificed 48 hours after the 
f i r s t  i n j e c t i o n .  P o o l e d  b l o o d  f r o m  the o r b i t a l  
e xsangu inat ion of these mice was used to o b t a i n  a 
biochemical profile using the Royal Marsden Hospital 
autoanalyser. Uninjected animals were used as controls. 
The results of this study are shown in Table 1.2. Most 
noteworthy was the acute elevation in blood urea levels 
sug g e s t i n g  acute renal d a m a g e  w h i c h  was v e r i f i e d  by
49
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macroscopic and microscopic scrutiny of the tissues removed 
at necropsy from a moribund animal. The kidneys appeared 
swollen and haemorrhagic. Histopathological examination 
(performed by Dr. S. Sparrow, MRC T o x i c o l o g y  Unit, 
Carshalton) revealed damage throughout the nephron and 
deposits within the lumen. A homogenate of renal tissue was 
assayed for CB3717 using a high p e r f o r m a n c e  liquid 
chromatography technique (HPLC) (as described in more detail 
in Chapter III) and revealed 15.5mg CB3717/kg wet weight 
tissue. This represented the deposition of approximately 
half the total dose of CB3717 administered to the mouse. 
This evidence suggested that the most likely cause of death 
following a lethal dose of CB3717 was due to renal failure 
caused by drug precipitation in the renal tubule. This is 
concordant with the poor solubility of CB3717 in acid 
conditions.
The other interesting feature highlighted in this study 
was the elevation in plasma alanine transaminase levels 
accompanied by the histological appearance of periacinar 
necrosis in hepatic tissue. The desirability of further 
exploration of CB3717 hepatotoxicity became more apparent 
when the clinical study was under way. Chapters II and V 
deal with this subject in more detail.
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1.8 Summary
Antifolates have a place both in the past and present 
of cytotoxic chemotherapy. Efforts to produce new drugs 
with superior properties to the classical dihydrofolate 
reductase inhibitor, methotrexate, have so far failed to 
produce any with significant advantages or comparable 
antitumour activity in man. The concept of exploiting 
inhibition of the enzyme thymidylate synthetase by a folate 
analogue represented a new approach and resulted in the 
development of CB3717 at the Institute of Cancer Research. 
The evidence to support the belief that TS is the cytotoxic 
locus of this compound has been reviewed herein along with 
the animal antitumour and toxicology studies. The further 
evaluation of this intriguing new. drug, both clinically and 
biochemically is the subject of the rest of this thesis.
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CHAPTER II 
PHASE I CLINICAL TRIAL OF CB3717
II.1 Introduction
The clinical evaluation of new chemotherapeutic agents 
has become standardised into four different stages beginning 
with the Phase I or early trial. During this introductory 
study one or several dose schedules are investigated to 
determine the toxicities of the drug in man, with particular 
reference to their predictability and reversibility. In 
addition, by virtue of gradual escalation from a starting 
dose, caclulated from animal toxicology studies, a maximal 
tolerated dose and the dose limiting toxicity are defined, 
leading to the recommendation of a dose regimen which is 
associated with acceptable side effects (Monfardini S. et al 
1981, G e h a n e  A. & S c h n e i d e r m a n  M .A . 1982). T he
establishment of antitumour effect is not the purpose of the 
appraisal at this stage (Carter S.K. Selawry 0. & Slavik M.
1977) but is often sought none the less, if only to 
encourage the investigators. A recent study of a large 
number of patients receiving "Phase I" drugs under the 
auspices of the National Cancer Institutes (USA) showed an 
overall low response rate (-2%). It is perhaps noteworthy 
that not one of the drugs which was inactive in "Phase I" 
had become established clinically (Von Hoff D., presented at 
the Fourth NCI-EORTC Symposium on New Drugs in Cancer 
Chemotherapy, December 1983).
\ ^
This generalised plan for transition from animal to 
patient treatment with cytotoxic agents is useful, but not 
ideal, and open to criticism. Until recently, in the-USA,'
/ ;■ ' ■"'54
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preclinical toxicology screens were far more extensive than 
in the UK, involving several animal species, of which one 
had to be non-rodent. The starting dose for man was 
estimated at one third the minimal toxic dose, in milligrams 
per square metre of body surface area, of the most sensitive 
large animal species (Garter S.K. et_ al 1977). SOme workers 
felt that such screening was wasteful and rarely helpful in 
predicting toxicity in the clinic (Rozencweig M. et a_l 1981) 
with sufficient data being obtainable from rodent studies. 
(Guarino A.M. et al 1979)
The number of different dose schedules to include and 
the option of dose escalation within patients are other 
areas open to discussion when a balance between medical 
resources and scientific exactitude is sought (Carter S.K. 
et al 1977). The other crucial question is whether or not 
it is always justifiable to seek to distinguish a maximal 
tolerated dose or the limiting toxicity if a more precise 
biochemical end point is relevant. For example, when 
considering the evaluation of a thymidylate synthetase 
inhibitor, finding a dose which substantially reduces plasma 
thymidine levels might be a more satisfactory point at which 
to terminate the dose escalation than at the development of 
an unacceptable toxicity, which could be attributable to the 
physical properties of the compound.
The Phase I trial of CB3717 began in September 1981 at 
the Royal Marsden Hospital and Charing Cross Hospital. 
Curative antitumour activity in mice necessitated a five day 
treatment regimen (see Chapter I) and it is generally 
believed that cycle specific drugs such as antimetabolites 
have more therapeutic effect if given in repeated doses or 
by long infusion when there is the possibility of affecting 
more cells at the susceptible stage of cell division - S
; J;  ^_ > j
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phase (Connors T.A. 1976). Hence both five day and one day 
treatment schedules repeated at three week intervals, were 
investigated in order to balance scientific dictum with 
practical considerations. The starting dose, calculated as 
less than one third the LD10 in mice e x p r e s s e d  as 
units/surface area, was lOOmg/m'v
II.2 Materials and Methods
II.2.a Drug Formulation
CB3717 (N- (4- (N- ((2~amino-4-hydroxy-6“quina'xolinyl)methyl) 
prop- 2 -ynylaming)benzoyl)-L-glutamic acid)was synthesised by 
Imper ial C h e m i c a l  I ndustries PLC (Macclesfield Park, 
Wilmslow, Cheshire) as the anhydrous diacid powder which was 
96.72% pure as determined by protonmagnetic resonance, 
u l t r a - v i o l e t  s p e c t r o s c o p y  and high p r e s s u r e  liquid 
chromatography. The impurities comprised H^O (2.06%) Cl~ 
(0;26%) CB3705, the unsubstituted species (0.44%), a
first unknown impurity (0.33%) and a second unknown impurity 
(0.19%). None of the known impurities were considered to 
have biological effects at the doses to be used. The small 
q u a n t i t y  of u n k n o w n  i m p u r i t i e s  were p r o b a b l y  not 
quinazolines as the spectroscopic properties were different. 
CB3717 was formulated at a concentration of lOmg/ml in 0.15M 
sodium bicarbonate adjusted to pH 9.0 with sodium hydroxide 
and was sterilised by millipore filtration by the pharmacy 
staff of the Royal Marsden Hospital (Fulham Road, London). 
It was then stored at 4°C for a maximum of 21 days over 
which period stability studies had shown no detectable 
degradation of the material. The dose to be administered to 
individual patients was diluted to a volume of 250ml in 
0.15M sodium bicarbonate (pH 9.0) for infusion into a 
peripheral vein over 1 hour. Volumes of 1 litre 0.15M
c  ■
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sodium bicarbonate'were used for 1 2  hour infusions.
11.2.b Patient Characteristics
Patients with malignant disease who had failed on 
c o n v e n t i o n a l  c h e m o t h e r a p y  and p a t i e n t s  for w h o m  no 
satisfactory chemotherapy existed were recruited to the 
study. Verbal consent was obtained. Wherever possible the 
conventional criteria for inclusion were upheld (Hb > 
100g/l, WBC >3 x 10^/1, platelets >100 x 10^/1, normal blood 
urea, electrolytes, creatinine and liver function tests,
C 1
glomerular filtration rate >60ml/min as determined by Cr 
EDTA clearance, perforinance status WHO grade <2 and absence 
of serious intercurrent disease). Patients with hepatic 
d y s f u n c t i o n  secondary to m e t a s t a t i c  disease or renal 
impairment.were also included at low dose levels, as were a 
few of poor performance status, subject to the discretion of 
the physician. The characteristics of the patients included 
in' the study are summarised in Tables II.1 and II.2. The 
trial was approved by the Ethical Committee of The Royal 
Marsden Hospital.
11.2.c Dose Escalation
In the early stages of the study two schedules were 
adopted using a starting dose of 1 0 0 mg/m^.
Schedule A - 1 hour i.v. infusion lOOmg/m’6 x5 
days Q 3 weeks .
Schedule B - 1 hour i.v. infusion lOOmg/m xl 
day Q 3 weeks
Three patients were entered at each dose level and if no
57
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TUMOUR TYPE
Lymphoma 4
Choriocarcinoma . 1
Adult Lymphocytic Leukaemia 1
Acute Myeloid Leukaemia 1
Squamous Cell Carcinoma Bronchus 1
Ovarian Carcinoma 1
Teratoma 1
Primary Unknown 1
TOTAL 11
Age Range 13-73 Median Age 42
M:F 7:4
WHO PERFORMANCE STATUS 
Grade
1%
20%
50%
0%
30%
0
1
2
3
4
TABLE.11.1: Characteristics of Patients Treated by 5 Day
Schedule
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TUMOUR TYPE
Ovarian Carcinoma 
Melanoma
41
13
1 1Breast Carcinoma 
Colonic Carcinoma 5
Adenocarcinoma Bronchus 5
Hepatoma 1
Myeloma 1
Fibrosarcoma 1
Liposarcoma 1
Osteosarcoma 1
Apudoma 1
Squamous Cell Carcinoma 1
Teratoma/Seminoma 1
Choriocarcinoma 1
Hypernephroma 1
Primary Unknown 2
TOTAL 99
Age Range 22-74 Median Age 52
M: F 31:68
WHO PERFORMANCE STATUS 
Grade
Mesothelioma
Lymphoma
Large Cell Bronchus
5
4
3
0
1
2
3
4
7%
30%
36%
22%
4%
TABLE II.2: Characteristics of Patients Treated by 1 day 
Schedule
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significant toxicity occurred the dose was escalated in- the 
sequence shown in Tables II.3 and 11.4. Doses we r e  
e s c a l a t e d  in i n d i v i d u a l  p a t i e n t s  w h e r e  p o s s i b l e .  
M o d i f i c a t i o n s  were made to the schedules wh e n  the 
development of toxicity necessitated. The 5 day regimen was 
used in 11 patients reaching a top dose of 170mg/m^ x5 but 
was accompanied by a high incidence of myelosuppression, 
unpredictable hepatic dysfunction and malaise, so was 
discontinued (see Results section). In addition,, the 
observation of transient hepatic dysfunction in the majority 
of patients treated by a single infusion constrained the 
dose escalation (see Results section) and attempts were made 
to ameliorate this toxicity, the mechanism of which was 
unknown. It was postulated that a biliary precipitate might 
be induced by CB3717 treatment when high peak plasma levels 
were achieved, as such a process had been observed in rats 
(Newell DR et a_l 1982). This could be contributory to 
disturbance of liver function. Reduction of peak drug 
levels in the plasma by prolongation of the infusion to 1 2  
hours was thus deemed logical and 18 patients were treated 
in this manner. Further, two pat i e n t s  c o n c u r r e n t l y  
receiving steroid therapy were noted to have been spared the 
hepatic toxicty and associated m a l a i s e  and so on an 
empirical basis another schedule was introduced, comprising 
the administration of prednisolone 30mg daily for one week 
after CB3717 treatment, beginning the day after infusion. 
The outcome of these schedule manipulations is presented in 
the results section.
Patients with impaired renal function (glomerular 
filtration rate (GFR) <60ml/min) and grossly abnormal liver 
function tests (alkaline phosphatase >200 IU/1) were treated 
at reduced levels. These precautions were introduced in the 
face of the anticipated development of renal toxicity (as
60
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Dose (mg/m^) Total No. Doses Given
75a 3
1 0 0 5
140 9
170 1
aDose reduced to 75mg/m^ in 3 patients because of 
unacceptable toxicity at higher doses.
TABLE II.3 : Dose Escalation in 5 Day Schedule
S
?
Dose (mg/m ) Total No. Doses Given
140 3
200 41
280 13
300 63
330 12
360 16
400 70
450 36
500 24
550 6
600 1 1
a700 1
a700mg/m Administered in error
TABLE II.4 : Dose Escalation in 1 Day Schedule
predicted by the animal toxicology study described in 
Chapter I) and the early evidence of hepatic toxicity during 
the trial.
The 99 patients who entered the single dose schedule 
trial received a total of 296 doses. -'Fifty- four patients 
were treated by 1 hour infusion (172 courses), eighteen by 
12 hour infusions (41 courses) and twenty seven by 1 hour 
infusion with steroid cover (83 courses). Twenty nine 
patients received only 1  course, thirty three patients 
received two courses, and the rest received between 3 - 2 0  
courses.
II.2.d Patient Monitoring
Full blood counts, serum urea, e lectrolytes, 
creatinine, liver function tests, protein, albumin, calcium, 
phosphate and prothrombin times were measured prior to 
treatment and twice weekly thereafter (extended to weekly at 
later stages of the trial). Renal function was monitored by 
estimation of the glomerular filtration rate by ~*^Cr EDTA 
clearance (Chantler C. e_t a_l 1969) prior to starting 
treatment and 2-3 weeks after each treatment. In 14 
patients the enzymes N-acetyl JB-glucosaminidase (NAG) and 
leucine am inopept idase (LAP) in add i t i o n  to JB2 
microglobulin levels were measured in urine collected pre­
treatment and on days 1,3,5,7,10,14 and 20 post treatment 
(Jones B.R. ejt a_l 1980 and using radioimmunoassay test 
Pharmacia, GB Ltd). Disease response was evaluated weekly, 
when feasible, by clinical examination and measurement of 
tumour masses. Radiography, 'ultrasonic, isotopic and 
computer assisted tomographic scanning were repeated at 
appropriate intervals.
63
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II.3 Results of 5.Day Schedule
II.3a Myelotoxicity
This treatment regimen, using a starting dose of
O . ......
lOOmg/m administered on 5 consecutive days, was associated 
with considerable toxicity of an unpredictable pattern and 
necesitated dose reduction in 3 patients. Myelotoxicity, 
affecting mainly leucocytes and platelets, occurred after 7 
of the total 18 courses and was contributory to the death of 
4 patients. Details of the leucopenia and thrombocytopenia 
observed are shown in Table II.5 and II.6 . One patient with 
squamous cell bronchial carcinoma tolerated his first course
a  - ...
of lOOmg/m x5 but developed myelosuppression on the second 
course of I40mg/m^ x5. His third course of lOOmg/m^ x5 was 
also associated with myelotoxicity as.was his fourth dose of 
7 5 m g / m *  x5. E x a m i n a t i o n  of his m a r r o w  r e v ealed no
carcinomatous infiltration, and he had received no prior 
chemotherapy or radiotherapy. Another patient received only 
3 days of treatment at at a dose of 100mg/m^ and developed 
leucopenia (0.2xl0^/l) and thrombocytopenia (93x10^/1) on 
day 10. She subsequently received a second course of 
75mg/m^ on 3 days and died 9 days later with profound 
leucopenia (<0.1xl0^/l) and thrombocytopenia (9xl0^/l). She 
h a d  p r e v i o u s l y  b e e n  t r e a t e d  w i t h  a d r i a m y c i n ,  
cyclopho.sphamide, cisplatinum, and chlorambucil and had 
undergone whole abdomen irradiation so that her marrow was 
undoubtedly compromised at the outset. The one patient 
treated at 170mg/m^ had been subjected to 6  cycles of
64
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Dose No. of Courses Associated
mg/m2 with Leucocyte Toxicity Grade:
0-1* 2 3 4
75 0 0 la 2 bc
1 0 0 - 3 0 0  2
140 8 0 0  1
170 0 0 0  ld
Toxicity Grade: 0-1 = >3x10^ cells/1*
2  = ' 2 - 2 .9x10* cells/ 1
3 = 1-1.9x10 cells/1
4 = <1x10 cells/1
Nadir Day 9-13 x 11 
Recovery Day 14-18 x 17
f*Toxic death day 9 
Toxic death day 10 
^Toxic death day 12 
dToxic death day 13
*Criteria for treatment WCC >3.0xl0^/l
TABLE II.5: Toxicity To Leucocytes - 5 Day Schedule
(2 Leukaemia Patients Excluded From 
The Table)
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Dose^
mg/m
Number of Courses Associated With
Platelet Toxicity Grade:
0 1 2 3 4
75 0 0 1 0 2
1 0 0 3 1 0 1 0
140 8 0 0 0 0
170 0 0 0 0 1
Toxicity Grade 0 = >100x10 platelets/1
1  = 75-99x10^ platelets/1
2 - 50-74x10^ platelets/1
3 = 25-49x10 platelets/1
4 = <25x10 platelets/1
Nadir Day 8-12 x = 10
Recovery Day 12
^Toxic death day 9 
Toxic death day 10 
cToxic death day 13
TABLE II.6 : Toxicity To Platelets - 5 Day Schedule (2
Leukaemia Patients Excluded From The Table)
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cisplatinum, vinblastine and bleomycin chemotherapy followed 
by abdominal radiotherapy f o r :a testicular teratoma. He 
became severely myelosuppressed (leucocytes O.lxlO^/ 1 , 
platelets '9‘xl 0^/1) and died on day 12.
Haemoglobin values fell appreciably after 6  courses, 
(details Table II.7) which in one case was definitely 
a s s o c i a t e d  with g a s t r o i n t e s t i n a l  b l e e d i n g  d u e  to 
thrombocytopenia. It may be significant that the 4 non 
leukaemic patients who e x p e r i e n c e d  m y e l o t o x i c i t y  had 
elevated plasma alkaline phosphatase levels before treatment 
started (245, 375, 500, 900 IU/l).
II.3.b Hepatotoxicity
The first p a t i e n t  treated with CB3717 d e v e l o p e d  
elevation of plasma alanine transaminase (ALT) levels 
heralding the appearance of mild hepatic dysfunction as the 
most frequently observed toxicity in the whole study. The 
pattern of ALT elevation in this choriocarcinoma patient is 
s h o w n  on Fig II.1 along with the p  h u m a n  c h o r i o n i c  
gonadotrophin (J3HCG) levels which were used as a marker for 
her tumour. After the more pronounced rise in plasma ALT 
(peak value 769 IU/l) following the second treatment at 
140mg/m^ x5, a third course was administered at the same 
total dose by a continuous 120 hour infusion. On this 
occasion, ALT levels did not rise .further and gradually 
returned towards normal.
Fourteen of the eighteen 
associated with abnormalities 
detailed in Table II.8 ) with no 
Alkaline phosphatase values were 
normal pre-treatment levels bu
courses of treatment were 
of transaminase levels (as 
apparent dose relationship, 
unaffected in patients with 
t in 3 patients with raised
\
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Number of Courses Associated With 
Dose • Haemoglobin Toxicity Grade:
mg/m
0 1 2 3 4
75 0 0 3a 0 0
1 0 0 0 4 1 0 0
140 6 1 1 0 o
170 0 0 0 , 1 0
aFall
loss
in haemoglobin associated with 
secondary to thrombocytopenia
gastrointestinal blood
Toxicity Grade 0 = > 1 1 0 g/l
1 = 95-109g/l
2 = 80-94g/l
3 = 65-79g/l
4 = <65g/l
TABLE II.7 : Haemoglobin Toxicity - 5 Day Schedule
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Dose
mg/m 2
No. of Courses Associated With Alanine 
Transaminase Elevations:
75 2 1 0 0  0
1 0 0 " ■ 1 - 2 e lc
o(N
140 1 3 0 1 3ad
170 0 0 0 1 0
Toxicity Grade 0 = <1.25x normal (<27.5IU/1)
1 = 1.25-2 .5x normal (27.5-55IU/1)
2 = 2.5-5X normal (55-110IU/1)
3 = 5-1Ox normal (110-220IU/1)
4 = >10x normal (>220IU/1)
^Elevation to 769IU/1 
Patient had ALT of 46IU/1 before treatment
^Patient had ALT of 55IU/1 before treatment
Patient had ALT of 43IU/1 before treatment
ePatient had ALT of 28IU/1 before treatment
TABLE II.8 : .Peak Plasma Alanine Transaminase Levels After
CB3717 Treatment - 5 Day Schedule
S'
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levels (245, 340 and >500 IU/L) two fold elevations occurred 
after CB3717. Hyperbilirubinaemia was seen after one course 
at 75mg/m x5, (60 IU/l), and after another course at
o
17 0 m g / m  x5, (72 IU/l) in two p a t i e n t s  with m a s s i v e
metastatic involvement of the liver and abnormal pre­
treatment alkaline phosphatase levels.'
11.3.c Malaise
The development of abnormal liver function tests 
coincided with feelings of malaise, lethargy and anorexia 
necessitating bed rest in 8  patients, although in some this 
was also associated with periods of myelosuppression.
11.3.d Dermatological Toxicity
Five patients developed rashes which, in three cases, 
were itchy, erythematous and maculopapular, localised to the 
trunk and proximal part of the arms and legs and appeared 3- 
4 days post treatment. Figure II.2 is a photograph of one 
such patient. Symptomatic relief was obtained with oral 
antihistamines and local hydrocortisone cream. One patient 
later tolerated a further course of CB3717 without the 
d e v e l o p m e n t  of a rash after he had been started on 
p r e d n i s o l o n e  1 0 mg b.d as a m e a n s  of c o n t r o l l i n g  
hypercalcaemia and improving appetite.
\
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.FIGURE II.2: Erythematous Maculopapular Rash In a
Patient Treated With 140mg/m2 CB3717 
for 5 Days
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A patient with adult lymphocytic leukaemia noticed a 
slight acneiform rash on his face, similar to one he had 
previously experienced when on methotrexate therapy. One 
other patient, with acute myeloid leukaemia, developed a 
purpuric rash on his abdomen and the flexures of his limbs 
t w o  d a y s  a f t e r  f i n i s h i n g  the t r e a t m e n t  c o u r s e .  
Thrombocytopenia was a feature of his disease (pre-treatment 
platelets 80x10^/1, platelet nadir 19x10^/1 day 4, platelets 
27x10^/1 on the day of rash appearance).
11.3.e Gastrointestinal Toxicity and Mucositis
Mucositis with oral ulceration occurred in two patients 
coincidentally with periods of myelosuppression and was 
associated with oral fungal infection.
Two patients with lymphomatous bowel involvement 
developed diarrhoea and in one this continued from day 1  of 
t r e a t m e n t  until his death (attributed to p r o g r e s s i v e  
disease) 8  days later.
11.3.f Miscellaneous Toxicities
Pancreatitis, with the formation of a pancreatic 
pseudocyst, complicated the second course of treatment of a 
patient with extensive intra-abdominal lymphoma. This was 
most probably related to enlarging peri-pancreatic lymph 
nodes and pancreatic metastatic involvement or possibly to 
concurrent dexamethasone treatment (Cluff L.E. and Caldwell 
J.R. 1977). Another patient developed an unexplained 
pyrexia on day 1 0  with an exacerbation of the erythematous 
maculopapular rash which had appeared on day 7 .
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II.3 .g Renal Toxicity
Elevation of blood urea or creatinine levels was not 
seen except in two patients succumbing to progressive 
disease and myelotoxicity. They had pre-terminal rises in 
blood urea levels (16mmol/l) but this was not thought to be 
drug related. ~*^Cr EDTA clearances were not repeated, 
unfortunately, in 8  patients because of disease progression, 
or patient death.
11.3.h Antitumour Effects
Two patients with lymphoma had short-lived, minor 
responses with some reduction (<50%) in the size of involved 
lym p h  node masses. One patient with s q u a m o u s  cell 
bronchial carcinoma experienced disease stabilisation for 1 0  
weeks. The patient with adult acute lymphocytic leukaemia 
developed a hypocellular marrow with regrowth of blasts 
subsequently.
II.4 Results of 1 Day Schedule
11.4.a Renal Toxicity
Renal toxicity was assessed by m e a s u r e m e n t  of 
glomerular filtration rates, (GFR), as this is a much more 
sensitive indicator of renal function than blood urea or 
creatinine. Seventy patients with adequate renal function 
(GFR >60ml/min) were treated and repeat ^ C r  E D T A  clearances 
were obtained on forty four at cessation of treatment, 
which involved between 1 and 20 courses. Fourteen patients 
with pre-treatment GFR 41-60ml/min and fifteen patients with 
pre-treatment GFR <40ml/min were also treated at doses up to 
400mg/m and 300mg/m^ respectively. Follow-up GFR data was
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collected on 7 and 12 patients from these groups. Table
II.9 shows the reductions in GFR which occurred at different
dose levels. Excluding patients who developed worsening
renal function associated with pelvic disease, the majority
had slight reductions in GFR amounting to <20%. Five of the
good risk patients (GFR >60ml/min) treated at doses up to 
9450mg/m had reductions of 20-50% pre-treatment GFR values. 
At doses of 500-600mg/m^, reductions in GFR of 20-50% and 
>50% occurred more frequently indicating that renal toxicity 
was dose l i m iting for CB3717 (using this s c h e d u l e  of 
administration) with a maximal tolerated dose in the region 
of 600mg/m . Some variability of response to the higher 
doses was observed, p o ssibly related to the state of 
hydration of individual patients over the 24 hours post, 
treatment. One patient (pre-treatment GFR 119ml/min) 
treated at 600mg/m on 4 occasions showed no elevation of 
serum urea or creatinine until the day of her final 
treatment (urea 14.5 mmol/1, creatinine 204 mmol/1) and died 
of acute renal failure 3 weeks later (see Toxic Deaths 
section). In another patient the GFR fell from 95ml/min to 
60ml/min after one dose at 600mg/m but increased to 
83ml/min after two further doses at 400mg/m^. The numbers 
of patients in the poor risk groups were small but doses of 
200-300mg/m<6 were associated with GFR reductions of <20% in 
11/16 patients and reductions of 20-50% in 5/16 patients.
Urinary Enzymes
The levels of urinary enzymes (NAG and LAP) and ^ 2
microglobulin which were measured in fourteen patients
' '  9before and after doses of 300-500mg/m CB3717 are shown in
Figures II.3 II.4 and II.5 with a legend giving some details 
of the patients. Reported normal means (+2 SD) have been 
taken from BR Jones et_ aJ^  1980. Some of the patients had
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FIGURE,11.3; Urinary N-Acetyl Glucosaminidase Excretion 
In Patients Treated With CB3717
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Patient Number Pre-Treatment Course Number •
GFR ml/min
1 35 8  (previous Cisplatin,
carboplatin)
2  116 5
3 172 1
4 76 3
5 95 2
6  104 1
7 93 2
8  61 3 & 4
9 6 6  1
10 100 6 8  47 1, 3 & 5
1 1  61 1
1 2  128 1
13 50 3 (previous cisplatin,
carboplatin)
14 37 1 (previous cisplatin,
carboplatin)
Key For Urinary Enzyme Data (Figures II.3, II.4, II.5)
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S
raised levels of one or more of these parameters at the 
start of the treatment courses shown and in the case of 
patients 2,4,7 and 8 this may have been due to previous 
treatment with CB3717. A consistent pattern of disturbance 
was not apparent but approximately 50% of the treatments 
were associated with some elevation of urinary enzymes 
indicative of renal damage. The numbers were too small to 
establish a dose relationship.
II.4.b Hepatic Toxicity
Transient elevations in plasma alanine transaminase 
levels (similar ..to those described following 5 day treatment 
schedules) occurred frequently (see Table 11.10) after 
single infusions of CB3717, usually beginning on day 2-3 and 
peaking on days 10-21. In addition, ALT levels generally 
rose higher with successive courses of CB3717, but in 
thirteen patients who received more than 4 treatments, 
enzyme levels began to return towards normal by the fifth to 
sixth course (example shown in Fig.II. 6 ). No dose 
relationship was evident as demonstrated in Figure II.7 and 
Table 11.11. Comparison of the group of patients who had 
near normal liver function tests prior to treatment (ALT and 
alkaline phosphatase <1.25 x normal) with the group who had 
abnormal liver function tests (alkaline phosphatase >1.25 x 
normal but ALT normal) did not reveal any significant 
difference in ALT elevation after treatment (x^=4.86 p=0.4) 
Table 11.12).
Increases in plasma alkaline phosphatase levels were 
induced by CB3717 treatment but to a lesser extent than 
for ALT. Table 11.13 gives details of this in those 
patients whose pre-treatment alkaline phosphatase levels 
were <1.25 x normal. Neither prolongation of the infusion
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First Course Number of Courses With ALT Toxicity Grade: 
Dose (mg/m )
0 1 2 3 4
140 - 2
200 - 5 3 2 1
280 2  - 1  1
, 300 9 9 9 9 3
330 1 1 1 1
360 - - 2 1
400 4 6  4 3
450 1 2 - - -
500 “ 2 2 3 1
600 2  1  1  - -
Toxicity Grade: 0 = <1.25 x normal (<27.5 IU/1)
1 = 1.25-2.5 x normal (27.5-55 IU/1)
2 = 2.5-5 x normal (55-110 IU/1)
'3 = 5-10 x normal (110-220 IU/1)
4 = >10 x normal (>220 IU/1)
♦ \ ■ ^
TABLE 11.11: Peak Plasma Alanine Transaminase Levels After
First Courses of CB3717 - 1 Day Schedule
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S
ALT Toxicity Grade
0 1 2 3 4
Pre-treatment ALT 
& Aik. P. Normal . 
(<1.25 x N)
54 65 46 25 1 1
Pre-treatment ALT 
Normal, but Aik P 
Abnormal (>1.25 
x N)
9 23 17 1 1 4
x^ test = 4.86 P = 0.4
Toxicity grades 0 = <1.25x normal (<27.5 IU/1)
1 = 1 . 2 5 - 2 . 5x normal (27.5-55 IU/1)
2 = 2.5-5X normal (55-110 IU/1)
3 = 5-10x normal (110-220 IU/1)
4 >10x normal (>220 IU/1)
TABLE 11.12: Comparison of Plasma Alanine Transaminase
Elevation After CB3717 Treatment in Groups of Patients With 
Normal and Abnormal Alkaline Phosphatase Levels Prior to 
Therapy
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to 1 2  hours nor the administration of prednisolone for one 
week after treatment made a significant difference to the 
patterns of enzyme abnormality observed (see Table 11.14) 
(x2  = 2.96, 0.9>p> 0.5, x 2  = 5.23 , 0.5>p>0.1)
Hyperbilirubinaemia (mainly conjugated) occurred after 
18 courses (details on Table 11.15) in seventeen patients. 
Three patients were retreated with no further episodes of 
hyperbilirubinaemia but one other patient experienced 
elevation in bilirubin after 2 courses. Ten of these 
patients had pre-treatment alkaline phosphatase levels >300 
IU/1 and metastatic hepatomegaly.
P r o t h r o m b i n  t i me s were n ot p r o 1onged ex c e p t  in 
jaundiced patients. Serum albumin levels were low prior to 
treatment in the majority of patients and this made it 
difficult to interpret the effect of CB3717, although no 
marked fluctuations in levels occurred.
II.4.c Myelotoxicity
Myelosuppression developed sporadically throughout the 
dose escalation and, as in the 5 day schedule, affected the 
leucocytes and platelets. Leucopenia (WBC <3.0xl0^/l) 
occurred in seventeen patients and thrombocytopenia in six, 
with mean nadir on days 10 and 9 and recovery by days 15 and 
.13 respectively (see Table 11.16 for details). Impaired 
r e n a l  f u n c t i o n  w a s  a p o s s i b l e  r i s k  f a c t o r  for 
myelosuppression as of the eight patients with nadir WBC 
<lxl0^/l, three had pre-treatment GFR of 41-60ml/min and 
three had pre-treatment GFR 21-4Oml/min. Eight of the 
seventeen patients had alkaline phosphatase levels of 
>200IU/1 (4 of which were >400IU/1) and one patient had a 
raised serum bilirubin.
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s
Aik. P. Toxicity Grade:
0 1 2 3 4
No. of Courses 78 97 28
Toxicity Grades 0 - <1.25 x normal (<118 IU/1)
1 = 1.25-2.5 x normal (118-315 IU/1)
2 = 2.5-5 x normal (315-475 IU/1)
3 =  5-10 x normal (475-950 IU/1)
4 = >10 x normal (>950 IU/1)
TABLE 11.13: CB3717-Induced Elevation of Plasma Alkaline 
Phosphatase Levels in Patients- With Normal Pre-Treatment 
Alkaline Phosphatase Levels (<1.25 x normal)
88
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Treatment
Schedule
0
ALT
1
Toxicity
2
Grade 
3 4
A 1 hour 1 1 15 1 0 10 3
B lh + 1  week 
prednisolone 1 0 6 5 1 1
C 12 h 2 5 5 3 3
A vs. B x 2  = 5.23 p >0.05 (0.5> p>0.1) 
A vs. C x 2  = 2.96 p >0.05 (0.9> p>0.5)
0  = <1.25 x normal
1  = 1.25- 2.5 x normal
2  = 2.5-5 x normal
3 = 5-10 x normal
4 = > 1 0  x normal
TABLE 11.14: CB3717 Hepatotoxicity - Comparison of The
Effect of 1 Hour Infusions, 12 Hour Infusions And 1 Hour 
Infusions With Steroid treatment On Peak Plasma Alanine 
Transaminase Levels After First Courses
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Bilirubin Toxicity Grade
0 1 2 3 4
No. of Courses 270 11 5 1 1
0 = <1.25 x normal (<21mmol/l)
1 = 1.25-2.5 x normal (17-42.5mmol/l)
2 = 2 . 5 - 5  x normal (42.5-85 mmol/1)
3 = 5-10 x normal (85-170 mmol/1)
4 = >10 x normal (>170 mmol/1)
TABLE 11.15: Hyperbilirubinaemia After CB3717 Treatment
(One Day Schedule)
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Haemoglobin values fell below 100g/l with 47 courses of 
treatment (16%) but generally recovered in time for further 
treatment and rarely necessitated transfusion (details on 
Table 11.17) .
11.4.d Malaise
Approximately 75% patients experienced malaise with 
symptoms of anorexia, lethargy, depression and occasionally 
mild nausea, rather. similar to the prodroma 1 phase of 
hepatitis. In mo s t  cases the severity of m a l a i s e  
parallelled the disturbance in liver enzyme levels and 
lasted between days 3-14 but a few patients who had only 
trivial or no elevation in ALT levels still experienced 
co n s i d e r a b l e  c o n s t i t u t i o n a l  upset. C o n v e r s e l y  a few 
patients with marked enzyme elevations were apparently 
una f f e c t e d  in this respect. A o n e w e e k  course of 
prednisolone, 30mg daily, was of some help in preventing 
malaise (although not universally) and was administered to 
patients who were particularly distressed by the symptoms.
11.4.e Dermatological Toxicity
Twelve patients developed an irritating erythematous 
maculopapular rash of varying severity on the trunk and 
limbs (see Fig. II.2) which progressed to exfoliation on one 
occasion. One patient experienced an immediate urticarial 
reaction lasting for 2 hours after an infusion of CB3717 and 
later developed a purpuric rash-on the extensor surface of 
her limbs. Interestingly, no patient receiving, prednisolone 
for one week after their CB3717 treatment developed a rash.
A radiation recall rash was seen in 2 patients, one of 
whom had been irradiated with inverted Y and axillary fields
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Platelet Toxicity GradeLeucocyte Toxicity GradeDose 
mg /m
200 40
300 57 61
10330 11
16360 15
67 69
550
600
Nadir day 7-16, x =_10 
Recovery Day 11-19 x = 1 5
Nadir day 7-11, x =_9 
Recovery Day 11-15 x=13
Toxicity Grades:3: 0*1
lJ
Leucocytes
>3.0xl09 /la
2-2.9xl0®/l 
1 - 1 .9x10/1 
<1 .0 x1 0 / 1
Platelets
>1 0 0 xl 0 9/l
75-99xl09/l
50-74x 109/1
25-49x10/1
<25x109/1
^Criteria for inclusion to study WCC >3.0xl09/l 
bDose levels not associated with leucopenia or 
thrombocytopenia are omitted
TABLE 11.16: Leucocyte and Platelet Toxicity After CB3717
One Day Schedule
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Haemoglobin Toxicity Grade
0a la 2 3 4
No. of Courses 164 80 41 5^
aCriteria for inclusion to study Hb >100g/l 
One patient with sickle cell trait
Toxicity Grades: 0 = >110g/l
1 = 95-110g/l
2 = 80-94g/l
3 = 65-79g/l
4 = <65g/l
TABLE 11.17: Haemoglobin Toxicity After CB3717 Treatment
(One Day Schedule)
\
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six years previously. Her first treatment of CB3717 at 
2 0 0 mg/m gave rise to a slight burning sensation only but a 
second dose resulted in vivid erythema over the radiation 
sites (see Fig. II.8 ). The dermatological toxicities were 
not dose related.
11.4.f Gastrointestinal Toxicity and Mucositis
Nausea and vomiting were not problematic acutely but 
three patients experienced nausea with intermittent vomiting 
and d i a r r h o e a  for 2-3 days in the first we e k  after 
treatment, which may have been associated with infective 
episodes. Two patients complained of a sore mouth with some 
mucosal erythema and three patients complained of gritty 
eyes although their conjunctivae appeared normal.
11.4.g Miscellaneous Toxicities
Two patients experienced 'flu-like symptoms with 
myalgia and pyrexia for 2-3 days after treatment and one 
case was associated with a rash. Severe abdominal pain 
occ u r r e d  in two patients, one of w h o m  had m a s s i v e  
hepatomegaly and one other patient, treated with eOOmg/m* of 
CB3717, experienced loin pain between days 2-7. Another 
patient, with a pleural mesothelioma extending into the 
peritoneum, developed hepatic and pleuritic pain with rubs 
heard over these areas, in a s s o c i a t i o n  wi t h  p r o f o u n d  
malaise, on two occasions, 1-2 days post treatment. He 
tolerated 3 further courses, with prednisolone cover, 
uneventfully. ,
\
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FIGURE II.8: Radiation Recall Reaction In A Patient
Treated With Two Doses of CB3717 at 
200mg/m2
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II.4.h. Toxic and Early Deaths
T wo deaths were a t t ributable to drug related 
toxicities.
Patient 1. A 72 year old man with recurrent colonic
carcinoma causing sub-acute intestinal obstruction, who had
■ 7hepatic metastases, received two doses of CB3717 at 330mg/m^ 
by 12 hour infusions. The first t r e a t m e n t  was w e l l
tolerated but gave rise to modest elevation of plasma ALT to 
67 IU/1. A f t e r  the s e c o n d  dose, a p e r i o d  of
myelosuppression ensued (WBC 0.6 xlO^/1, platelets 34 xlO^/1 
day 7), associated with his general decline and obvious 
disease progression. Supportive m e a s u r e s  were not
instituted. Post mortem examination confirmed the presence 
of large tumour masses in the pelvis, abdomen and liver. 
Microscopic examination of liver tissue distant from 
metastases revealed pathology characterised by fatty change, 
cholestasis and the presence of Mallory bodies (mainly 
centrilobular in distribution). General liver architecture 
was well maintained. Professor P.J. Scheuer (Royal Free 
Hospital, London) reviewed these sections and confirmed the 
findings to be similar to those seen with a l c o h o l i c  
hepatitis, diabetes and obesity or caused by the drugs 
perhexilene maleate and stilboestrol. Macroscopically the 
kidneys were normal, but microscopic examination was 
unsatisfactory due to severe autolysis.
Patient 2. A female with stage III ovarian carcinoma 
(resistant to cisplatinum, chlorambucil, treosulphan and 
carboplatin (JM8 )), giving rise to a large abdomino-pelvic 
mass, was treated with the top dose of CB3717 used 
(600mg/m^), infused over 1 hour. Her pre-treatment ^ C r  
EDTA clearance was 119ml/min. Unfortunately, an exceptional
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breach of protocol resulted in her being retreated with 3 
more doses of 600mg/m^ before her glomerular filtration rate 
was reassessed and was found to be 25ml/min. She had shown 
signs of disease response and her serum urea and creatinine 
values had remained normal until the day of her fourth 
treatment when urea was 14.5mmol/l and. creatinine 204mmol/l. 
Ten days later the patient was admitted to hospital with 
worsening renal function (urea 33.4 mmol/1, creatinine 
447 m m o l / 1 ) , h y p e r b i l i r u b i n a e m i a  (46 m m o l / 1 ) , and 
myelosuppression (WBC nadir 0.2 xlO^/1, platelet nadir 69 
xlO^/1). The period of leucopenia lasted 10 days and the 
development of septicaemia necessitated the administration 
of gentamicin and piperacillin. Her renal function did not 
recover and her serum bilirubin increased to 77 mmol/1, 
although ALT and alkaline phosphatase levels returned to 
normal values. She died 21 days after her final treatment 
(urea 45.7mmol/l, creatinine 537mmol/l, bilirubin 70mmol/l). 
Post m o r t e m  e x a m i n a t i o n  revealed well differentiated 
mucinous cystadenocarcinoma - of the ovary with
widespread intraperitoneal tumour and hepatic metastases. A 
3cm mass was present in the pelvis posterior to the bladder 
and in the right subdiaphragmatic area. A 2cm mass was 
found adjacent to the common bile duct, but there was no 
evidence of obstruction. Disseminated candidiasis gave rise 
to granulomata in the lungs, heart and liver but no other 
hepatic pathology was described. The kidneys showed changes 
of i s c h a e m i c - t y p e  tubular necrosis with a d d i t i o n a l  
granulomatous abscesses. Marked hypoplasia of all elements 
in the bone marrow was observed..
Eleven patients died within 3 weeks of treatment but 
this could not be attributed to any drug associated toxicity 
and was thought to be' due to progressive disease in all 
cases.
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II.4.i Antitumour Effects
Patients were deemed evaluable for response assessment 
if they had m e a s u r a b l e  tumour m a s s e s  (clinically or 
radiographically) and received two or more courses of 
treatment. In addition, patients who received only one 
treatment but who had clearly progressive disease were 
included. Details of the responses are shown in Table
11.18. Antitumour effects were observed at doses as low as 
200mg/m . The case histories of the patients attaining 
complete and partial responses are described below.
II.4.j Case Histories of Complete and Partial Respnse 
Patients
I.G. was a 54 year old woman with stage III poorly 
differentiated adenocarcinoma of the ovary who had received 
previous treatment with cis-platinum, melphalan, carboplatin 
(JM8 ) and medroxyprogesterone. On beginning treatment with 
CB3717 she had a large a b d o m i n o - p e l v i c  mass causing 
intestinal obstruction. She received 13 courses of CB3717 
(1 at 400mg/m^, 11 at 450mg/m^ and 1 at 700mg/m^ in error) 
by 1  hour infusions and with prednisolone cover days 2 - 8 , 
which were well tolerated. Her tumour mass and ascites 
gradually resolved and after 9 treatments she attained a 
c o m p l e t e  response as d o c u m e n t e d  by abdojnino-pelvie 
ultrasound and clinical examination. Two months after 
cessation of treatment she relapsed with the development of 
ascites and multiple abdominal masses and failed to respond 
to further treatment at a dose of 600mg/m , dying of 
progress ive disease 12 days later. Her complete response 
lasted approximately 16 weeks.
S
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Tumour
Type
CR PR MR NC PD Total
Evaluable
Ovary 1 1 7 1 1 1 0 30
Breast - 3 1 2 2 8
Colon - - 2 3 - 5
Adenocarcinoma Bronchus - - 1 2 2 5
Large Cell Bronchus - 1 1 1 - 3
Lymphoma - - - -- 1 1
Mesothelioma - 1 1 1 2 5
Melanoma - ; - 3 9 1 2
Hepatoma - - , - 1 - 1
Primary Unknown — — — — 1 1
Choriocarcinoma - - ■. — - 1 1
Fibrosarcoma - - - - 1 1
Osteosarcoma - - - - 1 1
Apudoma - - 1 - - 1
Hypernephroma 1 1
CR = Complete Response —  The disappearance of all known 
disease for at least four weeks.
PR = Partial Response - 50% or more decrease in total
tumour size of the lesions which have been measured 
to determine the effect of therapy by two 
observations at least four weeks apart.
MR = Minor Response - 25-50% decrease in total tumour 
size of the lesions which have been measured to 
determine the effect of therapy.
NC = No Change - Less than 25% decrease in total tumour 
size and <25% increase in the size of one or more 
measurable lesions.
PD = Progressive Disease - A 25% or more increase in size 
of one or more measurable lesions, or the appearance 
of new lesions.
TABLE 11.18; Responses To CB3717 (One Day Schedule)
9?
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S.B. was a 6 6  year old female with recurrent breast 
carcinoma and a large left supraclavicular node mass. 
Treatment with tamoxifen failed and the combination of 
cyclophosphamide, methotrexate and 5-fluorouracil was poorly 
tolerated. Two courses of CB3717 at a dose of 4 00mg/m 2  were 
given (the second with prednisolone days 2 - 8 ) and she gained 
a partial response three weeks after the first treatment but 
relapsed six weeks later.
M.D. was a 53 year old female with recurrent breast 
carcinoma and multiple cutaneous erythematous lumps- on her 
trunk and neck. Prior therapy c o m p r i s e d  tamoxifen, 
aminoglutethimide, mitoxantrone, chlorambucil, predriisolone 
and v i n d e s i n e .  A p a r t  f r o m  a m i n o r  r e s p o n s e  to 
aminoglutethimide her disease had relentlessly progressed. 
She received seventeen courses of CB3717 (1 at 14 0 m g / m 2 , 2 
at 2 0 0 mg/m^, 1  at 280mg/m^, and a further 13 at 2 0 0 mg/m^ 
with prednisolone days 2 - 8 ) whilst continuing her part-time 
job as a nurse. The skin nodules gradually flattened and 
became paler. After seven courses she achieved a good 
partial response although cytology of the lesions remained 
positive (see Figures II.9 and 11.10). The response lasted 
46 weeks but relapse in the central nervous system became 
evident 4 months after cessation of CB3717 therapy. Re ­
treatment was not instituted and she died 4 months later.
B.B. was a 57 year old female with recurrent breast 
carcinoma who had soft tissue involvement in both breasts 
and metastatic hepatomegaly. Her disease was resistant to 
tamoxifen, adriamycin and vincristine. She had completely 
responded to c y c l o p h o s p h a m i d e ,  m e t h o t r e x a t e ,  and 5- 
fluorouracil* combinations initially but on relapse her 
disease proved refractory to. it. She received 3 doses of 
CB3717 (200mg/m‘6 plus prednisolone days 2—8) and after six
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weeks she had a greater than 50% reduction in both soft 
tissue disease and hepatomegaly. Shortly after her third 
course she became ill at home and died 4 weeks later. The 
cause of death was thought to be progressive carcinomatosis.
E.M. was a 71 year old female with stage IV ovarian 
carcinoma. Initial treatment with high dose cisplatinum
p
(lOOmg/m 4^ x5) resulted in a partial response but severely 
impaired renal function (GFR 35ml/min). The residual 
disease was resistant to chlorambucil, prednisolone and the 
p l a t i n u m a n a l o g u e ,  carboplatin (JM 8 ). At the start of 
CB3717 therapy she had a central abdominal mass and clinical 
ascites. Ultrasonic examination revealed pelvic and hepatic 
masses. T r e a t m e n t  with six courses of CB3 717 (1 at
200mg/m^, 1 at 280mg/m^, 3 at 330mg/m^ and 1 at 200mg/m^) 
caused the disappearance of the abdominal and pelvic masses 
al t h o u g h  a m e t a s t a s i s  could still be v i s u a l i s e d  by 
ultrasound in the right lobe of the liver. The patient^ also 
received continuous prednisolone (2 0 mg daily) which was 
instituted some months before CB3717 therapy was started. 
The ascites did not reaccumulate and after three treatments 
she was classed as a partial responder. Nine weeks after the 
last dose, she returned with ascites, an abdominal mass and 
multiple pulmonary metastases which proved resistant to two 
further doses of CB3 717 at 3 0 0mg/m^. She died of 
progressive disease having sustained a partial response for 
18 weeks.
B.E. was a 42 year old f e m a l e  w i t h  large cell 
bronchial carcinoma unresponsive to vindesine. A large 
subcutaneous tumour mass in the region of the left shoulder 
shrank by greater than 50% after the first treatment with
p
CB3717 at 300mg/m , given by 12 hour infusion. She received 
one more dose at 300mg/m^ and one at 360mg/m^. Her response
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FIGURE II. 9: Pre-Treatment Photograph of Patient With
Metastatic Breast Carcinoma
1 0 2
\
FIGURE 11.10; Photograph of Patient With Metastatic
Breast Carcinoma After 14 Treatments 
With CB3717 (140-280mg/m2)
103
was short-lived with regrowth occurring after 7-8 weeks.
D.A. was a 46 year old man with a pleural mesothelioma 
diagnosed in November 1981. After a period of disease 
stasis whilst receiving 14 monthly courses of carboplatin 
(JM8 ) enlargement of the mass visualised by chest x-ray led 
to the start of treatment with CB3717. Two treatments (1 at 
400mg/m , 1 at 450mg/m) resulted in a partial remission of 
the lung mass as determined radiologically and considerable 
symptomatic relief. A further 18 treatments at. 450mg/m 
were well tolerated whilst the patient carried out his full 
time job as a lorry driver. The partial response was 
m a i n t a i n e d  for 1  year, f o l l o w i n g  which his d i s e a s e  
progressed rapidly leading to his death.
Minor antitumour responses were seen in a further 14 
patients (details on Table 11.18). The majority of ovarian 
carcinoma patients had previously received large cumulative 
doses of cisplatinum, or carboplatin (JM8 ) followed by an 
alkylating agent.
II.5 Discussion
The expectation that CB3717 would have toxicities in 
man quite distinct from those of the classic antifolate, 
m e t h o t r e x a t e ,  and the reputed thymidylate synthetase 
inhibitor, 5-fluourouacil, was realised in part, but some 
similarities were observed.
In the early part of the study, the 5 day treatment 
schedule proved to be considerably more toxic than the 1  day 
schedule particularly with respect to the bone marrow. 
Myelosuppression occurred on repeated dosing even when dose
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reduction was instituted. The higher cumulative dose
9 9a d m i n i s t e r e d  of 5 0 0 m g / m ^  - 7 0 0 m g / m ^  is one p r o b a b l e  
explanation. Hepatic toxicity and associated malaise were 
troublesome in both regimens but more severe constitutional 
disturbance was apparent after 5 daily treatments. For all 
these reasons the 5 day schedule was abandoned as it seemed 
likely that the starting dose of lOOmg/m x5 was near to the 
maximal tolerated dose of this regimen. The appearance of 
antitumour effects early in the 1  day schedule (2 0 0 m g / m 2 ) 
influenced this decision.
It is impossible to be emphatic in any statement 
concerning the renal toxicity caused by CB3717 as patients 
varied considerably in their susceptibility. Doses of 200- 
400mg/m were generally associated with modest reductions in 
GFR (mean 17%). At levels of 500-600mg/m2 , precipitous 
reductions (>50%) occurred on 3 out of 10 occasions,  
suggesting that nephrotoxicity was dose limiting using this 
schedule of drug administration. The perturbations in 
urinary enzyme levels observed are further evidence for 
this. Tubular p r e c i p i t a t i o n  of CB3717 due to poor 
sol u b i l i t y  at acid pH is considered the m o s t  l i k e l y  
mechanism of renal damage with high dose methotrexate 
providing a precedent (Stoller R.G. et al 1975, Jaffe N. & 
Traggis D. 1975, Milano G. e_t al 1983) and mouse toxicology 
studies supporting the theory (see Chapter I, and Newell DR 
et c^ l 1982). This issue will be discussed further in 
Chapter III. Other mechanisms of toxicity to the kidney may 
also be implicated.
105
The occurr e n c e  of drug induced hepato toxicity 
necessitated caution in dose escalation, bearing in mind the 
unpredictable syndrome of liver failure which can ensue, as 
d e s c r i b e d  with several drugs including halothane and 
isoniazid in combination with rifampicin (reviewed by 
Pessa.yre D. et al 1977, Sherlock S. 1981). In this study, 
the disturbance of liver function was always reversible and 
repeated courses appeared to induce tolerance. Patients 
with very high levels of alkaline phosphatase were more 
prone to develop hyperbilirubinaemia than those with normal 
levels (1 . 0 out of 18 had pre-treatment alkaline phosphatase 
>300IU/1). In the four patients who were treated for longer 
than 6  mon t h s  there was no b i o c h e m i c a l  e v i dence of 
cumulative toxicity.
Methotrexate can also cause hepatic toxicity which 
presents differently depending on the dose schedule (Hersh
E.M. et. a_l 1965, Djerassi I. et_ a_l 1967, Gottlieb JA & 
Serpick A.A. 1970,). In particular, high dose methotrexate 
causes a pattern of liver enzyme abnormalities reminiscent 
of those seen with CB3717 (Rosen G. e^ t al 1974) but which 
appears to be dose related in indicence and severity (Pratt
C.B. et a._l 1975, Perez C. et aJ 1979, ). R e p o r t s  of
associated malaise are rare, but Rosen e_t al^  describe 
anorexia in all patients receiving high dose methotrexate 
(100-750mg/kg via 4 hour infusion) all of whom had some 
degree of ALT elevation (Rosen G. et al 1974). However 
other authors (Hersh E.M. et a_l 196 6 ) stated that no 
symptoms or signs could be correlated wtih abnormal liver 
function tests.
Treatments involving infusions 
FUdR directly into the hepatic artery 
causing chemical hepatitis in 1 0 %
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of 5-fluorouracil and 
have been reported as 
and 52% of patients
S'
re s p e c t i v e l y  (Oberfield . R. A. et al 1979). CB3717
hepatotoxicity is discussed more fully in Chaper V which 
describes the investigations into the possible mechanisms 
involved. The two therapeutic manoeuvres pursued clinically 
(prolongation of the infusion to 1 2  hours and administration 
of prednisolone) were clearly of no benefit in averting 
elevation of transaminase levels but some improvement in 
patient "well-being" was apparent with steroid treatment 
Objective assessment of malaise is difficult and although 
the symptoms described could be entirely attributable to 
liver disturbance the contribution of other CB3717 induced, 
b i o c h e m i c a l  a b n o r m a l i t i e s  has to be considered. In 
particular, disturbance of histamine metabolism, which is a 
feature of some antifolates especially DDMP (metoprine, 2,4- 
diamino-5- (3,,4I-dichlorophenyl)-6-methylpyrimidine) and TMQ 
(trimethyoxybenzylaminoquinazoline) (Duch D.S. et al 1978, 
Duch D S , e t  ■ etL. 1980), could play a role in causing anorexia, 
mild nausea and - dermatological toxicity. Chapter IV deals 
with this subject in more depth.
The rather unpredictable occurrence of myelotoxicity 
after CB3717 is comparable to that induced by methotrexate 
at low doses and had a similar time course. Hansen et a_l 
concluded that the individual toxic dose of a single 1  hour 
infusion of methotrexate, in a series of 49 patients, varied 
by a factor of 18 (50-900mg/m^, median 120mg/m^) (Hansen 
H.H. e_t a_l 1971). In the present study with CB3717, reduced 
renal function and severely impaired hepatic function seemed 
to be risk factors for myelotoxicity.
.Methotrexate also causes rashes in 10-15% of patients 
which may be unassociated with other toxicities (Bertino 
J.R. 1981b) and can give rise to erythema at previous 
irradiation sites (Jaffe N. et al 1975). This effect is
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comparable to that of CB3717.
Overall, with regard to toxicity, CB3717 behaves in a 
manner much more similar to m e t h o t r e x a t e  than to 5- 
fluorouracil or FUdR. These pyrimidine analogues produce 
more consistent and predictable myelotoxicity and stomatitis 
along with gastrointestinal disturbances (anorexia, nausea 
and v o m i t i n g  and diarrhoea) (Heidelberger C. 1982). 
Stomatitis and gastrointestinal toxicity are also features 
of methotrexate treatment (reviewed by Bertino J.R. i981b). 
In this respect CB3717 differs from both these compounds 
causing mucositis and diarrhoea rarely which correlates with 
the preclinical. rationale for its development.
The antitumour responses observed were encouraging and 
somewhat surprising considering the population under study. 
Further evidence of the activity of CB3717 will be sought in 
Phase II trials. In addition, the early relapse of several 
patients and their failure to respond on retreatment with 
CB3717 prompted the study of mechanisms of drug resistance. 
Here the development of a resistant L1210 mouse leukaemia 
cell line proved helpful and this work is elaborated in 
Chapter VI.
II . 6  Summary
The a d m i n i s t r a t i o n  of CB3717 in 0.15M s o d i u m  
bicarbonate as a 1 hour intravenous infusion at 3 weekly 
intervals has a maximal tolerated dose in the range of 550- 
600mg/m at which renal toxicity becomes dose-limiting. A 
recommended dose for use in Phase II trials is 400mg/m^ in 
patients with GFR >60ml/min, which is relatively well 
tolerated. Careful evaluation of renal function prior to 
and during therapy is recommended especially as some decline
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in renal function (<2 0 %) was observed in most patients 
receiving CB3717. Hepatic toxicity occurs frequently and 
requires monitoring by assessment of liver function tests at 
least twice between treatments. Tolerance may develop after 
several courses. Dose reductions to. 3 0 0 m g / m f  should be 
instituted when the pre-treatment GFR is less than 60ml/min 
or alkaline phosphatase levels are greater than twice the 
upper limit of normal. Phase II trials are already in 
progress at three centres in the UK (RMH Sutton & London, 
Glasgow and Newcastle) using these recommended doses.
There are several possibilities for future study with 
this new antifolate in the field of clinical cancer. The 
use of higher doses of CB3717 in combination with hydration 
or alkalinisation regimens in an effort to avoid renal 
toxicity is one obvious scheme. Exploration of protocols 
employing lower doses given on five consecutive days or on a 
weekly basis would also be logical. However the most 
outstanding and pertinent question still to be answered 
concerns the ability of CB3717 to establish a 'thymineless* 
state in man in association with its antitumour effect. It 
was not possible to do this within the Phase I trial as the 
methodology for measuring plasma nucleoside levels and 
intracelullar nucleotide pools was incompletely developed. 
Fortunately, current studies are now able to address this 
problem.
S
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CHAPTER III 
THE CLINICAL PHARMACOKINETICS OF CB3717
III.l Introduction
The importance of pharmacokinetic evaluation during 
early clinical studies with a new anticancer drug has been 
discussed by many authors (Nichol C.A. 1977, Erlichman C. 
Donehower R.C. & Chabner B.A. 1980). It is widely believed 
that this is the most useful stage at which to establish the 
absorption, distribution, elimination and metabolism of the 
drug in man. Knowledge of these factors may suggest ways in 
which to alter administration schedules to improve the 
therapeutic index and may help define groups of patients in 
w h o m  dose m o d i f i c a t i o n  would be prudent. This is 
particularly relevant to a population of cancer patients 
where renal and hepatic function are frequently impaired.
The development of a sensitive high performance liquid 
chromatography (HPLC) assay for CB3717 in plasma, urine and 
faecal homogenates led to the study of its pharmacokinetics 
in mice and rats (Newell D.R. et eL 1982). In these species 
biliary excretion was the major route of drug elimination. 
The desglutamyl metabolite, CB3751 was detected in faecal 
extracts and was attributed to colonic bacterial action as 
only the parent compound was detected in plasma and urine 
samples (Newell D.R. e_t a_l 1982, Newell D.R. et a^ l 1983). 
With the discovery of hepatic dysfunction as the most 
prevalent toxicity in man, further experiments in rats 
established that a dose related reduction in bile flow rate 
occurred (Nev/ell D.R. et al 1982). A precipitate in the 
bile was also observed which raised the possibility of this 
being either the parent drug or a related product.
Ill
Extrapolation to man begged a trial of the prolongation of 
the infusion time from 1  to 1 2  hours in an attempt to reduce 
peak pia sma drug levels and avert the presumed biliary 
stasis and thus perh a p s  avoid h e p atic toxicity. The 
pharmacokinetics of both 1  hour ana 1 2  hour intravenous 
infusions of CB3717 in man were investigated therefore, and 
attempts to correlate the pharmacokinetic parameters with 
the toxicities have been made. Finally a study of the 
urinary solubility of CB3717 within a wide range of pH 
values was undertaken to establish support for the proposal 
of drug precipitation in the kidney tubules as the mechanism 
of renal toxicity.
III.2 Materials and Methods
111.2.a Chemicals
CB3717 was supplied by ICI Pharmaceuticals (Alderley 
Park, Macclesfield, Cheshire) and CB3751 (4- (N- ((2-amino-4-
hydroxy-6 -quinazolinyl)methyl)prop-2 -ynylamino)benzoic acid) 
by Dr. T.R. Jones (Institute of Cancer Research, Sutton, 
Surrey). All other reagents were analytical grade and were 
obtained from Fisons (Loughborough, Leics.), BDH Chemicals 
(Poole, Dorset) or East Anglia Chemicals (Hadleigh, Ipswich, 
Suffolk).
111.2.b Patients, Protocol and Sample Collection
Verbal consent was obtained from patients selected for 
study whose characteristics are presented in Table III.l. 
A n t i - e m e t i c s  were not routinely used and a n a l g e s i c  
preparations were avoided where possible for the 24 hour 
period of study. Plasma levels of CB3717 were measured in 
t w enty d i f f e r e n t  p a t ients (sixteen f o l l o w i n g  1  hour
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infusion, three following 1 2  hour infusion, one following 
both 1 and 12 hour infusion). Blood samples (5-lOml). were 
collected into heparinised tubes from an intravenous cannula 
sited in the contralateral arm from that receiving the drug 
infusion. Patency was maintained by the injection of 1ml 
heparin (10 units/ml) after each sampling. The diacid of 
CB3 717 was dissolved in 250ml or 1 litre of 0.15M Sodium 
bicarbonate (NaHCO^), adjusted to pH9.0 for infusion over 1 
or 12 hours respectively. Sample collection times were as 
follows: 1 hour infusion - pre, mid, end infusion, 0.25, 
0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6 , 8 , and 23 hours post 
infusion. 12 hour infusion - pre, mid, end infusion, 0.5, 
1.0, 6 , 12 and 24 hours post infusion. Plasma was separated 
immediately by centrifugation and stored frozen (<-20°C).
Urine samples were taken from random pre-treatmemt 
specimens and 24 hour collections of urine were made, 
starting at the time of treatment, on 57 occasions (31 
following 1  hour infusion in twenty five patients and 26 
following 1 2  hour infusions in twenty one patients). 2 0 ml 
aliquots were taken from the 24 hour urine samples and 
stored frozen (<-20°C). An incomplete collection of faeces 
was made from one patient (No. 4) during a 5 day treatment 
schedule. Cerebrospinal fluid (CSF) was also acquired from 
this p a t i e n t  by lumbar p u n cture one hour after the 
completion of his drug infusion on day 1. Post mortem 
tissue and bile samples were retained for analysis from a 
patient who died from progressive disease 8  days after his 
second dose of CB3717 at 330mg/m^. In addition, 15ml 
volumes of ascitic fluid were aspirated from a-patient with 
ovarian carinoma at 1,2,4,6 and 23 hours after a 1 hour i.v. 
infusion, and were stored frozen (<-20°C).
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Ill .2 .c Sample Preparation
All samples we re thawed at room temperature.
URINE - The samples were adjusted to pH 9.0 by the 
dropwise addition of 1M Sodium hydroxide (NaOH) to ensure 
the complete dissolution of any CB3717 present.
FAECES - The total faecal collection was weighed, 
diluted to a 2 0 % (w/v) mixture with 0 .1 M trishydroxymethyl
ammonium-HCL buffer pH 9.0, left for 24 hours at 4° and then 
stirred for 30 minutes.
TISSUES - The tissues available from post mortem 
(primary tumour, metastatic tumour, small bowel, spleen, 
pancreas, kidney, bone marrow, liver, thyroid, cerebellum, 
cerebrum, myocardium, skin, adipose, large bowel) were 
h o m o g e n i s e d  in a teflon glass h o m o g e n i s e r i n  0 .1 M 
trishydroxymethylammonium-HCL buffer pH 9.0 as 5% (w/v) 
homogenates.
Two volumes of methanol were added to one volume 
(routinely 1ml) of plasma, CSF, urine, faecal and tissue 
homogenates, bile and ascitic fluid. These were mixed 
thoroughly and centrifuged at l,000g for 5 minutes at 4°. 
The supernatants were decanted into glass vials for analysis 
by HPLC within 12 hours.
III.2.d HPLC Analysis
Ns.
All HPLC analyses were performed on a Waters Associates 
Chromatograph (Waters Associates, Northwich, Cheshire) which 
consisted of two model 6000A HPLC pumps, a model 660 solvent 
programmer, a model 440 fixed wavelength detector (254nm and
115
280nm and a model 710 (A or B) Waters Intelligent Sample 
Processor. The outputs from the detectors were recorded on 
a standard chart recorder and, for some analyses, on an 
automatic integrator (Trivector Ltd., Sandy, Beds,). Peaks 
were measured either by peak height, determined manually, or 
by peak area, determined by automatic integration. HPLC 
solvents were filtered and degassed prior to use by passage 
through a 0.45 uM filter; polypropylene backed PTFE for 
organic solutions and cellulose nitrate for a q u e o u s  
solutions (Whatman Ltd., Maidstone, Kent).
Separations were performed on a uBondapak C18 column 
(25 x 0.46cm, Waters Associates) fitted with a CO:Pell ODS 
precolumn (6.5 x 0.21cm, Whatman Ltd.). Samples were eluted 
isocratically at a flow rate of 2 ml/min with a solvent 
mixture containing, by volume, 1  part glacial acetic acid, 
64 parts water and 35 parts methanol. Sample volumes were 
within the range 10-50ul.
Recovery of CB3717 from human plasma was essentially 
complete (94.4 + 3.4% x + SD) and linear (r=>0.999) over the 
concentration range 2-400uM (coefficients of variation; 20uM 
= 3.5%, lOOuM = 5.3%, 2 0 0 u M = 2.2%). Similarly, CB3717
estimation in urine was linear over the range 2-lOOuM 
(r=>0.999) (coefficients of variation; 20uM = 4.1%, lOOuM = 
1.0%, 200uM =1.0%). Quantification of CB3717 and CB3751 in 
CSF, ascites, kidney and faecal homogenates was achieved by 
compar ison with standard solutions dissolved in 0.15M 
NaHCC^, pH 9.0 and recovery taken as 100%. Chromatograms 
illustrating the analysis of CB3717 in plasma^are shown in 
Figure III.l. Peaks present in the HPLC effluent were 
identified by co-chromatography with CB3717 and CB3751 
standards and by their 254nm/280nm absorbance ratios.
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FIGURE III.1: HPLC Trace of Plasma Samples Pre
and Post CB3717 Treatment by 1 Hour i.v. Infusion 
of 400mg/m2 (Wavelength 280 nm)
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Ill.2 . e Protein Binding Estimation
2 0 ml of plasma was separated from blood venesected 
from a normal volunteer. Standard solutions of CB3717 in 
0.15M sodium bicarbonate, adjusted to pH 9*0, were further 
diluted in 1ml aliquots of 0.15M sodium bicarbonate or 1ml 
aliquots of plasma to give final concentrations of 1uM- 
2 0 0uM. These bicar b o n a t e  and p l a s m a  d i l u t i o n s  were 
ultrafiltered using an AMICON micropartition system with YMT 
membranes (Amicon House, Woking, Surrey). Centrifugation 
was at 1500g for 10 min at 15°. The ultrafiltrates were 
then analysed by HPLC.
III.2.F Urine Solubility Studies
Urine was collected from a healthy volunteer (pH 5.54). 
The pH was adjusted to 3.0 by the addition of concentrated 
hydrochloric acid (approximately 5 drops/lOOml urine). The 
solid diacid of CB3717 was added to 100ml of this urine and 
mixed to produce a super-saturated solution from which a 7 
ml aliquot of the suspension was decanted into a test tube. 
The remaining urine suspension was adjusted to pH 4.0 with 
5M, 1M and 0.1M sodium hydroxide and a farther aliquot was 
removed. This process was repeated adjusting the pH by 
increments of 1.0 up to pH 9.0, with addition of further 
CB3717 solid to ensure a s u p e r - s a t u r a t e d  solution. 
Duplicate samples were prepared by repetition of the whole 
procedure using a fresh urine collection. The aliquots of 
CB3717 suspension were then centrifuged at 2,000 r.p.m. for 
10 minutes at 4° and the resulting supernatants were 
filtered through 0.22uM MILLEX-GS filters (Millipore) into 
WISP vials. A standard solution of lmg/ml CB3717 in 0.15M 
sodium bicarbonate was made and HPLC analysis was performed 
on 5ul sample volumes using the method previously described.
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The solutions remained clear throughout the analysis.
111.2.g Pharmacokinetic Analyses
Following the end of the infusion plasma levels of 
CB3717 were fitted to a two compartment open model using a 
non-linear least squares analysis (Sampson J. 1969). The 
data were weighted either with the function (1 /y + yi)^ or 
with the function l/(y)^ (Ottaway J.H. 1973, Storer A.C. 
Da r l i s o n  M.G. & C o r n i s h - B o w d e n  A. 1975). The values  
obtained for the two-compartment model were corrected for 
the infusion period as described by Loo and Riegelman (Loo 
J.C.K. & Riegelman S. 1970). From the corrected values the 
alpha and beta p h a s e h a l f  lives, volume of the central 
compartment, steady state volume of distribution, total 
plasma clearance, area under the plasma concentration versus 
time curve (AUC) and the rate constants ^21 & ^el. were
calculated using the equations described by Wagner (Wagner 
J.C. 1975). In two patients, following a 12 hour infusion, 
a one compartment model was fitted to the data.
III.3 Results
111.3.a CB3717 Plasma Pharmacokinetics
Following a 1 hour infusion of CB3717, plasma levels 
decayed biphasically with first order kinetics as shown in 
Figures III.2, III.3 and III.4, where the computer fits of 
the plasma decay curves from patients treated at doses of 
100-5OOmg/m* are depicted. The plasma pharmacokinetic 
parameters, determined for 17 patients are given in Table
III.2. Peak plasma CB3717 concentration correlated with dose 
(r=0.839 p=0.01) and there was a weak correlation with 
plasma AUC (r=0.473 p=0.05) (see Figures III.5, III. 6 ).
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Other parameters were independent of dose. In the eleven 
patients who were studied during their first course of 
CB3717 and who received only a single hour infusion, hepatic 
toxicity, as measured by the peak rise in plasma alanine 
transaminase level, post treatment (see Table III.l) showed 
a weak p o s itive .correlation-with-peak p l a s m a  CB3717 
concentration (r=0.69 p=0.02, see Figure III.7). There was 
no correlation between hepatic toxicity and any of the other 
parameters determined, including k2 ^/ ki 2 ' ^el*
An example of the plasma levels of CB3717 in one of the 
four patients studied following a 1 2  hour infusion are shown 
in Figure III. 8 . C o m p a r i s o n  of Table III.2 and III.3 
reveals that the beta phase half lives and total plasma 
clearances are similar despite the prolonged infusion time. 
In patient 10, extending the drug infusion time from 1 to 12 
hours and using the same total dose decreased the plasma 
concentration from 81uM to 32uM.
III.3.b CB3717 Excretion and Tissue Distribution
The cumulative urinary excretion data (Table III.4) 
implied that renal excretion was not the major elimination 
route for CB3717 with only 27+2% of the amount administered 
excreted in the urine over the first 24 hour period, 
regardless of the dose. Strict correlation of CB3717 renal 
clearance with pre-treatment glomerular filtration was not 
possible as no analysis was made of CB3717 plasma protein 
binding in individual patients. However, the 24 hour 
urinary excretion of CB3717 after 57 doses was weakly 
correlated with pre-treatment GFR and reached significance 
because of the large numbers studied (r=0.374 p=0.01, Figure 
III.9) .
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Faecal elimination was investigated in one patient 
where 15% of the total dose of drug administered was 
detected as unchanged CB3717 in an incomplete faecal 
collection. In addition, a compound was observed which co­
chromatographed with CB3751, the desglutamyl metabolite of 
CB3717.
The only post mortem tissue found to contain CB3717 was 
the kidney where the concentration of 140 ug/g wet weight 
represented 5% of the total dose administered 8  days prior 
to the patient's death, assuming even drug distribution 
throughout the kidneys. Figure III.10 displays the data 
concerning the distribution of CB3717 into the ascitic fluid 
of a patient with ascites secondary to ovarian carcinoma. 
Equilibrium between plasma and ascitic fluid was observed 7 
hours after the end of the infusion. CB3717 was not 
detected in the sample of CSF taken one hour post infusion 
from patient 4 and hence the plasma to CSF ratio at this 
time point was at least 45:1.
III.3.C Protein Binding
CB3717 was 97.6+0.1% protein bound in human plasma. 
The free drug concentration was linear over the range 20- 
2 0 OuM CB3717 in p l a s m a  ( r = 0.9 9 , 'p <0.001). B e l o w  a
concentration of 20uM, CB3717 was undetectable in the plasma 
ultrafiltrates (<luM).
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XII.3.d Urinary Solubility of CB3717
Table III.5 shows the maximal concentration of CB3717 
which could be attained in Urine at pH 3-9. For comparison 
the results obtained by Stoller et al, when studying 
the solubility of methotrexate in urine, are shown Stoller 
R.G. et al 1975).
III.4 Discussion
The pharmacokinetic studies of CB3717 in man were 
pertinent to its appraisal in early clinical studies. The 
peak drug plasma concentrations observed lay within the 
range that is cytotoxic to cultured cells in vitro (I5 0  1 “ 
40uM) (Jones T.R. e_t 3^. 1981, Diddens H. Niethammer D. & 
Jackson R.G. 1983) and are similar to those which are seen 
in mice at doses which cure the Chester Beatty L1210 
leukaemia (Newell D.R. et a_l 1982). This may be relevant to 
the antitumour effects observed clinically (described in 
Chapter II), although the intracellular concentrations 
achieved are obviously of primary importance.
When CB3717 was administered as a one hour infusion 
there was-a positive correlation between peak plasma CB3717 
concentrations and the subsequent elevation of plasma 
alanine transaminase levels (Figure III.7). This reinforces 
the hypothesis, which is suggested by the frequency of 
hepatic disturbance, that the phenomenon is a direct toxic 
manifestation and not due to an idiosyncratic reaction. 
Although a dose-hepatotoxicity .relationship could not be 
demonstrated with CB3717 in the larger series of patients 
included in the Phase I trial (see Chapter II, figure II.4), 
this may have been a reflection of inter-patient variation 
in peak CB3717 plasma levels and the relatively small dose
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Urine pH ug/ml . uM
3 <5 <10
4 <5 <10
5 <5 <10
6  11 23
7 45 93
8  415 856
9 4820 9938
TABLE III.5.a: Solubility of CB3717 in Urine
Urine pH MTX Remaining in 
Solution (mM)
5.7 2 . 2
6.3 9.0
6.4 1 0 . 0
6.7 1 1 . 0
6.9 2 2 . 0
TABLE III.5.b; Solubility of Methotrexate in Urine
(From Stoller et_ al 1975)
range used. For example, in this pharmacokinetic study 
there was no significant difference between the peak CB3717 
plasma levels achieved following 300 and 500mg/m^ (Table
III.2, t test p=0.16). Furthermore, prolongation of the 
infusion to 1 2  hours was not successful in averting hepatic 
toxicity. This is perhaps not surprising as the peak plasma 
CB3717 levels observed at 300-330mg/m^ (12 hour infusion) 
were still w i t h i n  the c o n c e n t r a t i o n  range w h i c h  was 
associated with hepatotoxicity after one hour infusions. One 
patient treated at the same dose level (330mg/m ) by 1 hour 
and 1 2  hour infusions showed only a 60% reduction in the 
peak plasma CB3717 levels (81uM to 32uM).
Further d i s c u s s i o n  of CB3717 h e p a t o t o x i c i t y  is 
continued in Chapter V, but it is perhaps relevant to 
emphasise here that methotrexate especially in high dose 
r e g i m e n s  (lg~ 2 0 g/m^) has also been s h o w n  to p r o d u c e  
transient rises in alanine transaminase levels (Djerassi I. 
et a_l 1967, Rosen G. e_t a^ l 19 7 4, Jaffe N. & Traggis D. 1975) 
which are clearly dose related (Pratt C.B. et al, Perez C. 
et al 1979). However, Pratt reports that at the top dose 
range, 500mg/kg (~17.5g/m^), the peak plasma concentration 
of methotrexate was approximately 1600uM whilst after 
treatment at lOOmg/kg (3.5mg/m^) it was approximately 160- 
250uM. By comparison, peak plasma CB3717 concentrations of 
20uM have been a s s o ciated with hepatic d y s f u n c t i o n  
indicating a considerable difference in hepatotoxic potency.
The 24 hour urinary excretion of CB3717 comprises 
approximately 30% of the administered dose whereas a larger 
p r o p o r t i o n  of a m e t h o t r e x a t e  dose (up to 90%) can be 
recovered in the urine within a similar time period (Isacoff 
W.H. et 'al 1977 Calvert A.H. Bondy P.K.* & Harrap K.R. 1977, 
Christophidis N. et al 1981, Breithaupt H. & Kuenzlen E.
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1982). Significant quantities of 7-hydroxymethotrexate are 
also found in the urine of patients receiving high dose 
methotrexate (Jacobs S.A. e_t a_l 1976, Breithaupt H. & 
Kuenzlen E. 1982) and this is considered to be relevant to 
the renal toxicity seen in such regimens. Methotrexate and 
7-hydroxymethotrexate are both relatively insoluble at the 
acid pH generally present in the distal renal tubule and may 
precipitate giving rise to crystalluric tubular damage 
(S toller R.G. e_t a^ l 1975, J acobs S.A. ej: a_l 19 7 6 ).
Judicious use of alkalinisation regimens can successfully 
avoid this problem (Pitman S. et_ al_ 1976, Nirenberg A. et al 
1977). Although, in the case of CB3717, metabolites have 
not as yet been found in p l a s m a  or urine, the p a r e n t  
compound is a weak acid and insoluble at acid pH (see Table-
Ill.5). Studies in mice showed that nephrotoxicity was 
caused by precipitation of CB3717 in the renal tubules which 
could be prevented by an alkalinisation regimen (Newell D.R. 
et al 1982). Significantly, the autopsy kidney specimen 
from a patient who died 8 days post treatment with 330mg/m^ 
CB3717, contained a p p r o x i m a t e l y  5% of the total dose 
although microscopical examination was unsatisfactory due to 
autolysis and no crystalluria was seen. There had been no 
evidence of pre-terminal renal failure. The possibility for 
future dose escalation of CB3717 utilising hydration or 
alkalinisation regimens has been broached in Chapter II. 
Indeed this may be a logical step when administering doses 
similar to those used in this trial in an effort to prevent 
even minor reductions in glomerular filtration rates (GFR) 
(<2 0 %) and avoid the occasional • more significant reduction 
in GFR (20-50%) which occurred unpredictably, possibly due 
to poor hydration of individual patients, in the immediate 
post treatment period (see Table II.9).
\
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CB3717 is highly protein bound and consideration should 
therefore be given to the co-administration of other drugs 
with this property due to the possibility of displacement of 
CB3717 and consequent increases in the circulating level of 
free drug. In one patient, good distribution of the drug 
into ascitic fluid was seen; an observation which may be 
related to the activity of CB3717 observed against ovarian 
cancer. In contrast CB3717 did not partition readily into 
the CSF being similar to methotrexate in this respect.
o
Large systemic doses of methotrexate (500mg/m infused over 
24 hours) are required to obtain satisfactory concentrations 
within the CSF for adequate time periods (Wang J.J. et al 
1976) or alternatively, intrathecal or intraventricular 
routes of administration may be prefered (Shapiro W.R., 
Young D.F. & Mehta B.M. 1975). The low lipophilicity of 
both CB3717 and methotrexate accounts for their poor 
diffusion across the blood brain barrier, whereas more 
lipid soluble antifolates, for example metoprine (2,4- 
d iamino-5-(3 ' ,4 '-dichlorophenyl)- 6 -methyl pyrimidine) are 
more effective at entering the central nervous system 
(Stickney R.C. et al 1973).
In conclusion the results of this study have 
demonstrated that cytotoxic levels of CB3717 can be achieved 
in human plasma. Biliary excretion is probably the major 
elimination route for CB3717, a fact which should be borne 
in mind when prescribing for patients with abnormal liver 
function. Extensive retention of the drug in the kidney can 
occur, which may be related to the dose limiting renal 
toxicity, and prompts pursuit of hydration or alkalinisation 
regimens. In addition a tentative correlation between the 
incidence of hepatic toxicity and peak CB3717 concentration 
has been shown which requires further confirmation.
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CHAPTER IV
BIOCHEMICAL PROPERTIES OF CB3717 AND OTHER ANTIFOLATES:
' RELEVANCE TO CLINICAL TOXICITY
IV.la. Introduction
Anticancer chemotherapy is rarely devoid of toxicity to 
normal host tissue by virtue of its desired effect in 
preventing cell proliferaton (Connors T.A. 1976). Whilst 
tumour selectivity and specificity remain the ideal but 
elusive goals (McElwain T.J. 1976), the possible benefits 
of treatment have to be balanced against the unpleasant, and 
sometimes hazardous, side effects of nausea, vomiting, 
alopecia, mucositis, dermatitis and myelosuppression. In 
the few cases where cure is the rule, rather than the 
exception (for example, choriocarcinoma, Burkitt's lymphoma, 
acute lymphoblastic leukaemia of children and Hodgkins 
disease, McElwain T.J. 1976), the decision to treat defies 
argument. U n f o r t u n a t e l y  many solid t u m o u r s  r e m a i n  
refractory, or only p a r t i a l l y  responsive, to p r e s e n t  
cytotoxic regimens (eg, bronchogenic carcinoma, colorectal 
carcinoma, melanoma, bladder carcinoma, cervical carcinoma) 
so that palliation is the realistic aim and hence drug 
toxicity assumes greater significance. Attention to those 
features of drug related morbidity, which are not directly 
associated with its effect at a cytotoxic locus, can, 
therefore, be helpful. For example, cyclophosphamide and 
ifosfamide urotoxicity was found to be due to the renally 
excreted metabolite, acrolein, which is formed during the 
metabolic activation of cyclophosphamide but does not 
contribute to its antiproliferative activity (Brock N. Pohl 
J. & Stekar J. 1981a). Sodium-2-mercapto-ethane sulfonate 
(MESNA) was discovered to be effective as a uroprotective
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agent w i t h o u t  i m p a i r i n g  the a n t i t u m o u r  a c t ivity of 
cyclophosphamide (Brock N. Pohl J. & Stekar J. 1981b) and it 
is now recommended in Europe with high dose cyclophosphamide 
or ifosfamide regimens (Falkson G. e_t a_l 1982, Souhami R.L. 
et al 1983). Similarly doxorubicin cardiotoxicity, which 
becomes apparent at cumulative doses of >550mg/m has been 
extensively investigated (reviewed by Unveferth D.V. et al 
1982) and though debate continues regarding the mechanism, 
much effort has gone into the development of less toxic 
analogues (reviewed by Muggia F.M. & Rozencweig M. 1983).
Cisplatinum has proved to be a highly active but toxic 
compound, causing nephrotoxicity and severe nausea and 
vomiting. Exploration of hydration and forced diuresis 
regimens enabled its safer usage (reviewed by Penta J.S. 
Muggia F.M., & Salem P.A. 1983) and analogue development has 
been successful in producing at least two compounds with 
considerably diminished renal toxicity, carboplatin (JM 8 , 
CBDCA) (Calvert A.H. ejt ajL 1982) and iproplatin (CHIP, JM9) 
(Creaven P.J. et al 1982. Preliminary reports also suggest 
that carboplatin has comparable antitumour activity to 
cisplatin (Wiltshaw E. et al_ 1983).
The toxicities of CB3717 were def ined in .the Phase I 
clinical trial (see Chapter II). The mo s t  p r e v a l e n t  
toxicity was hepatic and its association with malaise, 
anorexia and lethargy invited i n v e s t i g a t i o n  w h i c h  is 
described in Chapter V. However the correlation between 
drug hepatitis and malaise was not absolute, implying that 
other properties of this quinazoline folate analogue might 
contribute to the symptoms. One possibility, with the 
precedent of various other antifolate compounds, was that 
CB3717 was causing disturbance of histamine metabolism (Duch 
D.S. e_t al 1978) and this was supported by the observation
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of dermatological toxicity in a proportion of patients.. In 
addition, it was considered prudent to investigate the 
effect of CB3717 on serum phenylalanine levels as transient 
hyperphenylalaninaemia has been documented after high dose 
methotrexate treatment (Hilton M.A. Kmetz D.R. & Patel C.C. 
1S76). The rationale for pursuing these two areas of 
research is discussed in more detail below, the primary 
objective being to elucidate the properties of CB3717 (both 
biochemical and biophysical) which might contribute to its 
toxicity profile.
IV.l.b. Histamine Metabolism
Histamine (B-aminoethylimidazole) is a vasoactive amine 
which is widely distributed in human tissues and involved in 
diverse physiological processes including gastric secretion 
and modulation of neurotransmission within the brain. Its 
release from mast cells during allergic reactions and from 
skin cells secondary to injurious stimuli gives rise to 
capillary dilatation and increased permeability, resulting 
in flushing and oedema. The s t i m u l a t o r y  eff e c t  of 
histamine on bronchial smooth muscle and on cutaneous nerve 
endings causes bronchial constriction and itch or pain 
(reviewed by Douglas W.W. 1980). Two different receptors, 
H-^  and R^r have been identified (Ash A.S. & Schild H.O. 
1966, Black J.W. et al 1972) and, subsequently, different 
classes of antagonists have proved useful in counteracting 
the unpleasant consequences of inappropriate localised, or 
systemic, histamine release. The H^ receptor antagonists 
are many and include proheptadine, chlorpheniramine and 
promethazine, being most useful in preventing urticaria and 
treating allergic rashes, hayfever, vasomotor rhinitis, 
pruritus and drug allergies. The H 2  receptor antagonists, 
cimetidine and ranitidine have found a use in the treatment
3.42
S
of peptic ulceration, by their effect on gastric acid output 
(reviewed by Feely J. & Wormsley K.G. 1983).
The importance of histamine to antifolate therapy 
arises from its routes of metabolism and a scheme showing 
the major pathways involved in man is shown on Figure IV.1 
(taken from Goodman and Gilman 'The Pharmacological Basis of 
Therapeutics, Sixth Edition). H i s t a m i n e - N - m e t h y l  
transferase (EC.2.1.1.8 ) was shown to play a major role by 
Schayer and Cooper who injected v o l u n t e e r s  w i t h  1 
microgram/kg -^C histamine and found that 46-55% of the 
urinary metabolites were accounted for by this route 
( S c h a y e r  R.N. & C o o p e r  J.A.D. 1956). B r o w n  e t al 
established S-adenosyl methionine as the methyl donor for 
histamine methyltransferase (Brown D.D. Axelrod J. & 
Tomchick R. 1959) and an effective assay was developed using 
methyl-^C-S-adenosyl methionine with extraction of the ^^C 
methylated histamine product into chloroform (Brown D.D. 
Tomchick I.R. & Axelrod J. 1959). These workers then 
developed a purification procedure for the enzyme and 
investigated its tissue distribution in several mammalian 
species. They found that histamine methyltransferase was 
present in many tissues with high concentrations occurring 
in skin,.lung, ileum, stomach and kidney. Guinea pig brain 
contained the highest concentration (Brown D.D. £t al 1959). 
Inhibition of enzyme activity by the weakly antihistaminic 
major tranquilliser, chJorpromazine, was noted and later Cohn 
pursued this ana established that amongst the antimalarial 
compounds several more potent ‘inhibitors of HMT existed 
i n c l u d i n g  q u i n a c r i n e ,  c h l p r o q u i n e ,  a m o d i a q u i n e ,  
p y r i m e t h a m i n e  and c h l o r g u a n i d e  (Cohn V. 1965). As 
pyrimethamine is thought to exert antimalarial activity by 
inhibition of dihydrofolate reductase, the established DHFR 
inhibitor, amethopterin (methotrexate) was also tested and
c h 2c h n h 2c o o h
HISTIDINE
L-HISTIDINE
DECARBOXYLASE
C H 0C H
HISTAMINE
DIAMINE OXIDASE
n -m d t h y l
TRANSFERASE
c i-lc o o h
MONOAMINE 
S, OXIDASE
[CONJUGATION WITH 
\ RIBOSE
C H
HISTAMINE N-METHYL
HISTAMINE
N-METHYL IMIDAZOLE 
IMIDAZOLE ACETIC 
ACETIC ACID ACID
s
IMIDAZOLE 
ACETIC ACID 
RIBOSIDE
FIGURE IV.1: Synthesis And Catabolism of Histamine 
(Taken from Douglas W.W., 1980)
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was found to be inactive against HMT at concentrations up to
_ O
10 M. Other workers subsequently found that antihistamines 
could also inhibit and sometimes potentiate HMT (Netter K.J. 
& Bodenschatz K. 1967, Taylor K.M. & Snyder S.H. 1972, 
Beaven M.A. & Shaff R.E. 1979) and the list of inhibitors 
was expanded further by Thithapandha and Cohn to include 
mercurial diuretics (eg, triamterene) and some local 
anaesthetics (eg, procaine, dibucaine) (Thithapandha A. & 
Cohn V.H. 1978).
It was Duch, Bowers and Nichol who were first prompted 
by the clinical reports of the toxicity of the antifolates 
metoprine (DDMP), and triazinate to propose a correlation 
between the inhibition of histamine metabolism by these 
compounds and the development of skin and central nervous 
system (CNS) toxicity in some patients (Duch D.S. e_t al^  
1978, Duch D.S. eMt al_ 1979). Metoprine is a lipophilic 
diaminopyrimidine antifolate with a long biological half 
life (Nichol C.A. e_t £_1 1977) w h i c h  was first used
clinically in 1954 (Murphy M.L. aJ 1954) and reintroduced 
in 1975 in combination with folinic acid rescue (Price L.A. 
Goldie J.H. & Hill B.T. 1975). This and later studies 
(Miller D.S. ejt£l 1976, Price, L.A.,.Hill'B.T. & Goldie J.H. 
1977, Alberto P. et al 1978, Currie V.E. et al 1980, Alberto 
P. et aJL 1980) reported blotchy erythematous skin rashes, 
mental haziness, headache and gastritis in a significant 
proportion of patient's. CNS toxicity, typified by frontal 
headache, lethargy and 'muzziness 1 was most apparent at 
higher dose levels (Miller D.S. ejt a_l 1976, Hindmarsh J.R. 
Hall R.R. & Kulatilake A.E. 1979). Triazinate, another DHFR 
inhibitor, also caused m o d e r a t e  to severe c e n t r a l  
neurological impairment with light headedness, somnolence, 
visual disturbances and weakness along with radiation recall 
dermatitis (Rodriguez V. et al 1975, Skeel R.T. jet al_ 19 76).
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Duch and coworkers confirmed that triazinate, metoprine and 
the closely related compound, etoprine, were potent HMT 
i n h i b i t o r s  and d e m o n s t r a t e d  t h a t  the m e t o p r i n e  
c o n c e n t r a t i o n s  achieved in rat brain (2xlO” ^M) were 
associated with elevations of brain histamine levels and 
were comparable with the plasma drug concentrations achieved 
in man (10“^ to (Duch D.S. et a^ 1978). The brain
was felt to be particularly sensitive due to its reliance on 
inactivation of histamine by methylation (Schayer R.W. & 
Reilly M.W. 1973) because of its lack of diamine oxidase 
(E.C.1.4.3.6 ) which can provide an alternative degradative 
pathway in other tissues (Schaff R.E. & Beaven M.A. 1976). 
Thus a strong case was made for an association between 
disturbed histamine metabolism and some of the toxicities of 
serveral antifolates.
The further possibility of inhibition of diamine 
oxidase (DAO) by such compounds was also studied (Duch D.S. 
et al 1980). Metoprine and triazinate weakly inhibited DAO 
whilst TMQ (trimethoxybenzylaminoquinazoline) proved to be a 
powerful inhibitor of DAO (8 8 % at 10“^M) and HMT (96% at 10~ 
^M) and caused histamine elevation in rat brain and kidney. 
The co n c l u s i o n s  d r a w n  from this work were that the 
development of novel antifolates should include assessment 
of their effect on histamine metabolism (Duch D.S. ejt a_l 
1980). Indeed these workers have subsequently produced a 
2,4-diaminopyrimidine antifolate (BW301U) with favourable 
properties in this respect (Duch D.S. et: a_l 1982).
In the Phase I trial, CB3717 caused dermatological 
toxicity in about 1 0 % of patients which was symptomatically 
r e l i e v e d  by^ s t e r o i d s  and a n t i h i s t a m i n e s ,  r a t h e r  
r e m i n i s c e n t l y  of m e t o p r i n e  (Price L. A. e_t al 1977). 
Generalised malaise and lethargy occurred frequently,
N
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usually in association with hepatic disturbances (see 
Chapter II). It was postulated that such features might be 
related to C B 3 7 1 7 - i n d u c e d  d i s t u r b a n c e s  of h i s t a m i n e  
m e t a b o l i s m .  A c r u d e  p r e p a r a t i o n  of h i s t a m i n e  
methyltransferase was therefore used to test the inhibitory 
effect of CB3717 and, for comparison, known HMT inhibitors 
were tested in the same system. The activity of CB3717 
against commercially prepared diamine oxidase was similarly 
investigated and an attempt was made to establish some 
structure activity relationship utilising quinazoline 
intermediates. Plasma levels of histamine before and after 
CB3717 treatment were measured by ICI to determine if any in 
vivo effect could be established.
IV.l.c Phenylalanine Metabolism
The effect of methotrexate on folate pools secondary to 
its inhibition of dihydrofolate reductase is well known.; 
Methotrexate also has the potential to disturb biopterin 
metabolism via inhibition of dihydropteridine reductase 
(Craine J.E. Hall E.S. & Kaufman S.J. 1972). The importance 
of this arises from the essential role p l a y e d  by 
tetrahydrobiopterin as cofactor in the hydroxylation of the 
three aromatic amino acids phenylalanine, tyrosine and 
tryptophan, by their respective hydroxylase enzymes (Kaufman 
S. 1958).' A scheme showing the various pathways involved is 
shown in Figure IV.2 (adapted from Tanaka T. e_t a_l 1981). 
Newly synthesised 7,8 -dihydrobiopterin is thought to be 
reduced to 5,6,7,8-tetrahydrobiopterin by dihydrofolate 
reductase and is then oxidised to quinonoid dihydrobiopterin 
as a result of phenylalanine hydroxylation. Quinonoid 
dihydrobiopterin may be reconverted to the active 5,6,7,8- 
tetrahydrobiopterin by dihydropteridine reductase or may 
tautomerise non-enzymatically to 7,8-dihydrobiopterin which
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FIGURE IV.2 : Enzymatic Hydroxylation of Phenylalanine To 
Tyrosine And The Biosynthesis of Biopterin And Its 
Function (Adapted From Tanaka T. et al, 1981)
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can be reduced by dihydrofolate reductase as described 
above. Methotrexate was found to inhibit dihydropteridine 
reductase purified from sheep liver with a Ki of 4 x 10“ ^M 
and was competitive with the pterin cofactor (Craine J.E. et. 
al 1972). Subsequently, potent inh i b i t i o n  of the 
phenylalanine hydroxylase activity in rat liver slices, in 
the presence of methotrexate, was observed (50% at <0.18mM) 
and intraperitoneal injection of methotrexate to rats gave 
rise to 90% inhibition of liver phenylalanine hydroxylase 
within 4 hours of a dose of lOmg/kg (Milstein S. & Kaufman 
S. 1975)* No inhibition occurred when a non enzymatic 
t e t r a h y d r o b i o p t e r i n  r e generating sy s t e m  was used to 
supplement the systems.
The condition of phenylketonuria which is characterised 
by grossly elevated blood phenylalanine levels and the 
excessive excretion of its metabolites (eg, phenylpyruvate 
and phenylacetate) in the urine, is associated with a 
clinical syndrome of mental retardation and frequently 
central nervous system abnormalities such as convulsions, 
increased muscle tone, hyperactive tendon reflexes, tremors 
and inceased irritability. (reviewed by Kaufman S. 1976). 
The disorder is inherited in an autosomal reccessive manner 
and in the m a j o r i t y  of p a t i e n t s  a d e f i c i e n c y  of 
phenylalanine hydroxylase is the causative biochemical 
lesion, although the reason why elevated phenylalanine 
levels should produce neurological impariment remains to be 
elucidated. Most theories are based on the belief that 
excess phenylalanine interferes with normal metabolism, 
especially that of tyrosine and tryptophan which are 
precursors of the neurotransmitters (catecholamines and 
serotonin) (Kaufman S. 1976). Indeed high l evels of 
phenylalanine do inhibit mammalian tyrosinase, (an enzyme in 
the pathway convering tyrosine to the pigment melanin,
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Miyamoto M. & Fitzpatrick T.B. 1957) which accounts for the 
fair skin and hair of phenylketonuri.es. Transport of 
tryptophan into the brain may also be i m p a i r e d  by 
c o m p e t i t i o n  from elevated blood phenylalanine levels 
(reviewed by Bender D.A. 1982).
The study of patients with atypical phenylketonuria, 
who develop neurological impairment despite a restricted 
phenylalanine diet, elucidated several other contributory 
b i o c h e m i c a l  l e s i o n s  ( K a u f m a n  S . 1 9 7  6 ). M i l d  
h y p e r p h e n y l a l a n i n a e m i a  and a s s o c i a t e d  n e u r o l o g i c a l  
d i s t u r b a n c e  has b e e n  a s c r i b e d  to b o t h  i m p a i r e d  
dihydrobiopter in synthesis (Tanaka T. €it_ a_l 1981) and 
deficiency of dihydropteridine reductase (Koslow S.H. & 
Butler J.J. 1977, Brewster G. et. a_l 1979) Koslow also 
measured serotonin and dopamine levels in brain biopsies 
from such a patient and found them to be low. Treatment 
with neurotransmitters or their precursors gave variable 
responses which was possibly dependent on the age at which 
it was instituted.
The relevance of this discussion to antifolate therapy 
is in relation to the development of neurological toxicity. 
It has been postulated that the somnolence and confusion 
which sometimes accompany high dose methotrexate therapy may 
be due to decreased availability of biogenic amines and 
serotonin (Abelson H.T. 1978), as an indirect result of 
dihydropteridine reductase inhibition. Certainly, patients 
on low dose methotrexate developed elevated phenylalanine 
levels wh e n  p r e s e n t e d  with- .an oral loading dose of 
phenylalanine (Goodfriend T.L. & Kaufman S. 1961) and 
Hilton reports transient hyperphenylalaninaemia (7 x normal) 
in a 19 year old patient treated with 200mg/kg methotrexate 
by 4 hour infusion (Hilton M.A. et al 1976). The hypothesis
N
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that CB3717 would also give rise to such an effect was put 
to the test in patients treated on the Phase I trial.
IV.2 Methods
IV.2.a Materials
The reagents used and the suppliers are listed below:
5-adenosyl-L— [methyl-^C] methionine (60mCi/mmol) and [1,4- 
^ C ]  -putrescine (96.6mCi/mmol) - Airier sham International PLC 
(Amersham , Bucks., England). Histamine dihydrochloride 
putrescine dihydrochloride, aminoguanidine dihydrochloride - 
Sigma London (Poole, Dorset, England). Cold S-adenosyl 
methionine - Boehringer Ingleheim Ltd. (Bracknell, Berks,. 
England). Sodium phosphate, sodium hydroxide, boric acid - 
BDH Chemicals Ltd (Poole, Dorset, .England). Isoamyl alcohol 
- Fisons S c i e n t i f i c  A p p a r a t u s  (Loughborough, Leics, 
England). Toluene - May and Baker Ltd (Dagenham, England).
C o m p o u n d s  screened: C h l o r p r o m a z i n e ,  quinacrine,
chlor o q u i n e  - S i g m a  London (Poole, Dorset, England). 
Pyrimethamine, trimethoprim, amiloride - gift from Merck, 
Sharp and Dohme (Hoddesdon, Herts, UK). Triamterene - gift 
from Smith, Kline and French (Welwyn Garden City, Herts, 
England). CB3717, CB3702, CB3703, CB3704 and quinazoline 
intermediates prepared by Dr. T.R. Jones, Institute of 
Cancer Research (Sutton, Surrey). Methotrexate donated by 
N i l s  K l a u s o n  K a a s  ( D e n m a r k ) .  T M Q
(trimethoxybenzylaminoquinazoline) National Cancer Institute 
(USA)* DDMP (metoprine; 2,4-diamino-5- (3,4-dichorophenyl) -
6 -methylpyrimidine) donated by Dept, of Pharmacy, University 
of Aston (Birmingham, England).
Enzymes; Diamine oxidase (0.25units/mg) - Sigma London
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(Poole, Dorset, England). Histamine methyltransferase 
prepared from rat brain as described.
IV.2.b Histamine methyltransferase - Enzyme Preparation
A crude preparation of histamine methyltransferase was 
p r e p a r e d  from rat brains. Seven Wi s t a r  rats were 
a n a e s t h e t i s e d  with ether then sacrificed by cervical 
dislocation. The brains were excised immediately, weighed 
and homogenised with 2 volumes of 0.1M sodium phosphate 
buffer adjusted to pH 7.4 (4°C) using 5 strokes of a Potter 
homogeniser. The homogenate was then centrifuged at 4°C, 
25,000g for 90 minutes. The supernatant was divided into 
5ml aliquots and stored frozen (-40°C) in sealed tubes. A 
fresh tube was used for each set of experiments.
IV.2.c Histamine Methyltransferase Assay
Histamine methyltransferase activity was determined by 
measuring the formation of -^C-N-rnethylhis famine from an 
incubation of the crude enzyme preparation with histamine 
and S-adenosyl-L[methyl--^C]methionine according to a method 
adapted from Axelrod (Axelrod J. 1971).
Reagents: Crude enzyme preparation in 0.1M sodium
phosphate buffer, 0.75mM cold S-adenosy1-methionine, 0.83mM 
S-adenosyl-L(methyl-^C) methionine (60mCi/mmol) , 0.5mM
histamine dihydrochloride, 0.5M sodium borate buffer (pH 
1 0 ), toluene/isoamyl alcohol (1 : 1  mixture).
In a final volume of the 250ul incubation mixture the 
following substances were dissolved: enzyme plus 12.5umoles 
sodium phosphate, 18.75 nmoles cold S-adenosyl-L-methionine, 
12.5 nmoles S-adenosyl-L- [ m e t h y l - ^ C ] - m e t h i o n i n e , 12.5
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nmoles histamine. In control tubes histamine was omitted 
and extra water was added to reach the same final volume. 
D u p l i c a t e  m i x t u r e s  were prepared in glass s t o p p e r e d  
centrifuge tubes and the reaction was initiated by the 
addition of histamine (test) or water (controls). These 
were then incubated in a pre-heated water bath at 37°C for 
varying time periods (0,20,40,60 minutes). The reaction was 
stopped by the addition of 0.25ml of 0.5M borate buffer (pH 
10). 3 ml of toluene/isoamyl alcohol (1:1) was then added
and the tubes were shaken for 1 0  minutes in order to extract 
the products. The tubes were then centrifuged for 5 minutes 
and 2 ml aliquots of the organic extract were added to 8 ml 
scintillant in scintillation vials. Counting was performed 
in an SL 30 l i q u i d  s c i n t i l l a t i o n  s p e c t r o m e t e r  
(Intertechnique).
The reaction was found to be linear up to 60 minutes 
incubation. The effect on the enzyme activity of several 
compounds (including known inhibitors) was then tested by 
adding varying amounts of these compounds to the incubation 
m i x t u r e  as a b o v e  ( 0 . 2 5 - 2 5 0 n m o l e s )  to g i v e  f i n a l  
concentrations from lxl0“^M to 1x10"“6 M. The reaction time 
was 60 minutes.
IV.2.d Diamine Oxidase Assay
Reagents: 0.2M sodium phosphate buffer (pH 7.2), 0.5M
s o d i u m  b o r a t e  b u f f e r  (pH 10.5), 0 . 8  m M p u t r e s c i n e
hydrochloride, [ 1 , 4 - ^ C ]  putrescine (specific acivity 
96.4mCi/mmol) lOmM aminoguanidine hydrochlorj.de, diamine 
oxidase 2mg/ml (0.25 units/mg) toluene.
Assay: The method of erizyme assay was adapted from
Okuyama and Kobayashi (Okuyama T. & Kobayashi Y. 1961) which
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measures the radioactivity of toluene extractable 
products of *^C labelled aliphatic diamines (eg, putrescine, 
cadaverine). Incubation mixtures consisted of 100 umoles 
sodium phosphate buffer (pH 7.2), 0.2 umol putrescine,
(O.luCi [1,4-^C] putrescine), 0.125 unit enzyme (500ug) and 
where appropriate lnmol-lurnol compounds for testing (to give 
final concentrations of lxl0“^M to lxlO~^M) in a final 
volume of 1ml. The reactions were initiated by the addition 
of enzyme and were performed in a pre-heated water bath 
(37°C) for 20 minutes. The addition of 1ml 0.5M sodium 
borate buffer (pH 10.5) and 20ul of lOmM aminoguanidine 
terminated the reaction. The radioactive products were 
extracted by mixing with '6 ml toluene. The mixture was 
centrifuged and 4ml of the toluene extract was counted in' 
8 ml.-of scintillant mixture using an Intertechnique SL 30 
liquid scintillation spectrometer.
IV.2.e Plasma Histamine Levels
Blood samples were collected from 5 selected patients, 
(treated with CB3717 at doses of 300-4OOmg/m^) before 
treatment and at varying time points after treatment. 5ml 
of whole blood was collected into tubes containing ethylene 
diamine tetraacetic acid (EDTA) anticoagulant and was 
immediately cooled to 4°C on ice. The plasma was separated 
by centrifugation in a pre-cooled centrifuge for 5 minutes, 
l m l  of p l a s m a  w a s  t h e n  a d d e d  to 1.5ml of 0.8M 
trichloroacetic acid to precipitate the plasma proteins and 
stabilise the histamine present. ‘ After being left overnight 
at 4°C the sample was centrifuged ana the supernatant was 
separated and stored at 4°C. H i s t a m i n e  assays were 
performed by Dr. D.S. Thomson (ICI Pharmaceuticals Division) 
using an automated fluorimetric assay involving condensation 
of histamine with O-phthalaldehyde (Evans D.P., Lewis J.A. &
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Thomson D.S. 1973).
IV.2.f Plasma Phenylalanine Levels
Blood samples were collected into EDTA tubes from 19 
patients treated with doses of CB3717 ranging from 140- 
550mg/m^ immediately prior to their infusion and at varying 
time points (12-168 hours) after treatment. The plasma was 
separated by centrifugation and the samples were stored 
frozen at -20°C. Phenylalanine assays were performed later 
by the Biochemistry Dept, of Queen M a r y ’s Hospital for 
Children,. Carshalton, Surrey using a Guthrie technique 
(Newman R.L. & Starr D.J.T. 1971). No dietary restriction 
was placed on the patients.
IV.3 Results
IV.3.a Histamine Methyltransferase
The crude preparation of rat liver homogenate exhibited 
adequate histamine methyltransferase activity which was 
linear from 0 to 60 m i n u t e s  (see figure IV.3). The 
blank/control values increased from 254 - 3,844 cpm (over 
an instrument background of -30 cpm) during this time course 
(see Figure IV.3). This was p r e s u m e d  to be due to 
methylation of histamine present in the crude tissue extract 
with a possible contribution from other naturally occurring 
substrates for histamine methyltransferase such as N©* methyl 
histamine and N<x- , N<=*--dimethylhisfamine (Barth H. ejt a_l 
1980). The incubation time chosen for testing^the effect of 
various compounds on histamine methyltransferase activity 
was 60 minutes. S t r u c t u r e s  of the a n t i f o l a t e s  and 
quinazoline compounds tested are shown in Figures IV.4 and 
5. Table IV.1 shows the percent inhibition caused by these
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and it is not i c e a b l e  that CB3717 did not cause .any 
inhibition of histamine methyltransferase at concentrations 
up to lxlO“^M whilst TMQ and DDMP were potent inhibitors at
— fkc o n c e n t r a t i o n s  of 1x10 °M. In some cases a high 
concentration of the test drug caused enzyme inhibition 
whereas a low concentration caused an increase in activity 
(eg, chloroquine, quinacrine, pyrimethamine). This will be 
discussed later. Table IV.2 shows cumulative results of 
compounds causing inhibition of partially purified and 
purified histamine methyltransferase from bovine brains, 
guinea pig brain and rat kidney (Thithapandha A. and Cohn
V.H. 1978, Duch D.S. et al 1978, Duch D.S. et al 1980, Cohn
V.H. 1980) . .
IV.3.b Diamine Oxidase
Table IV.3 shows the effect of various antifolates, 
antimalarials and quinazoline intermediates on diamine 
oxidase activity and for comparison the results obtained by 
Duch, Edelstein and Nichol using diamine oxidase partially 
purified from rat ceca are shown in Table IV.4 (Duch D.S. et 
£ ^ 1 9 8 0 ) .  CB3717 was only weakly inhibitory to diamine
oxidase at a concentration of lxlO^^M (26% inhibition) 
whereas TMQ and DDMP were more potent as inhibitors (29% at 
lxlO~^M and 31% at lxlO”"^M) which agreed with the published 
data. '
IV.3.c Plasma Histamine Levels
The levels of histamine in plasma from patients pre- 
and post CB3717 treatment are shown in Figure IV. 6 . The 
mean pre-treament value for the 5 patients was 13.4+4.3ng/ml 
and the m e a n  post t r e a t m e n t  value (6 - 1 2 0  hours) w a s  
14.7+4.4ng/ml (x + S.D., t test, p=0.658) which was' not
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significantly different.
IV.3.d Plasma Phenylalanine Levels
The phenylalanine levels pre and post CB3717 treatment 
are represented graphically in Figure IV.7. The upper limit 
of normal for non fasting patients is 2.5mg/100ml (Dr. 
Stern, personal communication) and some diurnal variation 
in blood amino acid levels is to be expected (Feigin R.DV 
Klainer A.S. & Beisel W.R. 1967). The majority of these 
patients were anorexic and eating less than normal amounts. 
No neurological symptoms or signs were noted except for 
malaise and lethargy which generally began 24-48 hours after 
treatment and lasted 7-14 days. Plasma phenylalanine levels 
rose to above the upper limit of normal in 13 patients at 
24-48 hour.s post treatment and 3 patients were noted to 
have marginally elevated levels just prior to CB3717 
treatment. They were all markedly cachetic, two had ascites 
and one had massive metastatic hepatomegaly. There was a 
sug g e s t i o n  of a dose related increase in values w i t h  
elevations to 3.5-7.3mg/100ml occurring 24 hours after 
treatment at doses of 400-500mg/m^.
IV.4 Discussion
IV.4.a Histamine Methyltransferase, Diamine Oxidase 
and Histamine Levels •
The crude preparation of HMT from rat brain displayed 
similar sensitivity towards the most potent antifolate type 
inhibitors, TMQ and metoprine, when compared with more 
purified enzymes (Cohn V. 1965, Thithapandha A^ et aJ 1977, 
Duch D.S. et. ajL 1978, Duch D.S. et al 1980, ). No attempt 
was made to elicit the type of inhibition involved. The
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antimalarials, quinacrine, chLoroquine and pyrimethamine were 
less effective as inhibitors in this system but even amongst 
the published data there seems fairly wide variation in the 
p erc e n t  inhibition achieved at a p a r t i c u l a r  drug 
concentration (see Table IV.l). The biphasic effect of some 
c o m p o u n d s  on the crude H MT (i.e. i nhibition at high 
concentrations, stimulation at low concentrations) has been 
observed by other workers, p a r t i c u l a r l y  wh e n  using 
substituted imidazole compounds with antihistamine activity 
(Taylor K.M. & Snyder S.H. 1972, Barth H. & Lorenz W. 1978). 
Taylor also found that chlor promazine, thioridazine and 
desmethylimipramine were capable of this and postulated a 
reversal of substrate inhibition rather than "activation" of 
HMT activity as the mechanism of "enhancement". The impure 
nature of the enzyme preparation used herein may also have 
been contributory.
The d i a m i n e  oxidase assay also p r o d u c e d  r e s u l t s  
comparable with those of Duch e_t jil (Duch D.S. ejt a_l 1980, 
see Table IV.3) with T M Q  and m e t o p r i n e  being p o t e n t  
inhibitors in both studies. Both assay systems used were 
therefore suitable for the assessment of the ability of 
CB3717 to perturb histamine metabolism i_n vitro. It was 
conclusively demonstrated that within the drug plasma 
concentration range found in patients, (20-200uM, see 
C h a p t e r  III) C B 3 7 1 7  d id not i n h i b i t  h i s t a m i n e  
methyltransferase or diamine oxidase. The weak inhibition 
of diamine oxidase by CB3717 at 10“^M (26%) is probably not 
significant. The limited structure activity relationship 
showed that the 2,4-diaminoquinazolines (CB3702, CB3703 and 
CB3704) were somewhat more potent inhibitors of DAO than the 
2,amino-4-hydroxy quinazolines CB3705 and CB3717 (see 
FigureIV.5 for structures). The d i a m i n o  q u i n a z o l i n e  
intermediates (which lack a benzoyl glutamate group) were
167
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al s o  c a p a b l e  of i n h i b i t i n g  D A O  w i t h i n  a s i m i l a r  
c o n c e n t r a t i o n  r a n g e  (1 0 ~ ^ - 1 0 “ ^ M ) and t h u s  the 
benzoylglutamate half of the quinazoline molecules appear to 
be unnecessary for this effect.
Confirmation of the lack of activity of CB3717 against 
histamine methyltransferase and diamine oxidase is derived 
from its failure to alter significantly the plasma histamine 
levels of the patients studied (although none of these 
developed rashes). The different methods of measuring 
p l a s m a  h i s t a m i n e  levels give w i d e l y  varying r esults 
depending on the assay used (Graham H. et <al 1968). Other 
workers, using a fluorimetric assay similar to that used in 
this study, reported mean values of 13.6iig/l and 15.7iig/l. 
for normal subjects (Noah J.W. and Brand A. 1961) which are 
in the range of the mean values for the CB3717 treated 
patients.
In summary, considering that several structural classes 
of antifolate drugs (pyrimidine, triazine, quinazoline, and 
pyridopyrimidine) are capable of inhibiting the histamine 
metabolising enzymes, an important negative result was 
achieved with the 2-amino--4-hydroxy quinazoline, CB3717, 
leading to the conclusion that the development of rashes in 
some patients treated with CB3717 is not related to reduced 
histamine catabolism. It now seems more likely that they 
are caused by localised release of histamine as part of a 
hypersensitivity reaction, which is not unusual with various 
types of drug. The poor penetration of CB3717 across the 
blood brain barrier (see Chapter III) and its^inability to 
inhibit HMT argue strongly against a role for. elevated 
histamine levels in the causation of patient malaise.
N
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IV.4.b Plasma Phenylalanine Levels
The finding that thirteen of the seventeen CB3717- 
treated patients under study showed transient elevation of 
plasma phenylalanine levels, up to 3 times the normal range, 
d e m o n s t r a t e d  that CB3717 was capable of p e r t u r b i n g  
phenylalanine metabolism in man. In the case reported by 
Hilton of a patient treated with methotrexate 200mg/kg, 
plasma phenylalanine rose up to 7 times the pre-treatment 
value by 2 2  hours after the start of the infusion and was 
still elevated 3 fold by 98 hours. No other amino acid 
measured showed any marked fluctuations from normal vaues 
(Hilton M.A. et al 1976). It was presumed that tyrosine 
levels were maintained by protein catabolism.
As discussed in the introductory section of this 
chapter, methotrexate is believed to exert its effect on 
phenylalanine levels by depletion of tetrahydrobiopterin 
(BH4 ) levels, the cofactor required for its hydroxylation. 
Serum biopterin derivative levels were found to be increased 
in patients given methotrexate (Leeming R.J. et al 1976, 
Leeming R.J. & Blair J.A. 1980) which is presumed to be due 
to dihydropteridine reductase inhibition. More recently the 
same group reported changes in biopterin pools with BH^ 
depletion in rats treated with oral methotrexate lOOmg/kg. 
No effect was seen after doses of lmg/kg (Blair J.A. Morar 
C. & W h i t b u r n  S. 1984). W o r k  by Duch and c o w o r k e r s ,  
however, failed to show reductions in BH 4  or total biopterin 
levels in tissues from rats treated w i t h  l O m g / k g  
methotrexate i.p. and metoprine, or from neuroblastoma cells 
in culture g r o w n  in the p r e s e n c e  of m e t h o t r e x a t e  
c o n c e n t r a t i o n s  s u f f i c i e n t  to c o m p l e t e l y  i n h i b i t  
dihydrofolate reductase (Duch D.S. et. a_l 1983). Treatment 
of rats with loading doses of phenylalanine along with
S
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methotrexate did reduce the level of tetrahydrobiopterin 
though. They conclude that the pathway from 7 ‘8 B H 2  to 
5,6,7 , 8  BH^ catalysed by dihydrofolate reductase is not 
generally involved in the de novo biosynthesis of B H 4 . It 
may only assume importance if abnormal BH^ utilisation 
occurs (for example with phenylalanine loading), producing 
excessive amounts of quinonoid BH 2  which isomerises to 7,8 
BH 2 . Clearly, elucidation of the biosynthetic pathways of 
tetr ahydr obiopter in and their reg u l a t i o n  ijn vivo is 
required.
Some workers feel that disturbance of aromatic amino 
acid m e t a b o l i s m ,  as m i ght occur with d e p l e t i o n  of 
tetrahydrobiopterin pools, may be crucial to the development 
of neurological toxicity which may follow methotrexate 
therapy. Treatment, with n e u r o t r a n s m i t t e r s  has been 
recommended (Cotton R.G.H. 1978, Leeming R.J. & Blair J.A. 
1978). In the case of CB3717 the mechanism of producing 
elevated pheylalanine levels is unknown but it is possible 
that it is due to inhbition of dihydropteridine reductase. 
Clearly jjn vitro testing of this hypothesis and measurement 
of terahydrobiopterin pools in patients before and after 
CB3717 administration would help establish or refute this. 
Leeming has reviewed the role of tetrahydrobiopterin in a 
variety of n e u r o l o g i c a l  diseases including m a l i g a n t  
hyperphenylalaninaema, senile dementia, Parkinson’s disease, 
Alzheimers disease, Huntington's Chorea and lead poisoning, 
all of which may be associated with deranged serum biopterin 
derivative levels. He concludes that no matter how such 
changes arise, they are likely to,be associated, with altered 
neurotransmitter synthesis (Leeming R.J. Pheasant A.E. & 
Blair J.A. 1982). The rather tentative suggestion that the 
malaise and lethargy which follow CB3717 treatment is linked 
to the slight elevation in serum phenylalanine levels
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requires further exploration although it is not totally 
unreasonable to postulate a role for neurotransmitter 
therapy as an antidote.
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CHAPTER V
INVESTIGATIONS INTO THE MECHANISM OF CB3717 HEPATOTOXICITY
V . 1 Introduction
Drug related h e p a t o t o x i c i t y  is a fairly c o m m o n  
occurrence and may complicate cytotoxic chemotherapy with 
agents such as 6 -mercaptopurine, methotrexate, mithramycin, 
L - a s p a r a g i n a s e , m i t o m y c i n  C, nitrosoureas, DTIC and 
anthracyclines (reviewed by Woolley III P.V. 1983). It is 
possible that the biochemical lesions which give rise to the 
antiproliferative effect of these drugs are responsible for 
the damage to liver tissue, but the central role of the 
liver in drug metabolism and excretion is obviously of 
importance in determining its sensitivity to all classes of 
drugs. The mechanisms reponsible are generally divided into 
two broad groups (Sherlock S. 1981). First, a direct 
interaction of a drug (or more usually a reactive drug 
metabolite) with cellular macromolecules may result in 
hepatocyte injury or death. Such an effect is usually dose 
dependent and will occur frequently in the population 
treated. For example, paracetamol (acetaminophen) toxicity 
is believed to be due to the reactivity of. one of its minor 
m e t a b o l i t e s  (probably N - a c e t y 1 - imidoquinone) which is 
produced by the liver mixed function oxidase system. This 
metabolite is usually detoxified by glutathione conjugation 
but, in conditions of excess, the metabolite covalently 
binds to hepatic tissues causing hepatocellular damage 
(reviewed by Black M. 1980).
The second mechanism of drug induced hepatic injury 
involves an immunological attack mounted against the 
antigenic challenge provided by the drug in combination with
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liver cell constituents. This so called "idiosyncratic 
response" occurs infrequently in a population (-1 %) and is 
not dose.related. Re-challenge with the offending drug (for 
e x a m p l e ,  h a l o t h a n e )  m a y  p r o d u c e  an o v e r w h e l m i n g  
hypersensitivity reaction with liver cell necrosis (Sherlock 
S. 1981).
The assessment of liver damage relies largely on the 
measurement of serum bilirubin, liver enzymes (alkaline 
phosphatase, alanine transaminase, aspartate transaminase, 
X g l u t a m y l  transpeptidase) and a l b u m i n  along wi t h  
estimations of the prothrombin time. Such tests are 
relatively sensitive, but are limited in specificity (Zilva 
J.F. & Pannall P.R. 1975). Intrahepatic or extrahepatic 
cholestasis is generally associated with rises in alkaline 
phsophatase. levels, whilst hepatocellular damage or necrosis 
results more often in elevated transaminase values. Small 
rises in all the enzymes may occur with either process.
The clinical and biochemical features of the hepatic 
disturbance caused by CB3717 treatment in man were described 
in Chapter II, the common finding being that of perturbation 
of plasma liver enzyme levels (in particular alanine 
transaminase) between days 4-21 after an infusion. The 
frequency of this phenomenon (-80%) strongly suggested that 
this was due to a direct toxic manifestation of CB3717. 
Mechanistically, the distinction between cholestasis and 
hepatocellular damage was not clear. On the occasions when 
hyperbi'lirubinamia was found, the majority was conjugated, 
suggesting cholestasis but this does not exclude an element 
of h e p a t o c e l l u l a r  n e c r o s i s .  T h e  o t h e r  p u z z l i n g  
characteristics of CB3717 hepatotoxicity were the apparent 
lack of dose dependency within the range 140~600mg/m , and 
the return towards normal of liver enzyme levels after 3-4
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treatments (see Chapter II). Liver biopsy was not justified 
in this p o p u l a t i o n  of pat i e n t s  but the post m o r t e m  
histological examination of liver tissue from one elderly 
patient revealed only the non-specific appearance of fatty 
change, cholestasis, and Mallory bodies in a centrilobular 
d i s t r i b u t i o n  with no d i s t u r b a n c e  of general liver 
architecture. A significant interpretation of this is 
impossible with the knowledge that the patient had received 
prior treatment with 5-fluorouracil and had required 
intravenous hydration due to intestinal obstruction for 5 
weeks prior to death.
During the Phase I trial no evidence was accrued to 
support the belief that CB3717 caused an irreversible or. 
progressive hepatic lesion, despite six patients receiving 
treatment for 6-15 months. On the other hand, methotrexate 
given in low dose chronically for psoriasis (2.5-50mg 
weekly) may give rise to hepatic fibrosis or cirrhosis and 
this may not be a c c o m p a n i e d  by p l a s m a  liver e n z y m e  
abnormalities (Coe R.O. & Bull F.E. 1968, Filip D.J. e_t al^  
1971, R o b i n s o n  J.K. et al 1980). However, the m a i n  
incentive in pursuing the aetiology of the CB3717-induced 
hepatic disturbance was the belief that there existed a 
direct relationship between this and the malaise syndrome 
which occurred in a similar proportion of patients. Efforts 
to prevent the hepatitis' were thus expected to influence 
.the acceptability of this new antifolate in a clinical 
setting.
To investigate the liver toxicity an animal model was 
required. Pre-clinical toxicology studies in mice had only 
d e m o n s t r a t e d ‘abnormality in liver function tests (i.e. 
alanine transaminase increased 8  fold) when lethal doses 
were used (300mg/kg i.p.). Histologically, periacinar
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necrosis was seen but the cause of death in these mice was 
thought to be extensive renal damage. A review of the 
literature revealed that the time course for elevation of 
liver enzymes after exposure to a hepatotoxin can differ 
markedly between rodents and man. Both paracetamol and 
morphine are examples of this and cause elevations of 
transaminases within 3-6 hours of treatment (James R.C. 
Goodman D.R. & Harbison R.D. 1982). Therefore, further 
experiments in mice were undertaken using therapeutic (or 
sub-lethal) doses of CB3717. Blood sampling within the 
first 24 hour period after treatment established that 
elevation of plasma alanine transaminase did occur but with 
a return to normal values by 24 hours, (described later in 
detail) so it seemed that an experimental system for 
studying the liver toxicity had been found.
The work described in this chapter attempted to test 
several hypotheses concerning the mechanism of CB3717 
hepatotoxicity and its possible prevention, by exploiting 
the mouse model. First, the extended biological half life 
of CB3717 in mouse liver and kidney was determined as
a development of the tissue distribution studies performed 
by other workers (Newell D.R. and Manteuffel-Cymborowska M., 
personal communication) which had shown that these organs 
were exposed to the majority of the administered drug. As 
mentioned earlier, glutathione depletion had been described 
in liver toxicity induced by paracetamol and some narcotics 
(Mitchell J.R. et al 1973, Davis D.C. et al_ 1974, James R.C. 
et al 1982) and therefore the effect of CB3717 on liver 
glutathione levels was studied. CB3705 (the N^^- 
unsubstituted 2-amino-4-hydroxy quinazoline) and CB3714 (the 
N^^-ethyl-2-amino-4-hydroxy quinazoline) were similarly 
investigated for their effect on plasma liver enzyme levels 
in an attempt to determine the importance, if any, of the
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N^-propargyi group of CB3717 in causing toxicity.
The success of N-acetylcysteine as an antidote to 
paracetamol poisoning, when administered sufficiently early 
(Piperno E. & Berssenbruegge D.A. 1976, Peterson R.G. & 
Rumack B.H. 1977, Prescott L.F. jat al^  1977, Walker R.M. et 
al 1982) suggested a trial of its effectiveness against 
CB3717 hepatotoxicity. Other compounds thought likely to be 
capable of preventing the toxicity were those which might be 
e xpected to reverse the act i v i t y  of CB3717 agai n s t 
thymidylate synthetase and dihydrofolate reductase and other 
folate dependent enzymes (that is thymidine, folinic acid, 
5-methyltetrahydrofolate). The mouse model was used to 
gauge the influence of any of these agents on the CB3717- 
induced elevations in alanine transaminse levels. The 
experimental methods and results of all the experiments are 
described below. This work was performed in conjunction 
with Dr. D.R. Newell.
V.2 Materials
The mice used throughout the experiments were C57 
black/DBA 2 Fj male animals. The reagents used and their 
suppliers are listed below. Analar grade was used unless 
specified to the contrary*
CB3717 (diacid), ICI Pharmaceuticals Division (Alderley 
Park, Macclesfield, Cheshire). CB3705 and CB3714, Dr. T.R. 
Jones, Institute of Cancer Research (Sutton, England). 
Paracetamol (N-acetyl-p-aminophenol), trishydroxymethyl 
ammonium hydrochloride (TRIS); 5 sulfosallcylic acid, 
glutathione (reduced), folinic acid (calcium leucovorin) - 
S i g m a  London (Poole, Dorset, England). Urea, s o d i u m  
hydroxide, sodium hydrogen phosphate, sodium bicarbonate
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(hydrogen carbonate), methanol, acetic acid, L-ascorbic acid 
- BDH Chemicals Ltd., (Poole, Dorset, England). Ellmans 
reagent [5,5’-dithiobis-(2-nitrobenzoic acid)], Aldr ich 
Chemical Company Inc, (Milwaukee, Wisconsin, USA). Diethyl 
ether, May & Baker (Dagenham, Essex, England). ^ C - C B 3 7 1 7  
(5.9'uC i / m g ). ^ C - h e x a d e c a n e  (CFR 65, batch 62 8 6 8  , 000 
DPM/ml), Amersham International PLC (Amersham, Bucks, 
England). Combustaid, permafluor V, carbosorb, Packard 
Instruments Ltd (Reading, Berks,' England). Sodium heparin, 
Duncan Flockhart & Co Ltd (London, England).
V.3 Methods
V.3.a CB3717 Hepatotoxicity in Mice
CB3717 for injection was dissolved at a concentration 
of lOmg/ml in 150mM sodium bicarbonate and was adjusted to 
pH 9.0. The mice were weighed and then injected intra- 
peritoneally with CB3717 at a dose of lOOmg/kg (260mg/m^) 
which falls within the dose range causing hepatotoxicity in
o
man (100-600mg/m ). Control mice were injected with 150mM 
sodium bicarbonate. Groups of three control mice and three 
CB3717-treated mice were sacrificed by exsanguination via 
cardiac puncture, under diethyl ether anaesthesia at the 
time points 1,3,6,9,24,48 and 72 hours. Blood was withdrawn 
into a 1ml syringe rinsed with sodium heparin (50 I.U. 
d i l u t e d  in IN saline). P l a s m a  w a s  s e p a r a t e d  by 
centrifugation in microfuge tubes, (700g for 2  minutes at 
room-temperature) pipetted into plastic vials then stored 
immediately frozen (-20°). The Samples were thawed at room 
temperature prior to measurement of alanine transaminase and 
alkaline p h o s p h a t a s e  levels (within one week) by the 
Biochemistry Department of The Royal Marsden Hospital using
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a Roche Cobas Bio Analyser.
V. 3.b Experiment to Determine The Long Term Exposure of 
Liver, Kidney and Plasma To ~^ C-CB3717 Following Intra- 
peritoneal Injection in Mice
Standardization of Packard Sample Oxidiser
Three mice were sacrificed by exsanguination under 
diethyl ether anaesthesia. Portions from the excised livers 
and the whole kidneys were weighed, wrapped in Whatman No. 1 
5.5cm filter paper and placed in Combusto Cones. 20ul of 
^ C - h e x a d e c a n e  was added to each of these either before or 
after combustion. Blanks of filter paper alone were 
similarly treated. 0.25ml of Combustaid was added to the 
samples prior to burning for 1 minute in the Packard 
Oxidiser 306. Collection was into 9ml scintillant and 9ml 
carbosorb with all machine settings as recommended by the 
manufacturer. Counting was performed in an SL30 liquid 
scintillation spectrometer (Intertechnique, St. Albans).
Standardization of CB3717 Injection Solutions
Total Radioactivity
Duplicate dilutions (1 in 50) of the 2mg/ml, lOmg/ml 
and 20mg/ml ^^C--CB3 7.17 solutions were prepared in 150mm 
sodium bicarbonate. lOOul aliquots of these were added to 
8 ml scintillant in scintillation vials. No evidence of 
immiscibility was seen. Blanks were also prepared using 
lOOul 150mM sodium bicarbonate and lOOul 150mM sodium 
bicarbonate plus 50ul -^C-hexadecane with 8 ml scintillant. 
Samples were counted on the SL30 liquid scintillation 
spectrometer. .
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Total UV Absorbance
The 2mg/ml, lOrag/ml and 20mg/ml solutions were diluted 
1 in 200, 1 in 1000 and 1 in 2000 respectively using 0.1M 
sodium hydroxide. The absorbance of these solutions at 
301.5nm (CB3717 301.5nm e=26,600) was recorded in a 1cm 
silica cuvette on a Unicam SP500 Spectrophotometer.
Radiochemical Purity
50ul aliquots of the solution of ^C-CB3717 prepared as 
a b o v e  w e r e  an a l y s e d  by h i g h  p e r f o r m a n c e  l i q u i d  
chromatography using the separation system described in 
Chapter III. 1ml fractions were collected into 8 ml Cocktail 
T scintillant and were counted. 50ul of the solution were 
put straight into 8 ml Cocktail T to obtain a 100% value. 
Counting was performed for 4 minutes on the SL30 liquid 
scintillation spectrometer.
Determination of Long Term Exposure of Mice to ^C-CB3717
An injection solution was prepared to contain 2mg/ml 
^ C-CB37_17 (5.9 5uC i/ml) d i s s o l v e d  in 0.15M s o d i u m
bicarbonate, adjusted to pH 9.0. A further two solutions 
were similarly prepared using cold CB3717 and a proportion 
of the ^ 4 C - C B 3  717 2 m g / m l  s o l u t i o n  to g i v e  f i n a l
concentrations of lOmg/ml and 20mg/ml. The activity of the 
solutions were thus 11.9uCi/ml (2mg/ml), 11. 5 u C i / m l  
(lOOmg/ml) and ll.OuCi/ml (200mg/ml).
Groups of mice (3 per time point per dose) were weighed 
and injected intraperitoneally with the above solutions to 
receive respectively doses of 20mg/kg, lOOmg/kg and 200mg/kg
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CB3717. The mice were then maintained on a normal diet with 
water ad libitum until the times of sacrifice at 26.5, 74, 
143, 243, 359 and 550.5 hours after treatment. At these 
time points, animals were anaesthetised with diethyl ether 
and then exsanguinated by cardiac puncture, the blood being 
withdrawn into syringes pre-rinsed with heparin. The plasma 
was subsequently separated by centrifugation and 2 0 0 ul 
aliquots were absorbed onto Combusto-pads placed within 
Combusto cones (Packard Instruments Ltd). The liver and 
both kidneys were excised and weighed. Two portions of the 
liver were sectioned and reweighed and along with the 
kidneys, these tissues were individually wrapped in Whatman 
No. 1 filter paper 5.5cm and placed in Combusto cones. All 
the samples were then subjected to the burn procedure as 
described in the standardisation section.
V.3.C Experiment to Determine The Effect of Paracetamol 
and CB3717 on Liver Glutathione and Plasma Enzyme Levels in 
Mice
The following experiments were performed on separate 
days using freshly made drug solutions as described below.
i) Paracetamol (N-acetyl-p-aminophenol) was dissolved 
in 150mM sodium chloride and 1M sodium hydroxide to give a 
final concentration of 40mg/ml at pH 10. Treatment doses 
were 400mg/kg, administered intraperitoneally, and control 
animals were injected with 150mM sodium choride adjusted to 
pH 10 with 1M sodium hydroxide.
\ ^
ii) CB3717 was dissolved in 150mM sodium bicarbonate
adjusted to pH 9.0 with 1M sodium hydroxide to give a 
concentration of lOmg/ml and 30mg/ml. Treatment doses were 
lOOmg/kg and 300mg/kg administered intraperitoneally and
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control animals were injected with 150mM sodium bicarbonate 
at pH 9.0.
Duplicate groups of 3-4 mice per time point were 
injected i.p. with either the drug or control solution. 
Animals were sacrificed by cardiac puncture exsanguination 
wh i l s t  under diethyl ether an a e s t h e s i a  at 4 hours 
(paracetamol treated) 1,3,4 and 6  hours (CB3717 lOOmg/kg) 
and 3 and 6 hours (CB3717 300mg/kg). Blood was withdrawn 
into a 1 ml syringe containing 20IU heparin and then was 
dispensed into microfuge tubes. Plasma was separated by 
centrifugation and stored frozen at -20°. Within one week 
the samples were thawed at room temperature and analysed for 
alanine transaminase and alkaline phosphatase levels. 
Plasma from the CB3717 treated animals were also analysed 
for drug levels using the high p e r f o r m a n c e  liquid 
chromatography technique described in detail in Chapter III 
section 2 .d.
Glutathione Assay
The livers were excised, weighed and assayed for 
reduced glutathione (# -glutamyl-cysteinyl-glycine) using a 
colorimetric assay adapted from Ellman (Ellman GL 1959). 
The tissue was homogenised with 3ml/g liver of ice cold 0.1M 
trishydroxymethylammonium chloride/4M urea buffer using five 
strokes of a teflon/glass homogeniser. 2 ml aliquots were 
removed, mixed with 0.5ml/g liver of 0.05M sodium hydroxide 
and incubated at 40° for 30 minutes. The protein was then 
p r e c i p i t a t e d  with 2 m l / m l  s a mple of 7.5% s o l u t i o n  
sulfosalicylic acid. Mixing was done in conical flasks by 
magnetic fleas and when the frothing subsided the contents 
were transferred to plastic tubes for centrifugation at 4° 
for 10 minutes. Duplicate 0.5ml aliquots of the supernatant
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were treated with 2.5ml 0.5M phosphate buffer (pH 6 .8 ) and 
0.5ml E l l m a n s  reagent (0.15 m g / m l  .5,5. f- d i t h i o b i s - ( 2 -  
nitrobenzoic acid) in 0.5'M phosphate buffer). After mixing, 
the absorbance of the samples at 412nm was read against 
reagent blanks. A standard curve for glutathione was 
prepared on each occasion using glutathione standards of 
0.41, 0.82, 1.64 and 3.28 mg/ml dissolved in water. 1ml
aliquots of these were treated in the same way as lg liver 
before reading the absorbance values at 412nm.
V.3.d Experiment to Determine The Interaction of 
N-acetylcysteine and Glutathione with CB3717
CB3717 was prepared at a concentration of 200uM in
0.05M phosphate buffer pH 7.0. Glutathione and N-acetyl
cysteine were prepared as standard solutions of 2 0 mM, 2 mM 
and 200uM in 0.05M phosphate buffer adjusted to pH 7.0 with 
1M sodium hydroxide. 0.25ml aliquots of the glutathione or 
N-acetylcysteine solutions were added to either 0.25 ml of 
CB3717 solution or to 0.25ml 0.05M phosphate buffer to give 
mi x t u r e s  of lOOuM, ImM, l O m M  N-acetyl c y s t e i n e  or 
glutathione + lOOuM CB3717. These samples were then 
incubated at 20° for 4 hours in the dark following which the 
thiol concentration of each was determined- using the Ellmans 
assay as described previously. The lOmM solutions of N-
acetylcysteine and glutathione required 1  in 1 0  dilution
prior to this.
V.3.e Experiment to Determine The Effect of N-acetylcysteine 
Administration on CB3717 Induced Hepatotoxicity in Mice
CB3717 solutions were pr e p a r e d  as for earlier 
e x p e r i m e n t s  at a c o n c e n t r a t i o n  of lOm g / m l ,  pH 9.0. 
Treatment doses were lOOmg/kg i.p. N-acetylcysteine was
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dissolved in water and 1 M sodium hydroxide to give a 
concentration of 50mg/ml at pH 7.0. Treatment doses were 
500mg/kg i.p. (LD50 dose for mice 3725mg/kg i.p.) (Johnston 
R.E. Hawkins H.C. & Weikel JH 1983).
i) Mice were injected with CB3717 and N-acetylcysteine
i.p. at time 0. Control groups comprised animals injected 
with 150mM sodium bicarbonate buffer pH 9.0, animals 
injected with CB3717 alone and animals injected with N- 
acetylcysteine alone. At 1,3,6 and 9 hours groups of three 
mice (treated and controls) were sacrificed under diethyl 
ether anesthesia. Blood sampling and liver extraction were 
performed and plasma enzyme levels and liver glutathione 
levels were determined as previously described.
ii) In another experiment test animals were injected 
with N-acetylcysteine, 500mg/kg, 30 minutes prior to 
injection with CB3717 lOOmg/kg then at 1,2,3,4 and 5 hours 
after treatment. Sacrifice occurred at 3 and 6  hours with 
blood and liver sampling as before.
V.3.f Experiment to Determine The Effect of Thymidine, 
Folinic Acid and 5-Methyltetrahydrofolate on CB3717- 
Induced Hepatotoxicity in Mice
CB3717 solution was prepared at a concentration of 
lOmg/ml as for earlier experiments. Thymidine was dissolved 
in water 50mg/ml. 5-methyltetrahydrofolate was prepared as 
lmg/ml solution dissolved in lOmM ascorbic acid in 150mM 
sodium chloride. Folinic acid solution was prepared from 
3mg/ml calcium leucovorin (Lederle) diluted 1 in three with 
lOmM ascorbic acid in 150mM sodium chloride to give a final 
concentration of lmg/ml.
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i) Mice were injected intraperitoneally at time 0 with 
CB3717 (lOOmg/kg). Thymidine (500mg/kg) was injected at 
time 0  and 4 hours, the latter time point being chosen on 
the basis of the pharmacokinetics of thymidine (Taylor G., 
personal communication). Control animals received 150mM 
sodium bicarbonate or CB3717 (lOOmg/kg) only. Animals were 
sacrificed at 6  hours and plasma was assayed for liver 
enzyme levels.
ii) Mice were injected intraperitoneally at time 0 with 
CB3717 (lOOmg/kg). 5-methyltetrahydrofolate (lOmg/kg) or 
folinic acid (lOmg/kg) was injected i.p. at time 0, or time 
0,2 and 4 hours. Control animals received either lOml/kg of 
the drug diluents or 5-methyltetrahydrofolate (lOmg/kg) or 
folinic acid (lOmg/kg) or CB3717 (lOOmg/kg) alone. Animals 
were sacrificed at 3 and 6  hours and plasma was assayed for 
liver enzyme levels.
V.3.g Experiment to Determine if CB3705 and CB3714 are 
Hepatotoxic in Mice
CB3705, the N^-unsubstituted analogue of CB3717, was 
dissolved in 150mM sodium bicarbonate at a concentration of 
9.2mg/ml .and 27.6mg/ml (pH adjusted to 9.0 with 1M sodium 
hydroxide)." CB3714, the N ^ - e t h y l  analogue of CB3717 was 
similarly prepared to give a concentration of lOmg/ml and 
30mg/ml. The structures of these compounds are shown in 
Figure V.5. The drugs were injected intraperitoneally at 
time 0 at doses of 92mg/kg and 276mg/kg of CB3705 and 
lOOmg/kg and 300mg/kg of CB3714,^ thus using doses that were 
e q u i m o l a r  to CB3717 l O O m g / k g  and 3 0 0 m g / k g  (0.21 and
0.62mmole/kg). Control animals received only 150mM sodium 
bicarbonate (pH 9.0). Animals were sacrificed at 3 and 6  
hours by cardiac puncture exsanguination under diethyl ether
186
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anaesthesia. Blood samples were collected and plasma 
separated in the manner described for previous experiments. 
In addition to plasma liver enzyme assays, plasma CB3705 and 
CB3714 levels were measured using an HPLC system similar to 
that used for CB3717 estimation and described in detail in 
Chapter III. lOOuM standards of CB3705 and CB3714 were used 
for calibration and in the case of CB3705 the HPLC solvent 
mixture comprised 30% methanol/70% aqueous acetic acid (1%) 
instead of the 35% methanol/65% aqueous acetic acid. (1%) 
mixture used for CB3714 and CB3717.
V.4 Results
V,4.a CB3717 Hepatotoxicity In Mice
lOOmg/kg CB3717 produced marked elevation of plasma 
alanine transaminase levels in mice with peak values being 
observed at 6  hours after treatment. Alkaline phosphatase 
levels were not affected. The results are presented in 
Table V.l and Figure V.l.
V.4.b Experiment to Determine The Long Term Exposure of 
Liver, Kidney and Plasma to 14C-CB3717 Following i.p. 
Injection in Mice
Standardisation of -^ C-CB3717 Injection Solution
The counting efficiency for ^ C - h e x a d e c a n e  was 89.7%. 
Correcting the counts obtained for the diluted solutions, 
the total radioactivity of the doses administered are shown 
on Table V.2.a. The concentrations of the solutions as 
determined by UV absorbance at 301.5nm are shown on Table 
V.2.b. The analysis by HPLC found that 95.8+0.84% of the 
test solutions comprised the peak attributed to CB3717.
187
S'
-p Cn
tQ 0 in CM CM O r-> C
<D 3 CM O O VO CO *H
+> rH , ^ O O o rH 1 1
<0 • • • ' • • O
■P > o o o o O rHrH
Q
En
r*
rH • 0
r- Q O
co • •H
CQ W s
u  . ro CO o in
.w  + l rH r- cr> as in VO CM cH
0 IX + l +1 + 1 + 1 +1 +1 + 1
3 to
«H as co rH CO CO r"- as rH
0 <3 CM as CO r- CM •—I i—i 0
>  <U rH CM in rH >
4J \ 0
-P 0 D PI
03 0 H
<DU'-' 0
B  Eh CQ
0
• C
Q -H
<D • 6
3 W 0
rH 10 •
<0 +| C cu
> CM vr in in VO co 0 •
IX U •<H
rH + l + 1 + 1 +1 +1 + 1 + 1 H
o — Cn
. U .rH CM o rH iH CM 0
4J \ CM CM CM rH CM CM CM C  \
C D cn
O IH c 6
U  ~ 0 OrH o
rH
_ _ 0 r-
(0 6 rH
u to
x: 0 CO
»H CQ
Pi a
■P -P
10 c
O 0 • •
e >—1 CO VO as CO CM rH
-P CM . I"- •
0 0 >
6 0
H  U ~ . w
H  Eh pi
CQ
c
Eh
188
s
Pl
as
ma
 
Al
an
in
e 
Tr
a
n
s
a
m
i
n
a
s
e
 
In 
Te
st
 
Mi
ce
 
(% 
C
o
n
t
r
o
l
)
3000 r
2000
1000
100
706030 40 50200 10
Time Post Treatment (hours) 
Values shown are x ± S.D. (n=3)
FIGURE V . 1: Plasma Alanine Transaminase Levels In Mice 
After CB3717 100mg/kg i.p. (Values Expressed As % Control)
189
s
Solution 14C-CB3717 
mg/ml
Dose Administered 
mg/kg
Total Radio­
activity of 
dose uCi/kg
2 2 0 510
1 0 1 0 0 481
2 0 2 0 0 446
TABLE V.2.a: Total Radioactivity of The Doses Of ^4C CB3717
Administered To Mice
Solution 14C-CB717 
mg/ml
A°3 01.5nm Calculated
mM
Concentration
mg/ml
2  diluted 1 : 2 0 0 0.550 4.1 1.96
2 0.555 4.2 2 . 0 2
1 0  diluted 1 : 2 0 0 0 0.280 2 1 . 1 10.13
1 0 0.290 2 1 . 8 10.46
2 0  diluted 1 : 1 0 0 0 1 . 0 1 0 37.9 18.19
2 0 1.050 39.5 18.96
TABLE V.2.b: Absorbance of Solutions of CB3717 at 301.5nm
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Scintillation spectrometry of the collected fractions 
detected .91.2+1% of the total radioactivity within the 
CB3717 peak. The radiochemical purity of the ^C-CB3717 was 
thus rather inadequate for the pu r p o s e s  of d e t a i l e d  
distribution studies but was sufficient for determining the 
half life in kidney and liver.
Long Term Distribution of ^C-CB3717 in Mouse Liver,
Kidney and Plasma
Pr e v i o u s  studies (D.R. N e w e l l  and M. M a n t e u f e l -  
Cymborowska, personal communication) had demonstrated the 
pronounced distribution of -^C-CB3717 within the liver and 
kidneys and a summary of this data is shown in Figure V.2. 
The results of the extended study are shown in Table V.3 and 
represented graphically in Figure V.3. The half life in 
liver and kidney is approximately 16.6 and 62.5 hours 
respectively (calculated using a non-linear regression 
program) (Sampson J. 1969). Both liver and kidney  
concentrated the drug as the concentration, within these 
tissues exceeded plasma CB3717 concentrations at all time 
points observed.
V.4.c Effect of Paracetamol and CB3717 on Liver 
Glutathione and Serum Enzyme Levels
i. Paracetamol
The effect of paracetamol on liver glutathione levels 
in mice has been well documented (Mitchell J.R. e_t al 1973, 
Davis D.C. ejt al 1974). Depletion is generally dose related 
up to 375mg/kg and a nadir is reached by 1 hour after
N
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treatment with levels remaining low for several hours. A 
time point of 4 hours was chosen for study on this occasion. 
Other workers have previously reported that the depletion 
reflected a loss of total glutathione and not a conversion 
to oxidised glutathione (Mitchel J.R. et aJL 1973). In fact, 
the assay used here measured total non-protein bound thiol 
(SH) levels but for practical consideration this can be 
assumed to approximate closely glutathione levels.
The results sho w n  on Table V.4 c o n f i r m e d  that 
p a r a c e t a m o l  causes a s i g n i f i c a n t  d e c rease in liver 
gl utathione levels (t test t=2.74, p0.029) with a mean
reduction to 55+31% of control values. Alkaline phosphatase 
levels were not significantly different in paracetamol 
t r e a t e d  m i c e  (t=0.4106, p = 0 . 7 0 2 ) but the a l a n i n e  
transaminase values were elevated approximately 5 fold in 
one animal, fourteen fold in another and only very slightly 
in the third. When considered as a group the difference was 
not statistically significant (t test t=-1.4865, p = 0.23 4) 
but clearly there was a suggestion of liver cell damage in 
some animals. On the basis of these data it was considered 
worthwhile to assess the effect of CB3717 in the same 
system.
ii CB3717
The decrease in liver glutathione induced by CB3717 at 
lOOmg/kg is shown graphically in Figure V.4 with results 
expressed as percent controls. Considerable variation was 
seen but nadir values (67 + 7%) were found 3 hours after 
treatment with recovery to 100% control at 6  hours. A 
slight overshoot to 122+13% control values occurred at 9 
hours. The pattern of plasma alanine transaminase elevation 
observed is also shown in Figure V.4. Plasma alkaline
195
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phosphatase level's were unaffected. A repeat experiment 
using both lOOmg/kg and 300mg/kg CB3717 confirmed these 
transient abnormalities (see Table V.5) although on this 
occasion lOOmg/kg led to only very slight reductions in 
liver glutathione (87+6% controls). The dose of 300mg/kg 
CB3717 produced larger increases in plasma transaminase 
levels s u g g esting a dose r e l a t i o n s h i p  to the h e p atic 
toxicity in mice. It was noted whilst performing these 
experiments that a precipitate had formed in the gall 
bladders of mice treated with CB3717 which were sacrificed 
at 3-9 hours.
V.4.d Effect of Incubation of CB3717 With N-acetylcysteine 
and Glutathione
The absorbance at 412nm of the solutions of N-acetyl 
cysteine and glutathione incubated in the presence and 
absence of CB3717 are shown in Table V.6 . The presence of 
CB3717 did not cause any significant loss of non-protein 
bound thiols. Some loss of thiols, presumably by oxidation, 
was evident, especially in the solutions of O.lmM N-acetyl 
cysteine and O.lmM glutathione w h e n  compared with the 
stronger concentrations. This was most obvious in the N- 
acetylcys.teine solution incubated without CB3717.
V.4.e Effect of N-acetylcysteine on CB3717 Induced
• Hepatotoxicity
i) The results.of the experiment when N-acetylcysteine 
was administered at a dose of 500mg/kg i.p. once only at the 
same time as CB3717 (lOOmg/kg) are shown on Table V.7 a and
b. The liver thiol levels showed some variability and no 
statisically significant differences were found between 
those animals treated with CB3717 alone and those treated
198
S
Q)
G•H
i—I
o  -N 2 
(0 : 
c  "•rl
3Co  o 
c
0 o 
e  u  co 
<0 
r—ICM
o144J
G
OCJ
cfP
CP
\
ffo
o
CO
cn
j*
\
foo
CP
OO
p  ro
co
(0 CPiH
CM \
£o
o
rH
CP
\
wtn o  
to o  
O  co
u
%•H
P CP
g"O
o
rH
"3< CO
rH. VO
+ +
rH CO
VO in
CO CO
co ro
+ 1in +CN CN
t—i r -
00
S'
CP
00
rH
+IT)
O
CO
CO 
rH. 
+ 1 in  
vo
co
CP
in
CN
rH
£'
04
VO
CO
o-
in
rH
H
+
VOo
CP
rH
in
+ 1co
o-
CO
+1vo
o
vo
CO
c:
Q
CO
+1
IX
CO
co
TJ
0
CO
CO
0
&
s
CQ
4-5
rH
3  
CO 
004
CM
CP
1
0 0
G co
O•r| TJ
s c0
CO
4J CP3
rH \
O w14 0
0 0
> rH•r|
P 4-J
<
r - TJ
t—1 0
4-1
CO 0
8
014
Eh
Uh
O 0
CO
0
•H
1—I s0
> CH
IH
CQ
CO
rH
0
>
0 0
rH P
CM
4-1
010
O 0
-P G•i-l
G g  
0  0
g 0
0 G
H 0
3 14CQ Eh
0
0 0
s G
• •
*H
§in•
8wp CO
1
0
rH
CM
199
s
Absorbance at 410nM 
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101 
99.6 
146 
99.9 
99.3 
104
♦Diluted 1 in 10
TABLE V.6 : Effect of CB3717 Incubation with N-acetyl
cysteine or Glutathione on Thiol Estimation
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*10mM N-acetylcysteine 1.744 1.766
InM N-acetylcysteine 1.632 1.626
O.lmM N-acetylcysteine 0.054 0.079
*10mM Glutathione 1.686 1.684
ImM Glutathione 1.632 1.620
O.lmM Glutathione 0.075 0.078
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with CB3717 and N-acetylcysteine at both 3 and 6  hours post 
treatment (t test p=0.204, p=0.269 respectively). The
administration of N-acetylcysteine did not prevent the rise 
in plasma alanine transaminase levels caused by CB3717 and 
no significant difference in the enzyme elevation was noted 
at 3 and 6 hours between groups which received CB3717 alone 
or in combination with N-acetylcysteine (t test p=0.247, 
p=0.941 respectively). The plasma levels of CB3717 are 
shown in Table V.7c. N-acetylcysteine did not significantly 
alter CB3.717 concentrations in plasma at 3 or 6 hours after 
treatment (t test p=0.42, p=0.27). All animals which
received CB3717.. (either with or without N-acetyl cysteine) 
were noted to have a precipitate in the gallbladder at the 
time of sacrifice,
ii. The results of the experiment using repeated 
injections of N-acetylcysteine (500mg/kg) at 30 minutes pre 
and 1,2,3,4 and 5 hours post CB3717 (lOOmg/kg) treatment are 
shown in Tables V.8 a, b and c. The effect of multiple N- 
acetylcysteine injections plus CB3717 was to cause a marked 
depletion of liver thiol levels at 3 hours post treatment in 
c o m p a r i s o n  to CB3717 t r e a t m e n t  given alone (t test, 
p=0.015). This effect was not sustained at 6  hours when 
thiol levels exceeded control values in both groups and no 
significant difference between groups was observed (t test 
p=0.627). Plasma alanine transaminase levels were similarly 
more elevated 3 hours after treatment in mice given the 
combination of N-acetylcysteine and CB3717 than in those 
given CB3717 alone (t test p=0.069). At 6 hours p o s t  
treatment both groups showed similar enzyme elevations (t 
test p=0.6). CB3717 levels in plasma were higher at 3 hours
in mice receiving N-acetylcysteine (t test,p=0.082). Once 
again all mice who received CB3717 were found to have a
204
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Time
(hours)
CB3717 + N-acetyl 
cysteine x6  (% control)
CB3717 
(% control)
3 56+10 88+13
6 112+65 133+24
x + S.D. x + S.D.
TABLE V.8 .a: Glutathione Levels in Livers of Mice Treate< 
With CB3717 (lOOmg/kg) + Multiple injections of 
N-acetylcysteine (6x500mg/kg i.p.)
• Time 
(hours)
CB3717 + N-acetyl 
cysteine x6 (% control)
CB3717 
(% control)
3 933+389 303+44
6 1509+341 19 05+1158
x + S.D. x + S.D.
TABLE V.8 .b: Plasma Alanine Transaminase 
Treated with CB3717 (lOOmg/kg) + Multiple 
acetylcysteine (6x500mg/kg i.p.)
Levels in Mice 
Injections of N-
Plasma CB3717 Concentration
Time
(hours)
CB3717 + N-acetyl 
cysteine x 6 (% control)
CB3717 
(% control)
3 151+23 118+9
6 71+43 • -
x + S.D. x + S.D.
TABLE V.8 .c: Plasma CB3717 Concentration 
Treated With CB3717 (lOOmg/kg) + Multiple 
acetylcysteine (6x500mg/kg i.p.)
(uM) in Mice 
Injections of N
N
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precipitate in the gall bladder at sacrifice and the mice 
who received repeated i.p. injections of N-acetylcysteine 
had an accumulation of fluid in the peritoneal cavity and 
were hypokinetic with ruffled coats after the fourth 
injection.
V.4.f The Effect of Thymidine, Folinic Acid and 
5-methyltetrahydrofolate on CB3717 Induced Hepatotoxicity
The results are displayed in Table V.9a and b. None of 
these agents ameliorated CB3717-induced alanine transaminase 
elevation in mice. Indeed 5-methyltetrahydrofolate and 
CB3717 caused significantly higher enzyme elevations than 
CB3717 alone at both 3 and 6 hours post treatment and on 
single and multiple injections.
V.4.g Comparison of Plasma Drug Levels and Alanine 
Transaminase Levels In Mice After Equimolar Doses of The 
Quinazolines CB37Q5, CB3714 and CB3717
The structures of these different quinazoline molecules 
are shown in Figure V.5 and their effect on plasma alanine 
t r a n s a m i n a s e  levels is detailed in Table V.10. A
precipitate was observed in the gall bladders of mice 
treated with CB3714 and CB3717 but not in those treated with 
CB3705. Neither CB3705 or CB3714 caused any significant 
elevation of plasma alanine transaminase levels at 3 or 6  
hours after treatment. The plasma levels of these two drugs 
were also markedly lower than CB3717 levels at comparable 
time points.
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Time Thymidine Thymidine +CB3717 CB3717
(hours) (% Control) (% Control) (%Control)
6  114+10 1381+654 .1905+1157
x + S.D. x + S.D. x + S.D.
TABLE V. 9 .a: Plasma Alanine Transaminase Levels In Mice
Treated With Thymidine (500mg/kg x 2) and CB3717 (lOOmg/kg) 
+ Thymidine
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FIGURE V.5 : Structures of CB3705, CB3714 and CB3717
209
\
CB3705
Time
Hours
ALT (% 
~ 1 0 0 mg/kg
control)
~3 00mg/kg
Plasma
lOOmg/kg
Cone (uM) 
300mg/kg
3 94+14 15+2 -
6 140+36 132+21 1.8+0.3 15+9
CB3714
Time
Hours
„ALT (% 
~ 1 0 0 mg/kg
control)
300mg/kg
Plasma Cone (uM) 
lOOmg/kg 300mg/kg
3 78+13 140+32 6+3 55+25
6 80+16 189+87 < 1 < 2
CB3717
Time
Hours
ALT (% 
~1 0 0 mg/kg
control)
~300mg/kg
Plasma
lOOmg/kg
Cone (uM)
3 00mg/kg
3 3 05+41 361+15 125+3 361+15
6 1905+1157 3627+1260 72+42 352+13
x + S.D. x + S.D. x + S . D . x _+ S.D.
TABLE V.1Q: Comparison of Plasma Levels of CB3705, CB3714
and CB3717 in Mice After Equimolar Doses and The Effect on 
Plasma Alanine Transaminase Levels
- " 210
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V. 5 Discussion
Reversible hepatic toxicity, with a transient increase 
of plasma alanine transaminase levels, was demonstrated in 
mice treated with therapeutic doses of CB3717. As mentioned 
earlier, although the time course of enzyme elevation 
differed from that in man (see Chapter II), for reasons 
w h i c h  r e m a i n  unclear, it was d e e m e d  w o r t h w h i l e  to 
investigate the problem in such an experimental system and 
to seek possible modulating factors.
The prolonged tissue distribution study of CB3717 in 
mice revealed the long exposure time of the kidneys and 
liver to the drug at fairly high concentrations. After 
treatment at 2 0 0 mg/kg (which is a therapeutic dose for mice) 
8.4nmoles/g and 1553nmoles/g of drug were present in liver 
and kidney tissue 23 days after treatment. One explanation 
for this in the kidneys could be related to drug 
precipitation and hence reduced renal elimination. By 
comparison, early studies of the persistence of methotrexate 
in normal mouse tissues using non toxic doses (l-3mg/kg i.p. 
on alternate days x 1-3 or lmg/kg i.v. on alternate days x3) 
reported that parent drug was present in the kidneys and 
liver 2 1  days after treatment and as long as 8  months in the 
liver in one instance (Fountain J.R. et al 1953). Charache 
also found persistence of methotrexate in the liver for more 
than 100 days in man and mouse (Charache S.R. Condit P.T. & 
Humphreys S.R. 1960). Baugh and co-workers subsequently 
established that methotrexate followed the biosynthetic 
routes of folic acid and was to some extent converted to 
poly-i -glutamyl derivatives (Baugh C.M. Krumdieck C.L. & 
Nair M.G. 1973).
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O t h e r  g r o u p s  h a v e  c o n f i r m e d  the p r e s e n c e  of 
methotrexate polyglutamates in various tissues of mice, rats 
and men (Whitehead V.M. Perrault M.M. & Stelcner S. 1975, 
Gewirtz D.A. ejt £]. 1979, Poser R.G. Sirotnak P.M. & Chello 
P.L. 1981, Krakower G.R.jNylen P.A. & Kamen B.A. 1982). The 
enzyme responsible, folyl polyglutamate synthetase (FPGS), 
has been partially purified from rat liver (McGuire J.J. et 
al 1980) and recently CB3717 was found to be a substrate for 
the enzyme (Moran R., personal communication) with a Km of 
a p p r o x i m a t e l y  50uM. It seems likely that CB3717 is 
converted to pOlyglutamate forms in the liver and kidney 
which might delay its elimination from these, tissues. 
Add i 1 1 o h a 1 ly at h i g h con c entr a t ions (>100u M ) C B 3 717 
inhibited FPGS (Moran R., personal communication). If this 
is the case, in vivo, presumably FPGS activity on natural 
folates might be perturbed. The importance of this to the 
h e p a t o t o x i c  p r o p e r t i e s  of CB3717 is u n c e r t a i n  but 
interestingly the polyglutamate forms of CB3717 have also 
been shown to be more potent inhibitors of thymidylate 
synthetase than the monoglutamate (in permeabilised cells), 
with stoichiometric inhibition occurring with the tri, tetra 
and pentaglutamate forms (Kisliuk R.L. e_t cil 1984). It 
seems possible that within the liver an interaction of 
CB3717 with FPGS could be relevant to its toxicity to this 
tissue.
The series of studies on liver glutathione levels after 
CB3717 treatment are difficult to interpret. The decrease 
of. liver thiol levels measured 3 hours after a dose of 
lOOmg/kg CB3717 varied from 67+7% control to 94+7% controls 
when all the experiments are considered. Recovery to values 
> 1 0 0 % controi values by 6  hours was observed in all cases 
except when the higher dose of 300mg/kg CB3717 was used 
(liver thiols 65+13% controls at 3 hours, 78+5% at 6  hours).
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In contrast, paracetamol can induce depletion of liver 
glutathione in mice at hepatotoxic doses (>375mg/kg) to 
values of -25% normal (Mitchell et: al 1973). which may not 
recover to normal even by 10 hours (Peterson F.J. ejt ajL 
1983). There is a species difference in susceptibility to 
paracetamol toxicity which correlates with the degree of 
glutathione depletion it causes, the mouse and hamster 
being much more sensitive than rats or guinea pigs (Davis 
D.C. et al 1974). However, the variable effect of CB3717 on 
mouse liver thiol levels, despite more consistent elevations 
of alanine transaminase levels, implies that this transitory 
perturbation may be caused by and not causative of, the 
hepatic injury. In support of this, other drugs have been 
noted to cause slight liver glutathione depletion in mice 
including cocaine (25-30% reduction at 1 hour) propoxyphene 
(20-30% at 3-6 hours) and m o r p h i n e  (50% at 3 hours) 
(Thompson M.L. Shuster L. & Shaw K. 1979, James R.C. et al 
1982), but there was no correlation between this effect and 
the observed rise in plasma alanine transaminase values 
caused by these narcotics. It may be that these compounds 
and CB3717 produce liver damage in the presence of adequate, 
though decreased, liver glutathione. Perhaps caution should 
be exercised in the co-administration of known glutathione- 
depleting agents with other hepatotoxic drugs in order to 
avoid additive effects.
The inability of N-acetylcysteine to prevent CB3717 
hepatotoxicity is consistent with the above conclusions. 
Once again, considerable variation was seen in the liver 
glutathione levels of animals treated once only with N-acetyl 
cysteine but there was no appreciable effect on the slight 
CB3717-induced depletion of glutathione at 3 hours. The 
more marked depletion of liver thiols observed in mice 
treated with multiple intraperitoneal injections of N-
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acetylcysteine plus CB3717 compared with those receiving 
CB3717 only, is difficult to explain. It may be related to 
the reported ability of large doses of N-acetylcysteine 
administered intraperitoneally to cause GSH depletion in 
rats (Vina J. et a^ 1980). These workers found that l.Og/kg 
N-acetylcysteine given i.p. to rats depleted liver GSH to 
42% control values by 4 hours. Recovery did not occur till 
24 hours later. Further work by the same group confirmed 
this finding but reported that oral N-acetylcysteine did not 
cause GSH d e p l e t i o n  (Estrela J.M. ej: 1983). Their
explanation for this is that if large doses of cyteine or N- 
acetylcysteine enter the blood plasma, they may be oxidised 
very rapidly. This can generate hydroxyl and thiyl radicals 
which cause GSH depletion. Oral administration, ensures 
maintenance of the amino acids in a reduced form with slow 
release into the small intestine and slow absorption. 
However, i.v. administration of N-acetylcysteine to severe 
paracetamol overdose patients remains the treatment of 
choice in man (Prescott L.F. 1983) which seem incompatible 
with this logic.
Recently some doubts have been expressed concerning the 
proposed mechanism of paracetamol-induced hepatotoxicity. 
Cimetidine, an H 2  antagonist, binds to cytrochrome P 4 5 Q and 
can inhibit hepatic drug metabolism. In mice, concomitant 
administration of cimetidine lOOmg/kg and paracetamol 
. (350mg/kg) protected the animals from paracetamol-induced 
hepatic injury, but did not significantly affect plasma 
pharmacokinetics of paracetamol, prevent depletion of 
hepatic glutathione or alter in vivo covalent binding of 
paracetamol to hepatic proteins (Peterson F.J. £t a_l 1983). 
The subject of d r u g - a s s o c i a t e d  d e p l e t i o n  of liver 
g l u t a t h i o n e  and the role of thiol donating a g e n t s  as 
protection is thus complex and probably not entirely
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relevant to CB3717 hepatotoxicity.
Reversal of the antitumour effect of CB3717 in L1210 
tumour bearing mice can be achieved by administering 
th y m i d i n e  (Jackman A.L. ejt al • 1984), H o w ever, no 
improvement in the hepatic effects of CB3717 occurred when 
thymidine was tried as an antidote, which strongly suggests 
that inhibition of thymidylate synthetase is not the 
hepatotoxic lesion. Furthermore, any effect of CB3717 on 
other enzymes of the folate pathway i.e. dihydrofolate 
reductase, should have been reversed by the provision of 
folinic acid or 5-methyltetrahydrofolate but neither of 
these agents were able to counteract the liver toxicity. 
This refutes the hypothesis that the antifolate properties 
of CB3717 are culpable.
The study of two related quinazoline molecules was 
enlightening. Neither the unsubstituted molecule
CB3705, or the ethyl compound, CB3714, caused any
elevation of plasma alanine transaminase levels. CB3714, 
however, is a fairly potent inhibitor of TS with an I^q for 
the L. Casei enzymes of 27nM and 38nM respectively (Calvert 
A.H. et al 19 8  0b) and this lends support to the belief that 
TS inhibition per se is not a hepatotoxic event. Further, 
despite approximately equimolar doses of CB3705, CB3714 and 
CB3717 being given, the plasma concentrations of both CB3705 
and CB3714 were very much lower than CB3717 at 3 and 6  hours 
after treatment. One explanation for this could be that the 
damage to hepatocytes caused by CB3717 may reduce its rate 
of clearance in the bile. Whatever the reason for the 
differing plasma pharmacokinetics of these quinazolines, the 
evidence points to the propargyl group of CB3717 as a
key feature in its hepatotoxicity. A few other compounds 
with triple carbon bond substituents have been cited as
S
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hepatotoxins including pargyline hydrochloride (Lowe M.C. 
1978) and danazol (Pearson K. & Zimmerman H.J. 1980). The 
toxicity is thought to be mediated by metabolic activation 
of the acetylenic substituent which causes a measurable 
decrease of hepatic microsomal cytochrome P 4 5 0  (White I.H. 
1978). Although metabolites were not detected in human and 
mouse plasma or urine (see Ghapter III and Newell D.R. et al 
1982) it is conceivable that small amounts of a reactive 
metabolite are formed by interaction of the N*^ propargyl 
group with c y t o c h r o m e  £ 4 5 0 * If this were the case, 
phenobarbitone pretreatment (a hepatic microsomal enzyme 
inducer) might worsen CB3717 toxicity. Alternatively, 
cimetidine, which binds to hepatic cytochrome P 4 5 0  and 
inhibits hepatic drug metabolism, should help prevent the- 
toxicity as has been recently reported for paracetamol and 
cocaine (Peterson F.J. ejt al_ 1983). Clearly both these 
studies need to be performed.
The nature and sig n i f i c a n c e  of the gall bladder 
precipitate observed in mice treated with CB3717 and CB3714 
requires exploration, particularly as only one drug is 
apparently hepatotoxic. Some preliminary studies by D.R. 
Newell (personal communication) performed on rats (who also 
develop a precipitate in the common bile duct and elevations 
of plasma ALT levels after CB3717 treatment) indicate that 
the precipitate is not cholesterol. It is possible that 
one, or a mixture, of the bile acids may be responsible.
In summary, these investigations of CB3717-induced 
hepatitis in mice have made an important contribution to the 
definition of those features of the drug which are most 
likely to play a role in its clinical liver toxicity. In 
addition, some areas for further study have been indicated 
with the hope that future effort will provide a more precise
216
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explanation for this phenomenon.
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CHAPTER VI
EXPERIMENTAL RESISTANCE TO CB3717 
VI.1 Introduction
The development of resistance to cytotoxic drugs is a 
common and frustrating problem in the treatment of clinical 
cancer. Many workers have explored the nature of such 
resistance by experimental systems with resistant tumour 
cell lines using both iri vivo and irv vitro models (reviewed 
by Selby P. 1984). Although these studies cannot reflect 
accurately the situation in patients many useful indications 
of the adaptive measures involved at a cellular level have 
been established. A well known and frequently cited example 
of such work concerns the dihydrofolate reductase inhibitor, 
methotrexate. Several mechanisms of resistance to this 
antimetabolite have been described which include an increase 
in levels of dihydrofolate reductase activity (Fischer G.A. 
1961, Friedkin M. e_t al 1962, Schrecker A.W. et_ a_l 1971) , a 
change in the cellular transport of methotrexate (Fischer 
G.A. 1962, Sirotnak F.M. Kurita S. & Hutchinson D.J. 1968, 
H a r r a p  K.R. jst. al 1971) and k i n e t i c a l l y  a l t e r e d  
dihydrofolate reductase (Jackson R.C. Hart L.I. & Harrap 
K.R. 1976, Jackson R.C. & Niethammer D. 1977). One or more 
of these changes may be present in cells which acquire MTX 
resistance (Niethammer D. & Jackson R.C. 1975). Further 
investigation of cells with elevated dihydrofolate reductase 
activity has implicated amplification of the DHFR gene as 
the basis for such an effect (reviewed by Bertino J.R. et al 
1981). Indeed, Schimke and coworkers concluded from their 
work with the murine sarcoma cell line S-180 that "the 
prolonged administration of a single drug in ever increasing 
concentrations which is retained in the environment is
220
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precisely that form of administration most likely to result 
in a m p l i f i c a t i o n  of genes in a stable state, ther e b y 
importing stable resistance". (Schimke R.T. e_t aJL 1978). 
In one leukaemic patient receiving MTX therapy, DHFR gene 
amplification was found when resistance to MTX emerged 
(Horns R.C. Dower W.J. & Schimke R.T. 1983).
In the preclinical studies, CB3717 was toxic to mouse 
L 1 2 1 0  leukaemia cells grown in continuous suspension culture 
with an ID^q concentration at 48 hours of 5uM (Jones T.R. e_t 
al 1981). Resistant cells were raised by exposure of these 
L1210 cells to incremental concentrations of CB3717, in 
culture medium containing negligible amounts of salvageable 
thymidine (<10~^). Approximately 100 fold resistance 
developed over 2 years with the emergence of L1210 cells 
refractory to the presence of CB3717 at a concentration of 
500uM. (The poor sol u b i l i t y  of CB3717 at neut r a l  pH 
prohibited the preparation of solutions in excess of 25mM 
which were diluted 1 in 50 in the growth medium to attain 
the final concentration of 500uM.) The subsequent isolation 
of several monoclonal lines and their characterisation, is 
described in this chapter and has afforded some further 
insight into the properties of CB3717 with the elucidation 
of at least one possible mechanism of clinical resistance. 
Additionally, some experiments to determine cross-resistance 
with other antifolate and f luoropyr imidine c o m p o u n d s  
produced interesting results, which are also described. 
This work was performed in collaboration with A.L. Jackman 
as indicated.
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VI.2 Materials
VI.2.a Chemicals
Reagent chemicals (analar grades when available) were 
ob t a i n e d  from BDH Ltd (Poole, Dorset) and Ho p k i n  and 
Williams Ltd. (Romford, Essex). Nicotinamide adenine 
dinucleotide phosphate, (reduced-NADPH), dihydrofolate 
(FH 2 )/ d e o x y u r i d i n e  m o n o p h o s p h a t e  (dUMP), 5 , 1 0 - 
methylene tetrahydrofolate (5,IO-CH 2 FH 4 ) were supplied by 
Sigma Chemicals Co. (London). JH-dUMP was supplied by 
Amersham International PLC.
VI.2.b Drugs
The quinazoline compounds CB3703, and CB3705 were 
prepared by Dr. T.R. Jones (JonesT.R. 1980). CB3717
was supplied by ICI Pharmaceuticals Division (Alderley Park, 
Macclesfield, Cheshire). Methotrexate by Nils Klaas Klausen 
(Denmark). 5-fluorouracil and 5-fluorodeoxyuridine by Sigma 
Chemical Co. (London).
VI.2.c Tumour Cells and Media
Mouse L1210 leukaemia cells and the resistant line 
(induced by culture of the sensitive LI 210 cells in 
i n c r e m e n t a l  sublethal doses of CB3717) w e r e  g r o w n  
continuously in suspension culture in RPMI 1640 medium 
containing 20mM Hepes buffer and 10% donor horse serum 
(mycoplasma and bacteriophage tested - Flow Labs) which was 
supplemented by 2mM glutamine. Resistant cells were 
passaged in the presence of 500uM CB3717 in addition.
222
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VI. 3 Methods
VI.3.a Cell Culture
Solutions of CB3717 for use in tissue culture were, 
prepared by dissolving the diacid powder in 1 0 ml deionised 
water with a few drops of IN sod i u m  hydro x i d e  to a 
c o n c e n t r a t i o n  of 25 m M  drug. One drop of phenol red 
indicator was then added, as a pH indicator, and the 
solution was sterilised by filtration through millipore 
Millex 0.22um filters. The pH was adjusted to neutral 
(orange/red) by the d r o p w i s e  addition of sterile IN 
hydrochloric acid using a sterile pipette. Solutions were 
stored at 4°C and used within 1 month.
L1210 cells and L1210 cells resistant to CB3717 
(L1210R3717) were diluted in fresh complete medium to a 
concentration of 5x10^ cells/ml. 10ml subcultures were used 
routinely in 25cm^ flasks. 0.2ml of the 2 5 m M  CB3 717 
solution (prepared as above) was added to the 1 0 ml medium  
for the resistant cell line (final concentration 500uM). 
Cells were counted in an improved Neubauer haemocytometer. 
Incubations took place at 37°C.
VI.3.b Colony Formation of The L1210 Cells Resistant to 
CB3717 500uM
L1210 resistant cells were serially diluted in complete 
medium containing 500uM CB3717 to achieve a concentration of 
40 cells/ml on day 1. As a lag phase prior to logarithmic 
g r o w t h  is usual when cells are diluted to such low 
concentrations, on day 2  cells were assumed to be still 
approximately at a concentration range of 40/ml. Further 
dilu t i o n s  of the cells were made to p r o v i d e  final 
concentrations of 6.5, 10, 15, 20 and 25 cells/ml in total
223
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volumes of 25ml (24ml medium). Just prior to plating, 1ml 
of warm 4% agar solution was rapidly injected into the 
flasks (to provide final volume 25ml) which were vigorously 
shaken. 4x5ml of this mixture was then plated onto small 
petri dishes using a sterile technique. The petri dishes 
were stacked in a sandwich box, the. sides of which were 
moistened by wads of dampened absorbent paper and the lid of 
which was sealed with tape. The box was left in the 
incubator at 37°C for fifteen days. After this time 
colonies were observed in all the dilutions, just visible to 
the naked eye, and fifteen were removed. This was achieved 
using a sterile pipette and a gentle suction force to lift 
individual colonies from the agar and place them in 1 0 ml 
plastic tubes containing 1 ml of complete tissue culture, 
medium. Dilution with a further 4ml medium took place the 
next day and after one week 7 of the colonies had given rise 
to satisfactory cell growths (C3,C5,C6,C7,C10,C14,C15). 
These monoclonal resistant cell lines were subcultured twice 
weekly thereafter in the presence of CB3717 (500uM) and one 
cell line, C15, was additionally passaged in the absence of 
drug for 9 months. It should be noted that prior to the 
successful colonisation of the resistant cells three earlier 
attempts using cell dilutions ranging from 2 - 1 2  cells/ml had 
been unsuccessful.
VI.3.c Growth Characteristics of L1210 Cells and 3 Mono- 
Clonal L121Q Lines Resistant to CB3717
L1210 cells and the monoclonal resistant lines C3, CIO, 
and C15, in suspension culture were counted using a modified 
Neubauer h a e m o c y t o m e t e r  and were then d i l u t e d  to a 
concentration of 5x10^ cells/ml in complete medium. The 
resistant cells had been grown in the absence of CB3717 for 
one week prior to the experiment but dilutions were made in
224
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the presence and absence of CB3717 (500uM) for comparison. 
Triplicate 5ml cultures were set up in 25cm2 flasks and the 
cells were counted 4.5, 28, 46.5 and 72 hours afterwards
with incubation at 37°C in the interim.
VI.3.d Estimation of Thymidylate Synthetase Activity 
(Performed v/ith A.L. Jackman)
The m o n o c l o n a l  resistant L1210 cell lines were 
subcultured in the absence of CB3717 for 14 days prior to 
preparation for thymidylate synthetase assay. Bulk cultures 
35-100ml) of the resistant cells and sensitive L1210 cells 
were prepared at a concentration of 7xl0^/ml and on the 
following day these were counted accurately and a precise 
measurement of their volumes was made. The cells were 
c e n t r i f u g e d  at - 1 7 Og for 5 m i n u t e s  in a p r e - c o o l e d  
centrifuge (4°), the supernatant was decanted off and the 
cell pellets were washed in ice cold saline and respun. 3ml 
of buffer (0.05M potassium phosphate/O.OlM mercaptoethanol 
pH 7.4) was added to each of the remaining pellets which 
were sonicated. Centrifugation at 50,OOOg for 1 hour in a 
pre-cooled centrifuge (4°) was performed and the supernatant 
was retained for t h y m i d y l a t e  s ynthetase e s t i m a t i o n .  
Thymidylate synthetase was assayed by a modification of the 
m e t h o d  of Calv e r t  (Calvert A.H. et a_l 1980a) w h i c h  
essentially involves counting the tritiated water by-product 
of the reaction b e t w e e n  ^ H - d U M P  and 5,1 0 - m e t h y l e n e  
tetrahydrofolate (unutilised ^H-dUMP being retained on a 
Dowex chloride column). Counting was performed on an SL30 
Inter technique liquid scintillation counter.. The 0.5ml 
incubation mixture contained lOOuM 3H dUMP (0.225uCi) and 
220uM (+)-L-5 ,1 0 -CH 2 FH^ (made by dissolving 7mg (+)-L-FH4  in 
5ml of 0.1M dithiothreitol with the addition of formaldehyde 
(20mM) and 0.1ml of IN NaOH). The reaction was started by
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the a d dition of 0.25ml of the e n z y m e  p r e p a r a t i o n  and 
incubation was for one hour at 37°C. Under these conditions 
less than 2% of the substrate was converted to product. The 
reaction was stopped by the addition of 1 ml iced water and 
the whole mixture was then run down a 3x0.5cm Dowex 1 
chloride column. Further elution with 2ml iced water gave a 
total effluent of 3.5ml which was mixed with 10ml of PCS 
scintillant and counted. The experiment was repeated nine 
months later using C15 resistant cells grown in the absence 
of CB3717.
VI.3.e Purification of Thymidylate Synthetase From C15 
and L1210 Cells With Estimation of Kinetic Constants 
(Performed with A.L. Jackman)
Bulk cultures of L1210 and C15 cell lines were used to 
prepare cell lysates as described above (C15 cells grown out 
of CB3717 for 1 month prior to experiment). Purification 
was achieved by salt precipitation followed by a single 
affinity chromatographic stage that, was dependent on 
reversible ternary complex formation with the biospecific 
ligand, CB3714 (N-(4 ((2-amino-4-hydroxy-6-quinazolinyl)
methyl)ethylamino)benzoyl-L-glutamic acid) (Jackman A.L. et 
a_l 1984), The fractions containing enzyme were pooled and 
the thymidylate synthetase activity was estimated using 
variable concentrations of substrate. CB3717 was made up as 
a ImM solution in 0.1M sodium hydroxide and diluted in water 
and was introduced to the assay mixture in different 
c o n c e n t r a t i o n s  in order to c a lculate the I ^ q for the 
purified thymidylate synthetase enzymes. Kinetic constants 
were c a l c u l a t e d  by the m e t h o d  of W i l k i n s o n  using an 
algorithm supplied by Dr. R.C. Jackson (Wilkinson G.N. 
1961) .
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VI.3.f Estimation of Dihydrofolate Reductase Activity
L1210 cells and three monoclonal CB3717 resistant 
strains (C3, CIO & C 15) were p r e p a r e d  as 150ml bulk 
cultures, CB3717 having been omitted from the culture medium 
of the resistant cells for 2  weeks prior to the experiment. 
Whilst in a logarithmic growth phase the cells were counted 
and then centrifuged at 170g for 5 minutes. The supernatant 
was discarded. The cell pellet was resuspended in 10ml of 
0.15M potassium phosphate buffer at pH 7.0 and was sonicated 
at 2 0 KHz for 10 s e c o n d s  u s i n g  a M S T  u l t r a s o n i c  
disintegrator. These preparations were then centrifuged at 
35,000g in a pre-cooled centrifuge (4°) for 1 hour following 
which the supernatant was decanted and dialysed overnight 
a g a i n s t  0.15M p o t a s s i u m  p h o s p h a t e  b u f f e r  pH  7.0. 
Dihydrofolate reductase was assayed spectrophotometrically 
(Osborn M.J. & Huenneken F.M. 1958). Dihydrofolate was 
dissolved in 0.25M mercaptoethanol with the minimum of 0 .1 N 
s o d i u m  h y droxide required to bring it into s o l u t i o n  
(lmg/ml). NADPH was dissolved in water (2mg/ml). lOOul 
NADPH, and 200 ul of the enzyme preparation from different 
cell lines were mixed in a cuvette, the total volume being 
made up to 1.8ml using 0.15M potassium phosphate buffer. )A 
reference sample was also prepared omitting the enzyme. The 
change in absorbance at 340nm was followed using a Cary 
model 16K recording spectrophotometer. lOOul of the 
dihydrofolate was added to each cuvette and the rate of 
change of absorbance at 340nm was determined again. The 
"baseline" activity seen before the addition of FH 2  was 
minimal and was attributed to the oxidation of NADPH by 
reactions other than the reduction of FH2. This rate was 
subtracted from the rate of the final reaction to give an 
accurate m e a s u r e  of d i h y d r o f o l a t e  reductase activity 
(Jackson R.C. ej: al^  1976). Results were calculated assuming
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a molar extinction change at 340nm for the reaction of 1.22 
x lO^cm” .^ The experiment was repeated on several occasions 
with the different cell lines including the C15 resistant 
cells which had been grown in the absence of CB3717 for 9 
months.
VI. 3.g Cross-Resistance Studies With L1210 and C15 Cells 
Resistant to CB3717
C15 cells were grown in the absence of CB3717 for 2 
weeks prior to each series of experiments. Bulk cultures of 
the L1210 and €15 cells were prepared at a concentration of 
5xl0 4  cells/ml. Drugs for use in tissue culture were 
dissolved in de~ionised water, diluted to the required range 
of concentrations and sterilised by filtration through 
millipore Millex 0 .2 2 um f i l t e r s . T h e  drug solutions were 
1 0 0  times the final concentration as 0 .1 ml of drug solution 
was added to 1 0 ml of cells in complete tissue culture medium
... o .. .. .
within 25cm flasks. Triplicate cultures were used with 
control flasks receiving 0 .1 ml sterile water in place of 
drug. Incubation at 37°C was interrupted only by cell 
counting at 24 and 48 hours and the results were expressed 
in terms of control cultures.
The c o m p o u n d s  tested were m e t h o t r e x a t e  (DHFR 
inhibitor), 5-fluorouracil (5-FU), 5-fluororo-2-deoxyuridine 
(FUdR) and two der ivatives of the N- (p- (((6 -quinazolinyl) 
methyl) amino) benzoyl)-L-glutamic acid series, CB3703 (2,4- 
diamino-5-methyl) and CB3705 (2-amino-4-hydroxy). Both 5-FU 
and FUdR are classed as thymidylate synthetase inhibitors by 
virtue of their metabolism to 5-fluoro-2-deoxyuridine 
monopohosphate (FdUMP) which is a TS inhibitor (Heidelberger 
C. 1982). Other mechanisms are probably involved in the 
cytotoxicity of 5-fluorouracil which is discussed in Chapter
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I (Friedman M.A. & Sadee W. 1978). CB3703 and CB3705 are
inhibitors of both thymidylate synthetase and dihydrofolate 
reductase, the Ki for L1210 TS being 470nM and 67nM 
respectively and the Ki for rat liver DHFR being 0.6pM and 
350pM respectively (Calvert A.H. et al 1980).
VI.4 Results
VI.4.a Characteristics of L1210 Cells and 3 Monoclonal 
Cell Lines Resistant to CB3717 (In The Presence and Absence 
of CB3717 500uM)
The resistant cells appeared morphologically similar to
the parent LI210 line although some irregularity of contour
and variability in cell size was apparent. The doubling.
time of the resistant strains was approximately twice that
of. the sensitive L1210 cells and the presence of CB3717 did
*
not affect them significantly as detailed below.
+ indicates grown in the presence of CB3717 
- indicates grown in the absence of CB3717
When C15 cells were re-exposed to CB3717 500uM after 9 
months passage in the absence of drug, no growth inhibition 
occurred proving maintenance of resistance over this period.
Cell Line Approx. Doubling 
Time (Hours)
L1210 12.5
22.5
24.5
24.0
24.5
24.0
26.5
C3-
C3+
C10-
C10+
C15-
C15+
s
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VI.4. b Thymidylate Synthetase Activity in L1210 Cells
Resistant and Sensitive to CB3717
The activity of thymidylate synthetase in the different 
cell lines is shown in Table VI.1.a expressed as nmoles/10^ 
cells/hour. All the resistant cell lines showed increased 
thymidylate synthetase activity (10-40 fold). Table Vl.l.b 
demonstrates the sustained increase in activity in the CIS 
cells grown in the absence of CB3717 for 9 months.
VI.4.c Purified Thymidylate Synthetase From L1210 and C15 
Cells:- Kinetic Constants and I^q CB3717
The kinetic constants and I^ q CB3717 for thymidylate 
synthetase purified from the sensitive and resistant L1210 
cells are shown in Table VI.2. The results suggest that the 
kinetics of the enzymes from these sources is identical.
VI.4.d Dihydrofolate Reductase Activity In L1210 and 
Resistant L1210 Cells
The dihydrofolate reductase activity of thedifferent 
cell lines is shown in Table VI.3 expressed as International 
Units/10^ cells, (llnternational Unit = lumole product 
transformed/min). DHFR activity was increased by 4.8-10.5 
fold in CB3717 resistant lines and in the C15 strain grown 
in the absence of drug for 9 months the increased DHFR 
activity was maintained.
S'
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Cell Line Thymidylate synthetase 
Activity nmoles product/ 
1 0  cells/hour
Increased Activity 
(fold)
L1210 0 . 2 0 1 -
C3 7.594 38
05 5.763 ■ 29 ....
C 6 2.315 11.5
C7 5.187 26
CIO 2.054 1 0
C14 2.748 14
C15 3.558 18
TABLE VI.1.a: Thymidylate Synthetase Activity in L1210 
Cells Resistant and Sensitive to CB3717
Cell Line Thymidylate synthetase Increased Activity
Activity nmoles product/ (fold)
1 0  cells/hour
L1210 0.07 -
C15- 2 . 1 0 30
TABLE Vl.l.b: Thymidylate Synthetase Activity In L1210 And
C15 Cells Grown In The Absence Of CB3717 For 
9 Months
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Cell Line Km for dUMP. 
(uM)
Km for 5,10 
-CH 2 FH 4  (uM)
I 5 0  for CB3717 
(nM)
L1210
Sensitive
2.4+0.5 17.9+1.6 14
C15 (L1210 
Resistant) 3• 8 + 0.62 18.16+4.8 14
x + S . D • x + S.D.
TABLE VI.2: Thymidylate Synthetase Kinetic Constants and 
Inhibition by CB3717
\
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Cell Line Enzyme Activity 
IU/10 cells
Increased Activity 
(fold)
LI 210 0.08+(0.019) (n=3)
C3 0.38 (n=l) 4.8
CIO "0.58+0.14 (n=2 ) 7.3
Cl 5 0.73+0.16 (n=2 ) 9.1
C15-* 0.84+0.07 (n=2 ) 10.5
x + S.E.
C15 grown in absence of CB3717 for 9 months
TABLE V I .3: Dihydrofolate Reductase Activity In L1210 Cells 
Resistant And Sensitive To CB3717
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VI.4.e Cross Resistance Studies
Examples of the dose response curves of the L1210 and 
C15 cells to GB3703, methotrexate, 5-fluorouracil and 
fluorodexoyridine are shown on Figures VI.1,2,3 and 4 with a 
summary of the calculated ID^q 's shown on Table VI.4.
VI.5 Discussion
The most striking difference between the sensitive 
and resistant L1210 cells was the increase in thymidylate 
s y n t hetase a c t ivity a p p arent in the seven survi v i n g  
monoclonal lines (10-40 fold). Additionally, three of the 
lines (C3, CIO & C15) sh o w e d  a slight e l e v a t i o n  of
dihydrofolate reductase activity (5-10 fold). In the C15 
line these changes in enzyme activity were found to be 
stable over a nine month period when CB3717 was withheld 
from the growth medium. This accords with the maintained 
100 fold resistance to CB3717 found on rechallenge with the 
drug. Furthermore the kinetic data attained for thymidylate 
synthetase purified >2000 fold (Jackman A.L. et. aJL 1984) 
from C15 and L1210 cells suggested that the enzymes were 
identical.
The cumulative evidence therefore points to increased 
production of thymidylate synthetase as the mechanism of 
r e s i s t a n c e  to C B 3 7 1 7  p o s s i b l y  s e c o n d a r y  to g e n e  
amplification. Proof of this hypothesis requires isolation 
of the TS gene and direct analysis of the CB3717 resistant 
L1210 DNA in comparison with the sensitive parental line 
DNA. Such a project is being undertaken by other workers 
who also have subjected samp l e s  with equa l l y  active 
thymidylate synthetase activity from L1210 and C15 cells to
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Drug L1210 ID 50 (uM) C15 ID50 (uM)
L1210
CB3703 0.0125
CB3705 5
MTX 0 . 1 3 5 / 0 . 2 2
(x 0.178)
5FU 0.22, 0.54
(x 0.38)
FUdR 0.0047, 0.0018
(x 0.00365)
0.033 2.6
500 100
0_.67 , 0.75 4
(x 0.71)
0.26, 0.28 0.7
(x 0.27)
0.0068, 0.0047 1.4
(x 0.00545)
TABLE VI.4: Summary of ID 5 Q Data in L1210 Sensitive and
Resistant Strains (at 48hrs)
S
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sodium dodecyl sulphate polyacrylamide gel electrophoresis 
using a silver stain to detect protein bands. In both 
preparations faint bands were visible around the 35-40,000 
molecular weight range although many other contaminating 
bands were visible in the L1210 preparation (Little P. & 
Willison K.R. personal communication). This gives some 
indication of the relatively increased p r o p o r t i o n  of 
thymidylate synthetase (with respect to other protein) 
present in C15 as opposed to L1210 cells. Their findings 
also concord with Dunlap and coworkers who isolated TS from 
Lactobacillus Casei and found it to have a molecular weight 
of a p p r o x i m a t e l y  70,000 c o m p r i s i n g  two sub units of 
approximately .35,000 each (Dunlap R.B. Harding N.G.L. and 
Huennekens F.M. 1971). Evidence for the overproduction of 
the TS enzyme by the C15 line has now been confirmed by 
measurement of the total enzyme by a dUMP binding assay 
(36pmoles/mg protein) (Jackman A.L. personal communication).
Some recent data on DHFR gene amplification suggest 
that stable mutations are more likely to be associated with 
expanded coding regions on large chromosomes rather than 
small paired chromosomal elements called "double minute 
chromosomes" ( Kaufman R.J. Brown P.L. & Schimke R.T. 1979, 
Curt G.A. e_t aJL 1983). This is because double minute 
chromosomes lack centromeres, do not segregate during cell 
division and are readily lost. The daughter cells receiving 
the extra DNA fragments have no survival advantage in the 
absence of the selecting agent and the* "mutation is readily 
lost. If amplification of the TS gene is responsible for 
CB3717 resistance in the C15 strain (which is stable in the 
absence of drug for 9 months) the above hypothesis would 
place the a m p l i f i e d  region on a large c h r o m o s o m e .  
Interestingly, karyotypfe analysis of these cells has failed 
to show a n y .double minute chromosomes or any obvious
240
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amplification (P. Little, personal communication).
The four fold resistance of C15 cells to methotrexate 
and the ~3 fold resistance to CB3703 (compared with L1210) 
may be attributed to the increased dihydrofolate reductase 
activity observed in this strain. Why this developed was 
not clear although one possibility was that in the presence 
of increased thymidylate synthetase, the cytotoxic locus of 
CB3717 moved to DHFR (Ki for rat liver enzyme 14nM, Jones 
T.R. et ad 1981) and induced an increase in the levels of 
e n z y m e  activity. Other w o r k e r s  have isolated a TS 
o v e r p r o d u c i n g  (up to 5 fold) 5 - F U d R - r e s i s t a n t  m o use 
fibroblast line which they also found to have slight (2 . 
fold) elevation of DHFR, in comparison with the parent line.. 
They postulated that an elevated DHFR level may provide a 
selective advantage to cells with increased TS activity 
(Rossana C. Rao L.G. & Johnson L.F. 1982). Their argument 
was that the possibility of increased TMP synthesis may 
cause a decrease in tetrahydrofolate pools and subsequent 
r educ t i o n  in rates of purine synthesis, with all its 
implications. Cells with overproduction of DHFR would be 
able to overcome this problem. In the case of the L1210 
resistant lines, a similar hypothesis for the small increase 
in DHFR activity could be put forward. As with TS, the 
change in DHFR activity was maintained in C15 cells grown 
out of drug for 9 months. C o m p a r i s o n  of the kine t i c  
properties of purified DHFR from C15 and L1210 cells would 
help indicate whether the increased activity reflected 
overproduction or altered turnover number.
CB3705, and CB3703, were r e ported as being 
inhibitors of both DHFR and TS. The Ki of CB3705 for TS is 
67nM making it a considerably less potent inhibitor than 
CB3717 (Ki for L1210 TS ~4nM) (Jackman A.L. et al 1984). In
previous tissue culture experiments thymidine alone was 
capable of reversing toxicity from CB3705 in L1210 cells 
(Calvert- AiH. et al 1980) implying that TS inhibition was 
the cytotoxic event. It was therefore not surprising that 
C15 cells with increased TS activity wersresistant (100 
fold) to CB3705.
The lack of resistance of C15 cells to 5-FU and FUdR 
was not anticipated but several possible reasons for this 
can be offered in explanation. FUdR is phosphorylated by 
the enzyme thymidine kinase to the nucleotide 5-^fluoro-2'- 
deoxyuridine monophosphate (FdUMP) which is a powerful 
compe ti t ive inhibitor of TS (Reyes P. and He i'deTber ger C. 
1965). 5-FU may also be metabolised to FdUMP via several 
pathways (reviewed by Heidelberger C. 1982) one of which 
involves prior conversion to FUdR. Increased activity of 
thymidine kinase in the C15 line might produce higher levels 
of FdUMP capable of inhibiting the increased TS. However, 
measurement of thymidine kinase by Dr. S.E. Barrie, using a 
recently developed method (Barrie S.E. et/ a_l 19 84) proved 
that this was not the case as TK activity in C15 and L1210 
cells was similar on two occasions (L1210 58nmoles/hour/10^ 
ce l l s ,  Cl 5 72 n m o l e s / h o u r / 1 0 ^  c e l l s  a nd LI 210
118nmoles/hr/loT cells, C15 90nmoles/hr/10^ cells) (personal 
communication). A decrease of activity in the enzymes which 
c atabolise 5-FU and its i n t e r m e d i a t e s  and of the 
phosphatases involved ..in the breakdown of FdUMP might also 
be responsible for the retained sensitivity of C15 to these 
fluoropyrimidines (reviewed by Ardalan D. e_t al^  1980) and 
altered drug transport mechanisms must also be considered. 
Furthermore, in the case of 5FU, incorporation into RNA may 
account for its cytotoxicity (Martin D.S. 1978, Roobol C., De 
Dobbeleer G.B.E. & Bernheim J.L. 1984) in which case C15 and 
L1210 cells w o u l d  be equally sensitive. Thus- the
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observation of non-cross resistance to fluoropyrimidines of 
a TS overproducing cell line provides plenty of scope for 
future investigation.
A decreased ability to transport CB3717 would, of 
course, be one other way in which the L1210 resistant cell 
line acquired resistance. Preliminary studies with 
CB3717 found no significant, dif f e r e n c e  b e t w e e n  the 
resistant and sensitive cell lines in the intracellular 
accumulation of drug which seems to occur very slowly by a 
different- process from that of the reduced folate cofactors 
and MTX (Jackman AL, personal communication).
Hepatoma cells resistant to FUdR have been reported 
previously as showing 6-10 fold elevated levels of TS 
(Priest D.G., Ledford B.E. & Doig M.T. 1980) and alteration 
of TS in FUdR resistant Ehrlich ascites carcinoma cells has 
also been described (Jastreboff M.M. Kedzierska D. & Rode W. 
1983). TS o v e r p r o d u c t i o n  in 5-FUdR r e s i s t a n t  m o u s e  
fibroblasts (up to 50 fold) was unstable with a half life of 
three weeks (Rossana C. et eil 1982). The -data presented in 
this chapter have established that the probable mode of 
resistance developed in L1210 cells to the quinazoline 
folate analogue, CB3717 is a stable overproduction of 
thymidylate synthetase (10-40 fold) and slightly increased 
activity of DHFR (5-10 fold). It is not inconceivable that 
such cellular changes could also be r e s p o n s i b l e  for 
resistance in the clinic.
N
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VII SUMMARY AND FUTURE CONSIDERATIONS
T h e  c o n c e p t  of "a c u r e  for c a n c e r "  is one 
romanticised by the media and.press but one which few, if 
any, clinicians and scientists would uphold, being cognisant 
of the multiplicity of the forms and clinical presentations 
which are encompassed by the term "cancer". Combined 
modality treatment and multiple drug regimens have made some 
headway against certain tumours, providing grounds for 
cautious pptimism. However, solid tumours still provide a 
formidable hurdle and a tremendous incentive for the 
development of new cytotoxic drugs.
One such agent, CB3717, evolved from the desire to 
produce an antifolate with different properties from, and 
lack of cross-resistance with, methotrexate, which is the 
classical agent within this group of antimetabolites. 
Thymidylate synthetase (TS) was sought as its cytotoxic 
locus instead of dihydrofolate reductase (DHFR), with the 
hope of avoiding antipurine effects. Additionally, it was 
hoped that the folate analogue structure of CB3717, based on 
a quinazoline ring, would avoid the problems that befall 
pyrimidine analogue TS inhibitors which require metabolic 
activation and are prey to myriad catabolic, inactivating 
enzymes. In Chapter I these ideas were reviewed in detail 
along with the biochemical evidence that CB3717 had achieved 
such goals irt vitro which included characterisation of the 
inhibition kinetics against purfied TS, cellular nucleotide 
and folate pool measurements (pre and post exposure to 
CB3717) and reversal of c y t o t o x i c i t y  by the d e l a y e d  
administration of thymidine. The therapeutic effect of 
CB3717 against a variety of mouse tumours coupled with its
245
S'
unique biochemical properties was sufficiently persuasive to 
warrant its clinical evaluation. Chapter I surveys both 
this data and the ensuing toxicological assessment in mice, 
where renal toxicity, due to drug precipitation in the renal 
tubule, was paramount. The results of studies of thymidine 
"salvage" in rodent tissues now suggest that the use of 
mouse antitumour models may be inappropriate for this type 
of agent (Jackman a.L. e_t al 1984).
The Phase I clinical trial involved some 99 patients 
and was the subject of Chapter II. The reason for the large 
numbers was primarily because of the frequent occurrence of 
mild hepatic toxicity which was apparent even at the 
s tarting dose. Eighty perc e n t  of p a t i e n t s  s h o w e d  a. 
variable rise in plasma alanine transaminase levels and 
malaise was experienced by a similar proportion so that an 
a s s o c i a t  ion of these toxicities se e m e d  j ustifiable. 
Altering the schedule of administration from a 1 hour to a 
1 2  hour infusion or prescribing prednisolone for one week 
after treatment were two ways in which amelioration was 
sought but with no effect, except modest improvement in 
well-being in some of the steroid-treated patients. A dose 
relationship, within the rather narrow dose range studied,
o
(140-600mg/m ) could not be established. Repeated courses 
(>4-5) were followed by a return to (or near to) normal 
enzyme levels in 13 patients.
Renal toxicity, as portended by the mouse studies, 
was dose limiting at 500-600mg/m^ and slight to moderate 
reductions in glomerular filtration rates were observed in a 
few pa t i e n t s  at doses b e t w e e n  2 0 0 - 4 0 0 m g / m ^ .  Other 
toxicities included occasional myelotoxicity and skin rashes 
which were not clearly dose related. The responses seen in 
ovary, breast, lung and mesothelioma were a rewarding
' 2 4 6
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adjunct.providing promise for Phase II evaluation at.the 
relatively well tolerated dose of 400mg/m^.
The pharmacokinetic evaluation of CB3717 in 17 
patients was described in Chapter III and it was established 
that there was linearity of dose with the peak plasma 
concentration of drug achieved, biphasic decay of plasma 
drug levels, approximately 30% drug excreted in the urine in 
the 24 hours after treatment and extensive plasma protein 
binding of drug (-97%). Metabolites were not detected in 
plasma or urine but parent drug was still present in renal 
tissue from a patient who died 8  days after treatment, 
lending support.to the belief that renal toxicity in man may 
also be related to drug p r e c i p i t a t i o n  in the acid 
environment of renal tubules. Hepatic toxicity, as measured 
by increases in alanine transaminase levels, failed to show 
any correlation with the pharmacokinetic parameters defined, 
with the exception of peak plasma drug levels ( 1 1  patients). 
It was felt this required confirmation in a larger series.
Chapters IV and V dealt with the investigations into 
the possible mechanisms of CB3717 clinical toxicity, in 
particular to the skin and liver. Disturbance of histamine 
catabolism, which is a feature of some other antifolates 
which cause dermatological and central nervous system 
toxicity, was not thought to be responsible for CB3717 
induced rashes after its lack of inhibitory effect against 
h i s t a m i n e  m e t h y l t r a n s f e r a s e  and d i a m i n e  oxidase w a s 
demonstrated. The ascertainment of fluctuations in plasma 
phenylalanine levels in patients shortly after CB3717 
treatment was of interest and invited speculation as to its 
probable cause (inhibition of dihydropteridine reductase) 
and possible implications (alterations of neurotransmitter 
levels).
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Clinical hepatotoxicity needed a suitable parallel 
within an animal species. The mouse provided this, once it 
was established that transient elevation of plasma alanine 
transaminase levels did occur, after a therapeutic dose of 
CB3717, although over a shorter time period. Unlike 
paracetamol, CB3717 did not cause consistent or marked 
depletion of liver glutathione levels and toxicity could not 
be prevented by N-acetylcysteine administration. Other 
antidotes, d i r ected at reversal of the e f f e c t s  of 
t h y m i d y l a t e  synthetase or d i h ydrofolate r e d u c t a s e  
inhibition, were tried, including thymidine, folinic acid 
and 5-methyltetrahydrofolate. None was successful. However, 
the discovery that analogues of CB3717 (CB3705 and CB3714) 
differing only in their substituent (hydrogen or ethyl
groups respectively) were not hepatotoxic to mice at 
equimolar doses suggested that there may be a link between 
the propargyl group at the position of CB3717 and liver
toxicity.
In the final experimental chapter, the development of 
resistance to CB3717 was discussed in the context of an 
L1210 tissue culture cell line which had acquired >100 fold 
r e s i stance by exposure of a sensitive cell line to 
incremental concentrations of drug. The characterisation of 
monoclonal derivatives from this line provided further 
evidence for TS being the cytotoxic locus of CB3717 with the 
finding of up to 40 fold increased TS activity as their 
predominant feature. The kinetic constants for TS purified 
from sensitive and resistant cells were identical and make 
overproduction of TS the most plausible explanation for the 
increased activity. The mutation was stable for up to 9 
months in one clone and lack of significant cross-resistance 
to methotrexate, 5-fluorouracil and 5-fluorodeoxyuridine was
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demonstrated.
E s t a b l i s h i n g  a novel drug such as CB3717 in the 
forefront of cytotoxic chemotherapy regimens presents 
c o n s i d e r a b l e  problems. E v a l u a t i o n  of its antitumour 
efficacy, as a single agent, against different tumour types 
in Phase II trials is but one of these. Patients considered 
suitable for these studies have usually become resistant to 
the most effective treatment known for their disease and 
new agents are f r e q u e n t l y  at the end of a queue of 
alternatives. E v a l u a t i o n  of any drug under these 
circumstances is false but it is considered to be the only 
ethical way in which it may be done. .....
In the case of CB3717 Phase II trials are well under 
way at three centres (Newcastle, Glasgow and The Royal 
M a r s d e n  Hospital) and some p r e l i m i n a r y  results are 
available. At the Royal Marsden Hosptial responses in 
breast carcinoma look promising (2 PR, 2MR out of 11) 
(Calvert A.H. Macaulay V., personal communication) whilst in 
ovarian cancer results have been disappointing (1 PR, 4 MR 
our of 17, Harland S.J., personal communication). This may 
reflect the fact that some breast cancer patients are now 
being entered having received no previous cytotoxic therapy 
whereas all the ovarian cancer patients had received 
previous high dose cisplatinum or carboplatin and secondary 
responses after such treatment are unusual (Sessa C. et al
1983). Indeed information from Newcastle e suggests that 
CB3717 may be more active when usedin less heavily pre­
treated ovarian cancer patients (A.L. Harris, personal 
communication). The overall picture emerging from all the 
centres concerned is that CB3717 is showing antitumour 
effects in a number of patients with "solid" tumours. It is 
probably an important observation since, with the exceptions
N
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of methotrexate and 5-fluorouracil, antimetabolites have in 
general only showed activity in leukaemia.
The i n t r o d u c t i o n  of a l t e r n a t i v e  s c h e d u l e s  of 
administration, requiring further Phase I type evaluation, 
may provide a means of m i n i m i s i n g  renal and h e p a t i c 
toxicity. A once weekly low dose infusion or hydration and 
a l k a l i n i s a t i o n  r e g i m e n s  are o b v i o u s  c a n d i d a t e s .  
Complementary to this would be the measurement of plasma 
n u c l e o s i d e  l e v e l s  (in p a r t i c u l a r  t h y m i d i n e )  and 
intracellular nucleotide pools before and after treatment to 
assess the ability of CB3717 to inhibit TS in man. 
Refinement of the complex assays involved has been achieved 
(Taylor G.A., personal communication) such that this sort of. 
study, previously performed in mice whose circulating 
deoxypyrimidine levels are considerably higher (Jackman A.L.
1984) may now be contemplated in man.
The toxicity of some anticancer drugs may be extremely 
unpleasant and dangerous but if the antitumour effect is 
good enough this may be tolerated. Cisplatinum provides an 
example of this. However new analogues devoid of renal 
toxicity have been developed, some of which may well 
supersede this useful agent. Similarly it may be that an 
analogue of CB3717 will emerge with improved solubility at 
acid pH and lack of hepatotoxicity. It is also reasonable 
to believe that such a group of compounds would be devoid of 
c a r c i n o g e n i c  p o t e n t i a l  as seems to be the case w i t h  
methotrexate (Bailin P.L. et_ a_l 1975, Rustin G.J.S. _et a_l 
1983) .
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Wherever its future lies, it is apparent that CB3717 
has emerged as a compound of great interest in experimental 
and clinical cancer. Perhaps further work will establish it 
not as a superior, but as a peer, of methotrexate
S
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